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Arginine vasopressin (AVP) and atrial natriuretic peptide (ANP) are small
peptide hormones consisting of 9 and 28 amino acids, respectively, which control
water balance in the body. Small and sick premature infants often have problems
with water balance but the current assays for AVP and ANP are unsuitable for
assessing the day-to-day clinical management of these individuals because most
assays require pre-extraction of the peptides from large plasma samples (up to 10 ml)
followed by long incubation periods (3-5 days). Clinically-useful assays would measure
AVP and ANP in small volumes of unextracted plasma within a few hours of
sampling. Two-site immunometric assays have the required speed because they use
excess antibody reagents and therefore reach equilibrium rapidly. Monoclonal
antibodies (MAbs) were the preferred reagents because they are highly specific and
can be produced in bulk quantities.
However, MAb production was difficult because AVP and ANP were poor
immunogens, even after conjugation to thyroglobulin, so immunization produced low
mouse serum antibody titres and subsequent cell fusions generated few antigen-specific
hybridomas. Culture supernatant screening for anti-ANP MAbs was relatively simple,
but screening for anti-AVP MAbs was complicated by a lack of suitable positive
control samples. Immune serum was initially the only positive control available but it
was later shown that early immunizations had failed to generate anti-AVP IgG in
the mice. An AVP-capture ELISA bound anti-AVP antibodies from high titre immune
serum but could not detect anti-AVP MAbs in culture supernatants, and produced false
positive results with the anti-immunoglobulin and anti-BSA antibodies which were
generated in response to contaminants in the thyroglobulin-conjugated immunogen. An
AVP-coated-plate ELISA also failed to detect anti-AVP MAbs under conditions in
which immune serum antibodies bound strongly, because higher AVP-coating
concentrations were required for efficient MAb detection, while RIA screening could not
detect MAbs which bound close to the tyrosine residue of AVP. Despite these
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difficulties, four anti-AVP MAbs (two IgGl, one IgM and one IgA) and four anti-ANP
MAbs (one IgG2a and three IgGl) were produced.
Two-site immunometric assays for AVP were possible with a range of antibody
combinations despite the small size of the peptide, although steric hindrance severely
limited antibody binding and none of the assays were sufficiently sensitive to measure
normal physiological AVP concentrations (1-5 pg/ml plasma). The two IgGl MAbs,
ESVP 1 and ESVP 2, recognized the AVP ring and the tail tripeptide, respectively,
and could bind simultaneously to AVP although their relatively low binding
affinities (2.8 x 108 and 2.2 x 108 1/mole, respectively) limited the sensitivity of a
two-site ELISA to 200 pg AVP/ml and that of a direct IRMA to 1 ng AVP/ml. An
immunofiltration assay with these MAbs could be carried out in only 1 hour, but its
detection limit was 10 ng AVP/ml. The most sensitive assay was an IRMA that used
125 I-ESVP 1 with a solid phase-bound affinity-purified polyclonal anti-tail antibody,
and that had a detection limit of 130 pg AVP/ml after a 4 hour incubation period. A
two-site ELISA that used ESVP 1 MAb-coated wells and biotinylated affinity-purified
polyclonal antibody was less sensitive because of high non-specific binding but was
used to analyse the separation of 125I-AVP from unlabelled AVP on a Sephadex G-25
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column and, therefore, to determine the specific activity of the purified I-AVP.
The four anti-ANP MAbs which were produced in this project (with binding
affinities of 8.3 x 107 to 2.4 x 109 1/mole), and three other anti-ANP MAbs, were tested
for compatibility in two-site assays but there were no pairs of MAbs which could bind
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to ANP simultaneously. Two-site assays could only be carried out using I-MAbs with
a polyclonal antibody preparation in the IRMA format, although steric hindrance
limited antibody binding. The detection limit of the most sensitive assay was
1 ng ANP/ml, whereas normal physiological ANP concentrations are in the range
5-70 pg/ml plasma. The ELISA format was unsuitable for two-site ANP assays because
ANP adhered non-specifically to coated ELISA wells, irrespective of the composition




ANP Atrial natriuretic peptide
AVP Arginine vasopressin
AVT Arginine vasotocin







EDTA Ethylenediaminetetraacetic acid, disodium salt
ELISA Enzyme-linked immunosorbent assay
FCS Foetal calf serum
HAT Hypoxanthine, aminopterin and thymidine
Hep Heptapeptide
HEPES N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid
HIV Human immunodeficiency virus
HRP Horseradish peroxidase
HT Hypoxanthine and thymidine
IRMA Immunoradiometric assay
KLH Keyhole limpet haemocyanin
LVP Lysine vasopressin
MAb Monoclonal antibody
MBS m-Maleimidobenzoic acid N-hydroxysuccinimide ester
MTM Mixed-thymocyte culture-conditioned medium
NBCS Bovine (new-born calf) serum
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AVP, the antidiuretic hormone of most mammals, is a nonapeptide which is
derived from a 166-amino acid precursor molecule (Russell et al., 1980; Land et al.,
1982) that is synthesized by the magnocellular neurones in the supraoptic and
paraventricular nuclei of the hypothalamus. The precursor is packaged into secretory
granules, then processed to produce AVP, neurophysin II and a glycopeptide of
unknown function as the granules are transported along the axons to the posterior
pituitary (Baylis, 1989) where they are stored at the nerve endings (Brownstein et
al., 1980). In the Brattleboro rat, a single base deletion in the gene coding for the
precursor molecule produces a protein which contains the AVP sequence but is not
recognized by the post-translational processing system (Schmale and Richter, 1984;
Ivell et al., 1986) so the AVP molecule is not released and the animal suffers
diabetes insipidus. Similar mutations might also occur in humans although central
diabetes insipidus is usually caused by damage to the hypothalamus or posterior
pituitary (Zerbe et al., 1981; Kaplowitz et al., 1982). AVP synthesis was also
reported in peripheral tissues such as the thymus, adrenal gland, ovary and testis
(Rehbein et al., 1986), and in foetal and neonatal skeletal muscle (Smith et al., 1992),
although its function at these sites is uncertain, and the peptide was detected in
various parts of the central nervous system where it may act as a neurotransmitter
(Zimmerman et al., 1984; Burbach and Liu, 1989).
AVP controls water reabsorption in the kidney and so maintains the
osmolality of the extracellular fluid within narrow limits. An osmoreceptor, located
within the circumventricular organs of the anterior hypothalamus (Baylis, 1989),
detects the hyperosmolality that is caused by solutes, such as sodium, which do not
readily penetrate cell membranes (Robertson, 1977; Schrier et al., 1979) and responds
by increasing AVP secretion from the pituitary. The osmotic threshold for AVP
secretion varies between individuals (Robertson, 1977; Schrier et al., 1979) but above
this point there is a close relationship between plasma osmolality and AVP
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concentration, although there is disagreement about the precise nature of this
relationship (Robertson, 1977; Weitzman and Fisher, 1977; Hammer et al., 1979;
Baylis et al., 1986). Once in the kidney, AVP binds reversibly to the V2 receptors on
the basolateral surface of the collecting duct epithelial cells, where it activates
adenylate cyclase (Valtin, 1987) and leads to the insertion of water channels into the
apical membrane (Harris et al., 1991). This produces a dramatic increase in the water
permeability of the collecting duct so that water, but not small non-electrolytes such
as urea, can flow along an osmotic gradient from the tubule lumen to the medullary
interstitium (Valtin, 1987; Harris et al., 1991). AVP also increases the urea
permeability of the inner medullary collecting duct, stimulates NaCl reabsorption
from the thick ascending limb of Henle's loop, and raises the glomerular filtration
rate of the juxtamedullary nephrons. These actions all increase the osmotic gradient
and therefore assist the reabsorption of water and the production of a concentrated
urine (Valtin, 1987). However, some individuals suffer renal insensitivity to AVP,
which causes nephrogenic diabetes insipidus (Zerbe et al., 1981).
AVP is also secreted in response to various non-osmotic stimuli, such as
hypovolemia, hypoxia, hypoglycaemia, nausea (Schrier et al., 1979; Baylis, 1989)
and pain (Kendler et al., 1978), which all seem to exert their influence via the
baroregulatory system (Robertson, 1977; Schrier et al., 1979). Baroreceptors in the
aortic arch and carotid arteries detect changes in blood pressure, while receptors in
the left atrium detect decreased volume (Miller, 1984; Elijovich and Krakoff, 1985;
Baylis, 1989). This system is much more sensitive to changes in pressure than in
volume but is considerably less sensitive than the osmoregulatory system (Dunn et al.,
1973; Miller, 1984; Baylis, 1989).
AVP is a potent vasoconstrictor (Elijovich and Krakoff, 1985) which was
originally detected because pituitary extracts raised the blood pressure of
experimental animals (Oliver and Schafer, 1895). It binds to the vascular VI receptors,
producing a calcium flux which causes smooth muscle contraction (Elijovich and
Krakoff, 1985; Vallotton et al., 1990). At normal physiological concentrations, AVP
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can produce significant vasoconstriction without raising blood pressure because the
increase in total peripheral resistance is balanced by decreased cardiac output
(Elijovich and Krakoff, 1985). Increased blood pressure is apparent only at the very
high AVP concentrations that are secreted in response to severe haemorrhage or
hypotension (Cowley et al., 1980; Miller, 1984), under which conditions AVP makes a
significant contribution towards the restoration of arterial pressure.
AVP secretion occurs in a pulsatile manner, the amplitude of the secretory
bursts depending on the degree of stimulation, while their frequency and duration
vary between individuals (Weitzman et al., 1977; Sadler et al., 1983). Plasma AVP
concentrations also fluctuate diurnally, with the highest concentrations tending to
occur at night independently of any change in plasma osmolality (George et al., 1975;
Uhlich et al., 1975). Consequently, the AVP concentration of a single plasma sample
may not seem to correlate with the subject's water balance status.
In contrast, measurements of urinary AVP are thought to provide integrated
values for AVP secretion over a period of time (Robertson, 1977; Thibonnier et al.,
1981; Miller, 1984; Moses and Steciak, 1986) and therefore to sensitively detect
sustained changes in secretion (Seckl et al., 1986). However, AVP excretion is only a
small fraction of the total renal clearance because most of the filtered AVP is
reabsorbed in the proximal tubule (Pruszczynski et al., 1984; Moses and Steciak, 1986)
where it is presumably catabolized, since both membrane-bound (Nardacci et al., 1975)
and cytosolic (Walter and Shlank, 1975) AVP-inactivating peptidases were reported
in renal tissue. Impaired renal function can drastically alter glomerular filtration
and tubular reabsorption (Pruszczynski et al., 1984) so that although significant
correlations between plasma and urinary AVP concentrations were reported in normal
subjects (Khokhar et al., 1975; Thomas and Lee, 1976; Thibonnier et al., 1981; Stern
and LaRochelle, 1982), no correlation was found in infants (Smith et al., 1990) or
children (Bald et al., 1988) with renal damage. AVP excretion does not therefore
reliably reflect either the secretion rate or plasma concentration of AVP during renal
failure. Even in normal individuals, however, AVP excretion fluctuates significantly
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with changes in the total solute clearance rate, independently of changes in AVP
secretion or plasma concentration (Robertson, 1977), so that urinary AVP values can be
difficult to interpret.
For many years, the only way to assay AVP was to determine its biological
activity in experimental animals. These laborious bioassays, which required intricate
surgical skills, relied on the detection of increased blood pressure (Dekanski, 1952),
increased urine conductivity (Yoshida et al., 1963) or decreased urine flow (Czaczkes
et al., 1964) in response to injections of AVP, and had the disadvantage that few
samples could be assayed per animal. The pressor assay (Dekanski, 1952), although
reproducible and precise, was insensitive because physiological AVP concentrations do
not increase blood pressure (Elijovich and Krakoff, 1985) therefore it could only be
used to assay highly concentrated samples. The antidiuretic bioassays (Yoshida et
al., 1963; Czaczkes et al., 1964), on the other hand, were reasonably sensitive but
were susceptible to interference from other antidiuretic substances in the sample
(Robertson, 1977).
More recently, rat kidney segments were used in extremely sensitive
cytochemical bioassays which relied on the detection of AVP-stimulated increases in
the Na+/K+ ATP-ase activity of the cells in the thick ascending limb of Henle's loop
(Smith and Mcintosh, 1984; Baylis et al., 1986). These assays could measure the AVP
content of unextracted plasma samples, even those from water-loaded subjects whose
low AVP concentrations were undetectable by other methods (Baylis et al., 1986).
However, although sensitive, these cytochemical assays were still very laborious and
suffered from high intra-assay and inter-assay coefficients of variation (Smith and
Mcintosh, 1984; Baylis et al., 1986).
Following the pioneering RIA work of Yalow and Berson (1959), many research
groups set out to produce anti-AVP antisera and develop RIAs for AVP. Immunization
was difficult because AVP is only weakly immunogenic, so many antisera had
relatively low AVP binding affinities and produced insensitive assays, although a
few high affinity antisera were reported (Oyama et al., 1971; Czernichow et al.,
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1975; Fyhrquist et al., 1976; Rooke and Baylis, 1982). Under normal physiological
conditions, plasma contains only 1-5 pg AVP/ml (Robertson, 1977), a concentration
range below the detection limit of most RIAs therefore plasma samples usually had
to be concentrated before assay. In contrast, urine contains higher concentrations of
AVP (Miller, 1984; Claybaugh and Sato, 1985) therefore several RIAs were able to
measure AVP in unextracted urine samples (Oyama et al., 1971; Freisenhausen et al.,
1976; Lishajko et al., 1981; Smith and Mcintosh, 1986; Bald and Rascher, 1990;
Panzali et al., 1990).
Although a few RIAs were sufficiently sensitive to measure plasma AVP in
unconcentrated samples (Robertson et al., 1973; Skowsky et al., 1974; Sadler et al.,
1983; Ysewijn-Van Brussel and De Leenheer, 1985), macromolecular substances in human
plasma interfered with RIA determinations (Robertson et al., 1970; Beardwell, 1971)
by causing enzymatic degradation of 125I-AVP (Robertson et al., 1973; Fyhrquist et al.,
1976) so that falsely high AVP concentrations were estimated in unextracted plasma.
This interference varied between antisera (Robertson, 1977), due to differences in
binding specificity (Chard, 1973; Thomas and Lee, 1976), but all RIAs were affected to
some extent (Robertson, 1977). Plasma extraction was therefore essential to remove the
interfering substances, although e-aminocaproic acid was reported to prevent tracer
degradation and allow RIA determinations in unextracted plasma (Fyhrquist et al.,
1976), which avoided the problem of the variable AVP recoveries that were found
with some extraction methods (Uhlich et al., 1975; Shimamoto et al., 1976; Moulin et
al., 1978; Glanzer et al., 1984). Serum was also reported to cause tracer damage
(Robertson, 1977) yet RIA data from unextracted serum correlated well with bioassay
data (Skowsky and Fisher, 1972a) and with the physiological status of the serum
donor (Wagner et al., 1977), which suggested that serum interference was negligible in
some RIAs.
Unextracted urine was not reported to cause tracer degradation, but it
contained widely varying concentrations of NaCl and urea which could disrupt
antigen-antibody binding (Miller and Moses, 1972; Chard, 1973) therefore urine was
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often extracted to remove this source of RIA interference. However, some antisera were
unaffected by high osmolalities (Oyama et al., 1971) so the AVP concentrations
estimated in extracted and unextracted urine samples were similar (Seckl et al., 1986;
Smith and Mcintosh, 1986; Panzali et al., 1990). Several research groups also showed
that urine contained immunoreactive, non-AVP, substances that only cross-reacted with
certain antisera (Thomas and Lee, 1976; Bald and Rascher, 1990) but which
co-extracted with AVP and were likely to be AVP metabolites (Thomas and Lee,
1976; Tausch et al., 1983; Claybaugh and Sato, 1985; Bald and Rascher, 1990). It was
therefore important to ensure that the antisera selected for RIA were specific for the
intact peptide.
AVP has been extracted from plasma and urine by many different methods,
most of which relied on non-specific adsorption of the peptide onto solid supports such
as Florisil (Beardwell, 1971; Uhlich et al., 1975; Thomas and Lee, 1976), Spherosil
(Edwards et al., 1970; Khokhar et al., 1978), Vycor (Ratcliffe and Edwards, 1971;
Ten Haaf et al., 1992), Fuller's earth (Johnston, 1972), Bentonite (Skowsky et al.,
1974; Shimamoto et al., 1976), Isorex 50 (Thibonnier et al., 1981), Amberlite XAD-2
(Gerbes et al., 1992), Amberlite CG-50 (Miller and Moses, 1971; Merkelbach et al.,
1975) and Rexyn H+ (Fressinaud et al., 1974), although minor procedural differences
between laboratories which used the same adsorbent produced a wide range of AVP
recoveries. However, batch-to-batch variation was reported with Florisil (Uhlich et
al., 1975), which co-extracted substances that caused RIA interference (Ratcliffe and
Edwards, 1971), while urinary AVP recoveries from Spherosil decreased with
increasing urine osmolality (Khokhar et al., 1978) despite a report that Spherosil
was unaffected by changes in osmolality (Ratcliffe and Edwards, 1971). More recently,
octadecasilyl-silica, in the form of C18 Sep-Pak columns, produced improved
extractions with consistently high AVP recoveries (LaRochelle et al., 1980;
Ysewijn-Van Brussel and De Leenheer, 1985) from both plasma and urine (Glanzer et
al., 1984), and had the advantage that AVP and ANP were extracted simultaneously
(Hartter and Woloszczuk, 1986; Bodola and Benedict, 1988), although octyl-silica (C8)
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columns produced even better results because they co-extracted fewer impurities and
allowed almost 100% recovery of AVP (Van de Heijning et alv 1991; Ten Haaf et al.,
1992). Other AVP extraction methods have included gel filtration on Sephadex G-25
(Robertson et al., 1970) or G-50 (Lishajko, 1983), protein precipitation by acetone
(Robertson et al., 1973; Moulin et al., 1978; Camps et al., 1983), dioxane
(Rougon-Rapuzzi et al., 1977) or ethanol (Camps et al., 1983), and specific binding by
anti-AVP antibody-coated Sepharose (Morton and Riegger, 1978), although these
methods were only suitable for plasma extraction and could not be used with urine.
The most efficient extraction methods isolated enough AVP from 1 ml plasma
for measurement by sensitive RIAs (Robertson et al., 1973; Skowsky et al., 1974;
Van de Heijning et al., 1991), although many extractions required 5-10 ml plasma
(Edwards et al., 1970; Beardwell, 1971; Johnston, 1972; Baylis and Heath, 1977)
particularly if they were combined with an insensitive assay. Prompt extraction was
important because AVP was unstable in plasma during storage at -20°C (Robertson et
al., 1973; Fyhrquist et al., 1976; Lishajko, 1983), although some workers disagreed
(Beardwell et al., 1975; Thomas and Lee, 1976; Baylis and Heath, 1977) which may
indicate that their antisera cross-reacted with degraded AVP (Beardwell et al.,
1975). After extraction, the solvent was removed by evaporation (Beardwell, 1971;
Camps et al., 1983) or lyophilization (Robertson et al., 1970; Rougon-Rapuzzi et al.,
1977), which increased the total preparation time significantly but allowed
concentration of the sample for RIA.
Very low antiserum concentrations were used in RIAs (Chard, 1973) therefore
long incubation periods were necessary to ensure maximal binding and, thus,
sensitivity. RIA sensitivity could, however, be increased by preincubation of the
sample and antiserum before addition of the tracer (Skowsky et al., 1974; Beardwell
et al., 1975). The total incubation period reported for AVP RIAs varied from 24 hours
(Beardwell et al., 1975; Burd et al., 1984) to 7 days (Robertson et al., 1973), but most
assays were incubated for 3-5 days (Beardwell, 1971; Husain et al., 1973; Skowsky et
al., 1974; Baylis and Heath, 1977) before separation of bound and free tracer.
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Many different separation methods have been reported. Separations which
relied on the adsorption of unbound tracer by charcoal coated with BSA (Miller and
Moses, 1972; Gerbes et al., 1992), dextran (Edwards et al., 1972; Johnston, 1972; Moulin
et al., 1978), Ficoll 400 (Ten Haaf et al., 1992) or plasma (Thomas and Lee, 1976;
Glanzer et al., 1984) could usually be carried out in less than 30 minutes, as could
antibody precipitation by ammonium sulphate (Edwards et al., 1970; Khokhar et al.,
1978), ethanol (Edwards et al., 1970), or PEG 8000 (Husain et al., 1973; Robertson et
al., 1973). However, high non-specific binding decreased the sensitivity of assays
which used these methods (Chard, 1973), while prolonged exposure to the separating
agent caused dissociation of antibody-bound AVP (Moulin et al., 1978; Valiquette and
Neubort, 1989). Precipitation by a second antibody avoided these problems but added
1-2 days to the total assay time (Beardwell, 1971; Uhlich et al., 1975; Baylis and
Heath, 1977; Rooke and Baylis, 1982) although precipitation by PEG-assisted
(Lishajko et al., 1981; Tausch et al., 1983) or pre-precipitated second antibody
(Ysewijn-Van Brussel and De Leenheer, 1985) could be carried out within 1-2 hours.
Separation by chromatoelectrophoresis (Oyama et al., 1971; Husain et al., 1973) was
unpopular because it was less convenient than other methods, while equilibrium
dialysis assays (Rougon-Rapuzzi et al., 1977) required specialized dialysis devices but
avoided the need for a discrete separation step because incubation and separation
occurred simultaneously. Separation could also be achieved simply by centrifugation if
the RIA antiserum was coupled to a solid phase such as microcrystalline cellulose
(Burd et al., 1984).
A competitive enzyme immunoassay for AVP was also reported (Uno et al.,
1982). However, it was a liquid-phase assay with a second antibody separation step
and therefore did not offer any advantage in terms of speed, sensitivity or convenience
when compared with RIA methods.
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1.2 ATRIAL NATRIURETIC PEPTIDE
The existence of a natriuretic hormone was postulated for many years (De
Wardener, 1977). ANP was finally discovered when De Bold et al. (1981) showed
that intravenous injections of atrial extract caused profound natriuresis and diuresis in
experimental animals, while ventricular extracts had no effect. a-ANP is a 28-amino
acid peptide (Flynn et al., 1983; Kangawa and Matsuo, 1984) that has a 17-amino
acid disulphide-bonded loop which is essential for biological activity (Misono et al.,
1984; De Bold, 1985). Human ANP is synthesized as a 151-amino acid prepropeptide
(De Bold, 1985; Kangawa et al., 1985) that is processed to form y-ANP, a 126-amino
acid propeptide (Ballermann and Brenner, 1985; Kangawa et al., 1985) which is stored
in secretory granules within the atrial myocytes (De Bold, 1985). a-ANP is cleaved
from the C-terminal of y-ANP simultaneously with secretion (Sei et al., 1992) so that
both a-ANP and a 98-amino acid peptide are released into circulation (Michener et
al., 1986; Itoh et al., 1988; Sundsfjord et al., 1988; Meleagros et al., 1989; Sei et al.,
1992). The right atrium synthesizes more ANP than the left atrium (Gutkowska et
al., 1984a, 1984b), while a very small amount is also synthesized in the ventricles
(Cernacek et al., 1988) and in the brain (Morii et al., 1985; Samson, 1987; Ueda et al.,
1987). However, brain ANP consists mainly of a-ANP(4-28) and a-ANP(5-28), which
are N-terminally truncated forms of a-ANP (Ueda et al., 1987) therefore precursor
processing in the brain differs from that in the heart. (3-ANP, a 56-amino acid
antiparallel dimer of a-ANP, was reported to exist in human atria (Kangawa et al.,
1985) and in the plasma of neonates (Ito et al., 1990) and chronic renal failure
patients (Itoh et al., 1988; Marumo et al., 1992) but was not found in normal adult
plasma (Theiss et al., 1987; Marumo et al., 1992) so its significance was uncertain.
ANP controls the blood volume and so protects the heart from overload. There
is a close relationship between atrial pressure and plasma ANP concentration because
distensional stimulation of the atrial wall stretch receptors causes a dose-dependent
increase in ANP secretion into the coronary sinus (Nicholls et al., 1987; Cernacek et
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al., 1988). ANP is therefore secreted in response to extracellular volume expansion due
to drinking (Larose et al., 1985), isotonic infusion (Lang et al., 1985; Burrell et al.,
1990), sodium loading (Sagnella et al., 1987; Naomi et al., 1988), renal failure
(Nicholls et al., 1987; Shenker et al., 1987) or congestive heart failure (Shenker et
al., 1985; Cemacek et al., 1988), central hypervolemia due to postural change (Larose
et al., 1985; Burrell et al., 1990) or immersion in water (Anderson and Bloom, 1986),
and increased perfusion pressure due to atrial pacing (Gutkowska et al., 1985),
paroxysmal tachycardia (Anderson and Bloom, 1986; Nicholls et al., 1987) or
hypertension (Arendt et al., 1985; Gutkowska et al., 1987).
ANP binds reversibly to the B-ANP receptors that are located in the kidney
(Napier et al., 1984; Cernacek et al., 1988), aorta (Napier et al., 1984; Schenk et al.,
1985), adrenal cortex (Anderson and Bloom, 1986; Takayanagi et al., 1987) and central
nervous system (Jacobs et al., 1987; Samson, 1987), thereby activating particulate
guanylate cyclase which produces the cGMP that mediates the biological effects of
the peptide (Schenk et al., 1985; Scarborough, 1989). The guanylate cyclase-free
C-ANP receptors, on the other hand, rapidly clear ANP from circulation (Maack et
al., 1987; Scarborough, 1989) by receptor-mediated endocytosis and transport to the
lysosomes (Scarborough, 1989), so that it has a plasma half-life of only 2-5 minutes
in vivo (Gutkowska et al., 1987; Nicholls et al., 1987; Scarborough, 1989). The C-ANP
receptors also clear ANP metabolites since they can bind truncated peptides that are
not recognized by the B-ANP receptors (Takayanagi et al., 1987; Scarborough, 1989),
although only a small proportion of ANP undergoes extracellular degradation in vivo
(Gutkowska et al., 1987; Condra et al., 1988; Scarborough, 1989).
ANP acts at three main sites within the kidney, producing haemodynamic and
tubular effects which cause natriuresis and diuresis. It boosts hydraulic pressure in the
glomeruli by dilating afferent arterioles and constricting efferent arterioles, whilst
simultaneously increasing capillary permeability, therefore the glomerular filtration
rate rises (Cernacek et al., 1988). In the collecting duct, sodium reabsorption and
AVP-dependent water reabsorption are inhibited while sodium transport into the
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urine is increased (Raine et alv 1989; Zeidel, 1989). ANP also decreases renin secretion
from the juxtamedullary cells (Anderson and Bloom, 1986; Raine et al., 1989; Zeidel,
1989) therefore angiotensin II-stimulated water reabsorption in the proximal tubule
and aldosterone-mediated sodium reabsorption in the distal tubule are indirectly
inhibited (Raine et al., 1989).
ANP is a potent hypotensive agent which inhibits the arterial smooth muscle
response to vasoconstrictors such as AVP and angiotensin II (Ballermann and Brenner,
1985; Anderson and Bloom, 1986). It also increases capillary permeability so that
fluid shifts towards the extravascular space (Nicholls et al., 1987; Cernacek et al.,
1988), rapidly decreasing the blood volume and thus the heart's workload.
In addition to inhibiting renin secretion, and thus indirectly decreasing
angiotensin II and aldosterone secretion, ANP acts on the adrenal cortex to directly
inhibit both the synthesis and secretion of aldosterone (Anderson and Bloom, 1986;
Cernacek et al., 1988). ANP also decreases AVP secretion by action on the posterior
pituitary (Samson, 1987; Allen et al., 1988) and on the hypothalamus (Samson, 1987;
Cernacek et al., 1988), where it was shown to inhibit the firing of AVP-containing
neurones (Standaert et al., 1987). The functional antagonism between ANP, AVP and
the sodium-conserving renin-angiotensin-aldosterone system is therefore complemented
by the inhibitory effect of ANP on the secretion of the other hormones, so that fluid
and electrolyte balance are finely controlled.
Plasma ANP concentrations were reported to fluctuate diurnally (Donckier
et al., 1986; Richards et al., 1987a; Winters et al., 1988) but the fluctuations were
small (Richards et al., 1987a) and the timing of the peak concentration was in fact
posture-related, occurring shortly after the subjects assumed a recumbent position (Bell
et al., 1990), despite a claim to the contrary (Winters et al., 1988). However, ANP is
secreted in a pulsatile manner, with secretory bursts every 9 minutes and longer-term
oscillations of the plasma ANP concentration every 34 minutes (Haak et al., 1990),
therefore true diurnal variation would be difficult to detect and the ANP
concentration of a single plasma sample may not seem to correlate with the subject's
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physiological status.
Although most ANP is cleared from circulation by receptor-mediated processes,
a small proportion is filtered by the kidney (Scarborough, 1989) and excreted in the
urine (Greenwald et al., 1986; Marumo et al., 1986). Urinary ANP concentrations have
rarely been reported, but are roughly similar to plasma ANP concentrations (Marumo
et al., 1986, 1990, 1992). However, no correlation was found between plasma and
urinary ANP concentrations in normal adults (Marumo et al., 1990) and neonates (Ito
et al., 1990), or in patients with renal damage (Marumo et al., 1987; Ando et al.,
1988; Marumo et al., 1990), even though elevated plasma ANP concentrations were
reflected by elevated urinary ANP (Ando et al., 1988; Ito et al., 1990). It is therefore
doubtful whether urinary ANP measurements could offer any advantage over plasma
ANP determinations in the assessment of an individual's fluid balance status.
The earliest studies monitored ANP activity using bioassays which relied on
its natriuretic and diuretic properties in experimental animals (De Bold et al., 1981;
Gutkowska et al., 1984a) or vasorelaxant effect on preconstricted smooth muscle strips
from rabbit aorta (Misono et al., 1984; Napier et al., 1984) or chick rectum (Kangawa
and Matsuo, 1984; Misono et al., 1984). These bioassays readily detected ANP in
atrial extracts but were insufficiently sensitive to measure plasma ANP concentrations.
However, ANP research proceeded so rapidly that the peptide had been sequenced
(Flynn et al., 1983; Kangawa and Matsuo, 1984), synthesized and used to generate
anti-ANP antisera (Gutkowska et al., 1984b) within 3 years of its discovery. Many
research groups subsequently developed RIAs for ANP, encountering similar problems
to those which occurred with RIAs for AVP.
Under normal physiological conditions, plasma contains 5-70 pg ANP/ml
(Polesi et al., 1989; Watanabe et al., 1989), a concentration range at the limit of
detection of many RIAs therefore samples were usually extracted to concentrate the
peptide before assay. Some RIAs were apparently unhindered by unextracted plasma
(Gutkowska et al., 1985; Marumo et al., 1986), although it was frequently reported to
1 or
interfere with RIA determinations by causing enzymatic degradation of I-ANP
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(Yamaji et al., 1985; Hartter et al., 1986; Nishiuchi et al., 1986; Cernacek et al.,
1988) so that the ANP concentration of unextracted plasma was overestimated by
50-80 pg/ml (Yandle et al., 1986; Gutkowska et al., 1987; Cernacek et al., 1988; Sarda
et al., 1989). Some plasma interference seemed to be platelet-related since high-speed
centrifugation decreased both the platelet content and measurable ANP concentration
of the sample (Richards et al., 1987b), a phenomenon that was also observed in a
RIA for AVP (Sadler et al., 1983). Platelets have high affinity receptors for both
ANP (Schiffrin et al., 1986) and AVP (Thibonnier et al., 1984) and could therefore
cause interference if the RIA antiserum recognized receptor-bound peptide or if sample
processing released peptide from the receptors, although Tan et al. (1989) found no
evidence of platelet interference in a RIA for ANP with either extracted or
unextracted plasma. However, adequate centrifugation removes the risk that platelets
might affect the RIA result.
An albumin-like ANP-binding protein, which was detected by RIAs for ANP,
was recently discovered in plasma (Kato et al., 1988; Wilson et al., 1991b).
Acidification released ANP from the binding protein (Wilson et al., 1991a), which
explains the increased extractable ANP concentrations (Buckley et al., 1987) and
increased extraction efficiencies (Richards et al., 1987b; Sarda et al., 1989) that were
observed after plasma acidification, since extraction separates protein-bound ANP
from free ANP (Wilson et al., 1991b). However, the value of acidifying plasma
before extraction will remain uncertain until the physiological significance of the
ANP-binding protein is fully understood, particularly as acidification also releases
ANP from receptors (Jacobs et al., 1987) so that platelets could influence the final
assay result. Nevertheless, plasma extraction was essential to remove all sources of
RIA interference and allow accurate determination of ANP concentrations.
Non-specific adsorption onto C18 Sep-Pak columns has been the most popular
ANP extraction method (Gutkowska et al., 1987; Cernacek et al., 1988), with the
advantage that ANP and AVP were extracted simultaneously (Hartter and
Woloszczuk, 1986; Bodola and Benedict, 1988), although minor procedural differences
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between laboratories produced a wide range of reported ANP recoveries (Yandle et
al., 1986; Richards et al., 1987b; Naomi et al., 1988; Sarda et al., 1989). Other ANP
extraction methods have included non-specific adsorption onto Amberlite XAD-2
(Arendt et al., 1985), Vycor (Gutkowska et al., 1987) or Florisil (Burrell et al., 1990),
protein precipitation by ethanol (Winters et al., 1988) or heat treatment (Iinuma et
al., 1987), removal of protein by ultrafiltration (Cernacek et al., 1988), and
immunoextraction by anti-ANP antibody coated onto Sepharose (Yamaji et al., 1985)
or magnetic particles (Torok and Penke, 1991).
Most extraction methods isolated sufficient ANP from 1-2 ml plasma for
measurement by RIA (Yamaji et al., 1985; Gutkowska et al., 1987; Burrell et al., 1990)
although some extractions required 5-15 ml plasma (Arendt et al., 1985; Hartter et al.,
1986), while the methods described by Tordk and Penke (1991) and Iinuma et al.
(1987) needed only 0.25 ml and 0.5 ml plasma, respectively, because they were
combined with sensitive RIAs. Prompt extraction was important because ANP was
unstable in plasma (Nishiuchi et al., 1986; Richards et al., 1987b; Artner-Dworzak et
al., 1991) and serum (Hartter et al., 1986), even during storage at -80°C (Lijnen et al.,
1988; Burrell et al., 1990; Nelesen et al., 1992), and ANP activity was also decreased
by freeze-thawing (Biirgisser et al., 1985; Tan et al., 1990). After extraction, the
solvent was usually removed by evaporation (Richards et al., 1987b; Burrell et al.,
1990) or lyophilization (Yamaji et al., 1985; Hartter and Woloszczuk, 1986; Sarda et
al., 1989), a step which increased the total preparation time significantly and which
was unnecessary in some methods (Iinuma et al., 1987; Torok and Penke, 1991). Many
extractions were therefore time-consuming, although the heat treatment method could
be carried out in less than 30 minutes (Iinuma et al., 1987). However, even after
extraction and lyophilization, ANP was still unstable at -80°C (Nelesen et al., 1992)
therefore prolonged storage before assay was undesirable.
Long incubation periods were reported for ANP RIAs, with most workers
preincubating the sample and antiserum before addition of the tracer (Hartter et al.,
1986; Gutkowska et al., 1987; Cernacek et al., 1988). The total incubation period
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varied from 16 hours (Iinuma et al., 1987) to 6 days (Rasmussen et alv 1990), but most
ANP RIAs were incubated for 2-3 days (Gutkowska et al., 1987; Cernacek et al., 1988;
Sarda et al., 1989) before separation of bound and free tracer.
The most popular separation methods have been antibody precipitation by a
second antibody (Yamaji et al., 1985; Iinuma et al., 1987; Cernacek et al., 1988; Sarda
et al., 1989) or PEG-assisted second antibody (Gutkowska et al., 1985; Jiippner et al.,
1986; Rosmalen et al., 1987), and adsorption of unbound tracer by dextran-coated
charcoal (Gutkowska et al., 1984a; Lang et al., 1985; John et al., 1986; Sarda et al.,
1989). Other separation methods reported for ANP RIAs have included antibody
precipitation by PEG 8000 (Larose et al., 1985), or by second antibody coupled to
cellulose (Rasmussen et al., 1990) or Sephacryl S-1000 (Prowse et al., 1989), and
adsorption of unbound tracer by BSA-coated charcoal (Arendt et al., 1985).
A competitive enzyme immunoassay for ANP was reported (McLaughlin et al.
1987) but it was less sensitive than many RIAs and the total assay time was still
1-2 days. Its second antibody-coated microtitre plate format was more convenient for
handling than liquid-phase assays, and avoided the need for a discrete separation
step because incubation and separation occurred simultaneously, but it did not offer any
other significant advantage over RIA methods.
A few research groups also developed radioreceptor assays for ANP, using
receptor-containing membranes derived from rat kidney glomeruli (Ballermann, 1988;
Gutkowska et al., 1988) or bovine adrenal cortex (Biirgisser et al., 1985; Sagnella et
al., 1987; Ong et al., 1988; Capper et al., 1990), tissues which contain mainly B-ANP
receptors. Binding to these high affinity receptors occurred rapidly therefore the
incubation periods reported for radioreceptor assays varied from only 1 hour (Biirgisser
et al., 1985; Gutkowska et al., 1988) to 22 hours (Ballermann, 1988). Bound and free
IOC
I-ANP were then separated either by filtration (Biirgisser et al., 1985; Ballermann,
1988; Gutkowska et al., 1988; Ong et al., 1988) or by centrifugation (Sagnella et al.,
1987; Capper et al., 1990), so the total assay time was significantly shorter than that
required for most RIAs yet radioreceptor assay sensitivity was roughly similar to RIA
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sensitivity. However, B-ANP receptors recognize all biologically-active forms of ANP
therefore radioreceptor assays cross-react with any peptide that has a 17-amino acid
disulphide-bonded loop and an intact C-terminal (Gutkowska et alv 1988; Capper et
al., 1990). In contrast, RIA specificity varies between antisera, some of which
cross-react significantly with biologically-inactive ANP metabolites (Gutkowska et
al., 1985; Ballermann, 1988; Ong et al., 1988). All competition assays for ANP are
therefore likely to detect a range of ANP-related peptides in addition to a-ANP.
1.3 TWO-SITE IMMUNOMETRIC ASSAYS
In immunometric assays, labelled antibody binds non-competitively to the
analyte (Miles and Hales, 1968) and high reagent concentrations drive the reaction to
completion so that binding equilibrium is attained rapidly (Baker et al., 1985; Ekins,
1987). In contrast, competitive assays (Figure 1.1A) use low reagent concentrations to
achieve maximal sensitivity therefore long incubation periods are essential to ensure
that equilibrium is reached (Chard, 1987). Immunometric assays are therefore much
faster than competitive immunoassays.
In two-site immunometric, or 'sandwich', assays (Figure 1.1B), a labelled
antibody and a solid phase-bound antibody bind simultaneously to separate epitopes
on the analyte. Two-site assays are therefore more specific than competitive assays
because a positive response is obtained only when both antibodies are bound (Baker et
al., 1985; Chard, 1987; Ekins,. 1987; Gosling, 1990). Structurally-similar materials,
which cross-react in competitive assays by displacing the labelled analyte, are less
likely to participate in two-site binding (Baker et al., 1985) although cross-reaction
can occur if binding to one antibody increases the affinity of the second antibody for
the cross-reacting substance (Boscato et al., 1989). However, materials which bind to
only one antibody will cause interference by decreasing the capacity for two-site
binding so that the analyte concentration may be underestimated (Baker et al., 1985;
Boscato et al., 1985). Anti-immunoglobulin antibodies, which are found in the plasma
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FIGURE 1.1
Comparison of the standard curves obtained in competition assays and in two-site
immunometric assays
In competitive assays (A), unlabelled analyte competes with a fixed amount of
labelled analyte for binding to a limited quantity of antibody or receptor molecules,
in immunoassays or radioreceptor assays, respectively. As the unlabelled analyte
concentration increases, a decreasing proportion of labelled analyte is recovered in the
bound fraction. The example shown is a typical RIA standard curve obtained by the
method described in Section 2.4.2.
In two-site immunometric assays (B), excess labelled antibody and a second,
solid phase-bound, antibody bind to separate epitopes on the analyte therefore an
increasing amount of labelled antibody becomes bound to the solid phase as the
analyte concentration of the sample increases. The example shown is a typical direct
IRMA standard curve obtained with two analyte-specific MAbs as described in
Section 2.5.2.1.
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of some individuals, can also interfere in two-site assays because they cross-link the
reagent antibodies in the absence of analyte although this is prevented simply by the
addition of normal serum from the species in which the reagent antibodies were
raised (Hunter and Budd, 1981; Baker et al., 1985; Boscato and Stuart, 1988; Nahm
and Hoffmann, 1990; Levinson, 1992).
Competitive immunoassay sensitivity is dependent on the affinity of the
chosen antibody (Baker et al., 1985; Gosling, 1990). In contrast, the sensitivity of an
immunometric assay is largely determined by the specific activity of the labelled
antibody (Baker et al., 1985; Ekins, 1987) and is less dependent on its binding affinity
(Gosling, 1990). Immunometric assays are therefore more sensitive than competitive
assays that are based on the same antibody (Hunter and Budd, 1981; Baker et al.,
1985; Chard, 1987; Ekins, 1987). Two-site immunometric assay sensitivity can be
improved by decreasing the non-specific binding of labelled antibody, which increases
the signal-to-noise ratio of the system (Baker et al., 1985; Ekins, 1987). Assay
sensitivity will also increase if cooperativity between the antibodies produces circular
antibody-analyte complexes in which the two antibodies are linked through both
binding sites by two analyte molecules, with the effect that their affinity for the
analyte is enhanced (Ehrlich et al., 1982; Ehrlich and Moyle, 1984).
Immunometric assays usually have a wider working range than competitive
immunoassays (Hunter and Budd, 1981; Baker et al., 1985). This is advantageous for
those analytes which have a broad physiological concentration range because samples
are less likely to require dilution before assay. However, two-site assays are prone to
a high-dose 'hook' effect where the binding of labelled antibody decreases with
increasingly high analyte concentrations (Figure 6.23). This effect, which causes the
underestimation of very high analyte concentrations, occurs because the antibodies are
no longer in excess therefore free analyte competes with labelled antibody-bound
analyte for binding to the solid phase-coupled antibody (Baker et al., 1985; Chard,
1987). This problem, if expected, can be overcome either by increasing the antibody
concentration on the solid phase or by assaying the samples at more than one dilution
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(Baker et alv 1985).
Analyte labelling can alter the specificity of a competitive immunoassay if
the label obscures an epitope that is recognized by some of the antibodies in the
antiserum (Miles and Hales, 1968; Chard, 1987). An immunometric assay avoids this
problem, which is most severe with small analytes (Chard, 1987), because the
antibody is labelled instead of the analyte. Labelled antibodies are relatively
stable molecules (Chard, 1987; Ekins, 1987) which are unaffected by the plasma
proteases that can degrade labelled analytes such as 125I-AVP or 125I-ANP, therefore
immunometric assays can determine the analyte concentration of unextracted plasma
without risking the overestimation that can occur in competitive assays as a result of
tracer degradation. The sample analyte would still be prone to proteolytic attack in
unextracted plasma but this would be less serious during the short immunometric assay
incubation period than during prolonged competitive assay incubations and might be
adequately decreased by protease inhibitors.
The main disadvantage of the two-site immunometric assay is that large
quantities of purified antibody are required for reagent preparation. Polyclonal
antisera contain a relatively small proportion of specific antibody and therefore have
to be immunoaffinity-purified to produce the highly specific reagents that two-site
assays demand (Hunter and Budd, 1981; Baker et al., 1985). This procedure requires
large amounts of pure analyte which may be difficult to obtain, while the extreme
conditions that are needed to elute high affinity antibodies from the immobilized
analyte may cause denaturation (Siddle, 1985; Tijssen, 1985) therefore polyclonal
antibodies have not been widely used in two-site immunometric assays.
1.4 MONOCLONAL ANTIBODIES
Immunization stimulates antigen-specific B cells to proliferate and mature into
antibody-secreting plasma cells, each of which produces antibody specific for a single
epitope. Most immunogens have a large number of different epitopes and therefore
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stimulate many different B cells, producing a polyclonal antiserum that contains a
range of antibodies with different specificities, affinities and isotypes (Roitt et
al., 1985). Individual animals respond differently to the same immunogen, while
subsequent antigen contact alters the spectrum of antibodies secreted by any one animal
(Campbell, 1984; Tijssen, 1985). The properties of polyclonal antisera are therefore
extremely variable, while the supply of a particular quality of antiserum is strictly
limited to the volume obtained in one bleed.
The development of hybridoma technology (Kohler and Milstein, 1975, 1976)
allowed the production of monoclonal antibodies, which are homogeneous with respect
to specificity, affinity and isotype because each MAb is secreted by an isolated clone
of cells. Plasma cells have a finite lifespan and will not grow in culture but can be
fused with myelomas, which are plasma cell tumours, to produce hybridoma cell lines
that secrete antibody and will grow indefinitely (Galfre and Milstein, 1981;
Campbell, 1984). However, it is important to select a myeloma which does not itself
produce antibody, or the resulting hybridomas would secrete mixed-chain antibodies in
addition to the desired specificity (Galfre and Milstein, 1981) thus necessitating
immunoaffinity purification. After cell fusion, a selection procedure ensures that the
only cells to survive are the hybridomas, which are then separated to produce
monoclonal cell lines that can be grown either in vitro or in vivo (Galfrb and
Milstein, 1981).
MAbs usually have lower binding affinities than polyclonal antisera that are
raised against the same antigen (Siddle, 1985; Ehrlich et al., 1982) therefore they
make poor competitive immunoassay reagents. However, MAbs are ideal for
immunometric assays because they are monospecific, available in unlimited quantities
(Baker et al., 1985; Siddle, 1985), and can be purified by simple methods since they
are the only immunoglobulins in spent culture supernatant and can comprise up to 90%
of the antibody in ascitic fluid (Galfre and Milstein, 1981). Monospecificity is
advantageous in assays that have to distinguish substances with closely-related
structures, such as AVP and LVP (Table 5.3), but is a disadvantage for analytes
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which exhibit polymorphism since MAb-based assays may not recognize all forms of
the analyte (Campbell, 1984; Siddle, 1985). Unfortunately, MAbs may also bind to
epitopes on unrelated substances that could cause significant assay interference
(Campbell, 1984), a problem which does not occur with polyclonal antisera, whose
specificities are determined by the combined reactions of many different antibodies
(Goding, 1986). MAb-based assays are therefore prone to unexpected cross-reactions
which can only be eliminated by careful MAb selection, a problem that is
counter-balanced by the reagent standardization that MAbs permit.
1.5 AIMS OF THE PROTECT
AVP and ANP act together to control the fluid balance of the body. The
neonatal kidney responds to these hormones (Birk et al., 1989; Kojima et al., 1990)
although renal function is not fully-developed at birth (Bell and Oh, 1979). The urine
concentrating capacity is initially low (Aperia et al., 1983; Rees et al., 1984a;
Wiriyathian et al., 1986) and gradually increases over the first few months of life
(Svenningsen and Aronson, 1974; Aperia et al., 1983; Sulyok, 1988). However, healthy
neonates have a good diluting capacity so they can excrete excess water efficiently
(Aperia et al., 1983). In contrast, premature and sick infants often have fluid balance
problems that can decrease their survival prospects (Mcintosh and Smith, 1985).
Clinical management of these individuals is difficult because their symptoms can be
misinterpreted. For example, while hypernatraemia is usually a result of inadequate
fluid intake, hyponatremia might be caused by either sodium loss or water retention,
and incorrect treatment would worsen the infant's condition (Bell and Oh, 1979; Rees
et al., 1984b). Premature infants have a particularly low capacity to compensate for
inappropriate fluid and electrolyte administration (Bell and Oh, 1979).
Major haemodynamic changes occur at birth, when the lungs replace the
placenta as the site of gaseous exchange. In the normal infant, heart rate and cardiac
output increase, pulmonary vascular resistance decreases, and the ductus arteriosus and
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foramen ovale close so that the blood is directed through the lungs before delivery to
the peripheral circulation (Birk et alv 1989). These changes increase the left atrial
pressure, causing raised plasma ANP concentrations in the first few days of life
(Tulassay et al., 1987; Ito et al., 1988; Kikuchi et al., 1988), and are probably
responsible for the diuresis and natriuresis that cause postnatal contraction of the
extracellular fluid (Birk et al., 1989).
In the premature infant, the ductus arteriosus may remain open, or may reopen,
so that blood flows from the aorta into the pulmonary artery causing pulmonary
hypertension, further left atrial stretch and high plasma ANP concentrations
(Andersson et al., 1987) that correlate significantly with the severity of ductal blood
flow (Pesonen et al., 1990). However, glomerular immaturity blunts the postnatal
increase in glomerular filtration rate (Aperia et al., 1981) and so decreases the
efficiency of ANP-induced water excretion. Over-hydration increases the risk that
premature infants will develop patent ductus arteriosus, congestive heart failure (Bell
et al., 1980), respiratory distress syndrome (Stegner et al., 1987) and bronchopulmonary
dysplasia (Brown et al., 1978).
Infants with respiratory distress syndrome usually receive positive-pressure
ventilation. The increased thoracic pressure causes decreased venous return to the
heart and so stimulates the baroreceptors to promote AVP secretion (Rees et al.,
1984a; Wiriyathian et al., 1986; Stegner et al., 1987) that correlates with the
ventilation pressure (Stegner et al., 1987) and may cause water retention (Bell and
Oh, 1979; Stegner et al., 1987). However, tubular function develops later than
glomerular function so premature infants have a lower capacity than full-term infants
to carry out AVP-induced water reabsorption (Aperia et al., 1981). Ventilation was
also reported to compress the atria, decreasing stretch receptor stimulation and thus
ANP secretion in volume-expanded individuals, which would tend to further inhibit
water excretion although the ANP concentrations did not fall to normal levels
(Leithner et al., 1987). Kojima et al. (1990) reported elevated plasma AVP and ANP
concentrations in ventilated infants with bronchopulmonary dysplasia, and suggested
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that ANP is raised in an attempt to compensate for water retention induced by the
AVP that is secreted in response to pulmonary abnormalities.
Inappropriate AVP secretion is common in premature infants, occurring in
response to non-osmotic stimuli such as birth asphyxia (Wiriyathian et al., 1986;
Smith et al., 1990), respiratory distress, pneumothorax, intracranial haemorrhage
(Rees et al., 1984a; Wiriyathian et al., 1986; Sulyok, 1988) or meningitis (Rees et al.,
1980; Sulyok, 1988). The highest AVP concentrations occur in the most severely ill
infants (Stegner et al., 1987; Smith et al., 1990), who are therefore least able to
excrete a water load. Birth asphyxia causes particularly high AVP concentrations
(Wiriyathian et al., 1986; Smith et al., 1990) but may be complicated by tubular
damage that decreases the urine concentrating capacity (Svenningsen and Aronson,
1974; Aperia et al., 1983) or by glomerular damage which decreases urine output
(Smith et al., 1990).
Relatively little is known about the concentrations of AVP and ANP in
neonatal plasma, or about the way in which these hormones influence the fluid
balance and cardiovascular systems of premature and sick infants, because most assays
require larger samples than can be obtained from small infants. Urinary measurements
have provided most of the published AVP data, although there is no correlation
between urinary and plasma AVP concentrations in infants with renal damage (Smith
et al., 1990). All reported AVP and ANP assays require long incubation periods, while
sample extraction can increase the total assay time significantly. The current assays
are therefore unsuitable for diagnostic purposes because the condition of sick and
premature infants changes rapidly. The fastest AVP assay takes 26 hours to produce a
result from 2 ml plasma (Burd et al., 1984), while the fastest ANP assay takes
19 hours and requires 0.5 ml plasma (Iinuma et al., 1987). Although these assays
measure physiological peptide concentrations, the sample volumes are too large and
the incubations too long to be clinically-useful in the context of neonatal care.
There is a need for rapid assays that can measure physiological concentrations
of AVP and ANP in small volumes of unextracted plasma within a few hours of
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sampling. These assays would facilitate research on the effects of AVP and ANP
in sick and premature infants, and could ultimately allow more sophisticated
management of fluid balance than is currently possible. Immunometric assays could
provide the necessary speed while MAbs ensure fine specificity and continuity of
reagent supplies. The aims of this project were therefore:
1. To generate MAbs specific for AVP and ANP.
2. To determine whether two-site immunometric assays for AVP and ANP
could be developed with appropriate pairs of MAbs.
3. To determine whether these assays would have the sensitivity required to






Mice (BALB/c) and rats (Sprague-Dawley and Wistar strains) were supplied
by Bantin and Kingman, Hull, and housed in the Medical Faculty Animal Area.
2.1.2 TISSUE CULTURE MEDIA
Foetal calf serum, 200 mM L-glutamine, HAT supplement, HT supplement,
High Protein Hybridoma Medium, 50 mM 2-mercaptoethanol, penicillin-streptomycin,
RPMI1640 with 20 mM HEPES without L-glutamine, RPMI 1640 without HEPES, and
100 mM sodium pyruvate were obtained as sterile solutions from Gibco BRL, Paisley.
Acridine orange, ethidium bromide, polyethylene glycol 4000 and Oxoid
Dulbecco 'A' PBS tablets were obtained from BDH Laboratory Supplies, Glasgow.
Dimethyl sulphoxide was supplied by Sigma Chemical Company, Poole.
2.1.3 IMMUNOCHEMICALS
A Mouse Monoclonal Antibody Isotyping Kit was supplied by Amersham
International, Amersham.
Bovine (new-born calf) serum was obtained from Gibco BRL, Paisley.
Immunopure streptavidin-HRP conjugate was supplied by Pierce, Rockford,
Illinois, USA.
Normal rabbit serum, donkey anti-rabbit IgG HRP conjugate and sheep
anti-mouse y-globulin antiserum were provided by the Scottish Antibody Production
Unit, Carluke.
Rabbit (IgG fraction of antiserum) anti-mouse IgG (whole molecule) HRP
conjugate, affinity-isolated goat anti-mouse 'polyvalent immunoglobulins' HRP
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conjugate and affinity-isolated sheep anti-mouse IgG (whole molecule) HRP conjugate
were obtained from Sigma Chemical Company, Poole.
Rabbit polyclonal antibodies (anti-AVP serum, anti-ANP serum, anti-PAG
serum, TGI antiserum, affinity-purified anti-AVP-thyroglobulin and affinity-purified
anti-PAG) were provided by Dr. A. Smith, Department of Child Life and Health.
The murine anti-ANP MAbs ESA 4, ESA 5 and ESA 9 were a gift from
Dr. C. Prowse, Edinburgh and South-East Scotland Blood Transfusion Service.
2.1.4 PEPTIDE HORMONES AND ANALOGUES
125
I-ANP (human) was supplied by Amersham International, Amersham.
AVP, dCDAVP, dDAVP, dNMeAVP, Hep, OT, PAG and tGLVP were obtained
from Ferring AB, Malmo, Sweden.
ANP (human), AVP (acetate salt), AVT (acetate salt) and LVP (acetate salt)
were supplied by Sigma Chemical Company, Poole.
2.1.5 OTHER REAGENTS
125
Na I was obtained from Amersham International, Amersham.
Biotinyl-e-aminocaproic acid N-hydroxysuccinimide ester (Biotin-X-NHS) was
obtained from Calbiochem Novabiochem (UK) Ltd., Nottingham.
Pre-packed PD-10 columns, Protein A-Sepharose CL-4B, Sephacryl S-300,
Sephacryl S-500, Sephadex G-25 and Sephadex G-50 were supplied by Pharmacia,
Milton Keynes.
N-hydroxysulphosuccinimide and Iodogen came from Pierce, Rockford, Illinois.
Non-fat dried milk was purchased from J. Sainsbury Ltd., London.
Bovine albumin (fraction V), L-cysteine hydrochloride (anhydrous),
l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride, Freund's adjuvant
(complete and incomplete), glycerol, hydroxylamine (hydrochloride),
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2-iminothiolane (hydrochloride), keyhole limpet haemocyanin, 2-mercaptoethanol,
m-maleimidobenzoic acid N-hydroxysuccinimide ester, N,N-dimethylformamide,
polyethylene glycol 8000, pristane (2,6,10,14-tetramethylpentadecane), Rivanol
(6,9-diamino-2-ethoxyacridine lactate, monohydrate), sodium borohydride, sodium
m-periodate, streptavidin, 3,3',5,5'-tetramethylbenzidine, thyroglobulin (bovine),
Triton X-100 and Tween 20 (polyoxyethylenesorbitan monolaurate) were obtained from
Sigma Chemical Company, Poole.
Alhydrogel (aluminium hydroxide gel, alum) came from Superfos Speciality
Chemicals, Vedback, Denmark.
All other chemicals were of the highest grade available.
2.1.6 DISPOSABLE EQUIPMENT
Membrane-bottomed 96-well plates and a Single Vacuum Manifold were
supplied by Amersham International, Amersham
Sterilin RT30 polystyrene test tubes (75 x 12 mm) were supplied by BDH
Laboratory Supplies, Glasgow.
Immulon 1 and Immulon 2 flat-bottomed 16-well MicroELISA Duo-strips and
Immulon 4 16-well MicroELISA Divida-strips were supplied by Dynatech Laboratories,
Billingshurst.




The main buffers used in this project were as follows:
BUFFER COMPOSITION
A 0.25 M tri-sodium citrate/citric acid, pH 4.0
B 0.02 M sodium acetate/acetic acid, pH 5.0
C 0.1 M sodium acetate/acetic acid, pH5.0
D 0.1 M sodium acetate/citric acid, pH6.0, 5mM EDTA, 0.02% Tween20
E 0.05 M Na2HP04/NaH2P04, pH 7.0
F 0.05 M Na2HP04/NaH2P04, pH 7.0, 2% bovine serum
G 0.05 M Na2HP04/NaH2P04, pH7.0, 2% bovine serum, 3% Tween20
H 0.05 M Na2HP04/NaH2P04, pH 7.0, 1% Tween20
I 0.5 M Na2HP04/NaH2P04, pH 7.4
J 0.05 M Na2HP04/NaH2P04, pH 7.5
K 0.05 M Na2HP04/NaH2P04, pH 7.5, 0.9% NaCl
L 0.05 M Na2HP04/NaH2P04, pH 7.5, 0.9% NaCl, 1% BSA, 0.1% Tween20
M 0.05 M Na2HP04/NaH2P04, pH 7.5, 0.9% NaCl, 1% BSA, 0.5% Tween 20
N 0.05 M Na2HP04/NaH2P04, pH 7.5, 0.9% NaCl, 0.5% Tween 20
O 0.25 M Na2HP04/NaH2P04, pH 7.5
P 0.25 M Tris/HCl, pH8.5, 2% bovine serum
Q 0.25 M Tris/HCl, pH8.5, 2% bovine serum, 1% Tween 20
R 0.25 M Tris/HCl, pH8.5, 2% bovine serum, 4% Tween 20
S 0.25 M Tris/HCl, pH8.5, 1% Tween 20
T 0.05 M NaHC03 /NaOH, pH 9.0
U 0.05 M NaHC03 /NaOH, pH 9.0, 0.5% Tween 20
V 0.1 M NaHC03/NaOH, pH 9.0
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2.2 MONOCLONAL ANTIBODY PRODUCTION
2.2.1 PREPARATION OF IMMUNOGENS
Small peptides, such as AVP and ANP, are poor immunogens so they are
usually conjugated to large carrier proteins to increase their immunogenicity. Bovine
thyroglobulin and KLH were the carrier proteins used in this project.
2.2.1.1 AVP-Thvroglobulin (EDC Method)
AVP was conjugated to bovine thyroglobulin essentially by the method of
Skowsky and Fisher (1972b):
0.86 mg AVP and 4.3 mg thyroglobulin were dissolved in 0.3 ml distilled water.
0.1 ml 4 mg/ml l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC)
was added, followed by 2 pi 10 M NaOH which neutralized the solution and
prevented precipitation of thyroglobulin. The reaction mixture was vortexed and
incubated at room temperature for 24 hours, then 0.4 ml 1 M hydroxylamine was added.
After incubation for a further 6 hours, 0.1 ml aliquots were stored at -20°C.
2.2.1.2 AVP-Thyroglobulin (Enhanced EDC Method)
AVP was also conjugated to thyroglobulin in the presence of
N-hydroxysulphosuccinimide, which has been reported to enhance the coupling yield
of water-soluble carbodiimide-mediated reactions (Staros et al., 1986).
4.3 mg AVP and 21.5 mg thyroglobulin were dissolved in 1 ml distilled water.
0.5 ml 20 mM N-hydroxysulphosuccinimide and 5 pi 10 M NaOH were added, followed
by 0.5 ml 3 mg/ml EDC. The mixture was incubated at room temperature for 24 hours,
then 2 ml 1 M hydroxylamine was added. After incubation for a further 6 hours,
0.1 ml aliquots were stored at -20°C.
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2.2.1.3 AVP /LVP-KLH
A mixture of AVP and LVP was coupled to KLH by a modification of the
method of Lerner et al. (1981). m-Maleimidobenzoic acid N-hydroxysuccinimide ester
(MBS), a heterobifunctional reagent, was used to link the primary amine groups of
KLH to free sulphydryl groups that had been introduced into AVP and LVP.
Activation of KLH by MBS
10 mg KLH was dissolved in 625 pi 0.1 M sodium phosphate buffer, pH 8.0,
0.9% NaCl. 88 pi 2% MBS in DMF was added dropwise and the mixture was stirred
at room temperature for 20 minutes. Unreacted MBS was removed by gel filtration on a
Pharmacia PD-10 column equilibrated with degassed 0.1 M sodium phosphate buffer,
pH 6.7, 0.9% NaCl, 5 mM EDTA (PBS-EDTA). The buffer contained EDTA to chelate
oxidising metals which might interfere in the second stage of the reaction.
Thiolation of AVP and LVP
Neither AVP nor LVP contained free sulphydryl groups therefore these were
introduced using Traut's reagent, 2-iminothiolane (Traut et al., 1973; Jue et al., 1978).
All buffers were degassed to prevent oxidation of the sulphydryl groups.
A stock solution of 20 mg/ml 2-iminothiolane was prepared in Buffer C. AVP
(0.86 mg) was dissolved in 194 pi PBS-EDTA and mixed with 6 pi 20 mg/ml
2-iminothiolane. Simultaneously, 4.3 mg LVP was dissolved in 938 pi PBS-EDTA and
mixed with 62 pi 20 mg/ml 2-iminothiolane. Both reactions were incubated on ice
for 30 minutes.
Conjugation of m-maleimidobenzoyl-KLH to thiolated AVP and LVP
Immediately after their preparation, 5 mg m-maleimidobenzoyl-KLH was
mixed with the thiolated AVP and LVP. The pH was adjusted to 7.0-7.5, using
10 M NaOH, then the incubation mixture was stirred at room temperature for 3 hours.
0.1 ml aliquots were stored at -20°C.
Unconjugated vasopressin was not dialysed away because it was reported that
antibodies could be raised against unconjugated AVP (Roth et al., 1966b; Wu and
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Rockey, 1969) and LVP (Roth et al., 1966a; Bichet et al., 1986).
2.2.1.4 ANP-Thyroglobulin
ANP-thyroglobulin conjugate, a gift from Dr. C. Prowse, had been prepared by
the following method :
Bovine thyroglobulin was dissolved in distilled water then dialysed overnight
against 0.05 M sodium phosphate buffer, pH 7.2, 0.1 M NaCl, at 4°C. 4 ml 2.1 mg/ml
thyroglobulin was mixed with 6 mg EDC, added dropwise to 1 ml 1 mg/ml ANP in
0.15 M NaCl, and stirred for 15 minutes. The mixture was incubated overnight at 4°C,
then an additional 6 mg EDC was added whilst stirring. After incubation at room
temperature for 2 hours, the mixture was dialysed overnight against 0.15 M NaCl
at 4°C, then stored at -20°C in 0.25 ml aliquots.
2.2.2 IMMUNIZATION OF MICE
All immunogens were injected intraperitoneally.
Twelve-week-old female BALB/c mice were primed with immunogen
emulsified in an equal volume of Freund's complete adjuvant so that a drop floated on
water as a discrete creamy-white globule which did not disperse. Each mouse was
given either 50 pg AVP or 5 pg ANP, conjugated to carrier protein, in a total volume
of 0.1-0.2 ml. After 5 weeks, they were boosted with immunogen emulsified in Freund's
incomplete adjuvant then, after a further 5 weeks, with immunogen in alum
(aluminium hydroxide gel).
Tail-bleeding was carried out 14 days later. The mice were warmed in a
ventilated box positioned over a 25 W light bulb, until their tail veins were
well-dilated. Each mouse was restrained in a 50 ml polypropylene conical centrifuge
tube, with its tail protruding through a 0.5 cm-wide slot, then one of the lateral tail
veins was cut with a clean razor blade. Blood was collected into heparinized
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haematocrit tubes by capillary action, then the cells were removed by centrifugation
in a haematocrit centrifuge for 1 minute. The serum was assayed for anti-peptide
antibody by RIA or ELISA (Section 2.2.4).
Further boosts of immunogen in alum were given, if necessary, at intervals of
at least 5 weeks until antibody titres of more than 1/3000 were obtained. Three days
before cell fusion, the mice received a final boost of immunogen in Dulbecco 'A' PBS.
2.2.3 CELL CULTURE
All cells were cultured under sterile conditions in a 5% COz/air atmosphere
with 90% humidity, at 37°C. Tissue culture flask caps were kept loose to allow for
gas exchange.
2.2.3.1 Preparation of Culture Media
Foetal calf serum (FCS) was heat-inactivated by incubation at 56°C for
30 minutes (Campbell, 1984). All medium supplements were stored at -20°C, except
sodium pyruvate which was stored at 4°C.
500 ml RPMI1640 with 20 mM HEPES without L-glutamine was supplemented
with 5 ml 200 mM L-glutamine, 2.5 ml penicillin-streptomycin solution (containing
10,000 IU/ml penicillin and 10,000 pg/ml streptomycin), 5 ml 100 mM sodium pyruvate
and either 25 ml, 50 ml or 75 ml heat-inactivated FCS, to produce 5%, 10% or
15% FCS medium, respectively.
HAT medium, which contained 100 pM hypoxanthine, 0.4 pM aminopterin and
16 pM thymidine, was prepared by the addition of 10 ml HAT supplement to
500 ml 15% FCS medium. HT medium contained 100 pM hypoxanthine and
16 pM thymidine, but no aminopterin, and was prepared by the addition of 10 ml HT
supplement to 500 ml 15% FCS medium.
Serum-free medium was prepared by the addition of 5 ml 200 mM L-glutamine,
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2.5 ml penicillin-streptomycin solution and 0.5 ml 50 mM 2-mercaptoethanol to
500 ml High Protein Hybridoma Medium. Sodium pyruvate was not required.
Confirmation of culture medium sterility
Freshly-prepared culture medium was stored at room temperature, in the dark,
for 24 hours. A few drops were added to 4 ml sterile nutrient broth and incubated
at 37°C for 7-10 days. Sterility was confirmed if the nutrient broth remained clear,
whereas contamination caused turbidity. Severely contaminated media were discarded
but slight contamination could be removed by passage through a bottle top filter
(0.2 pm membrane).
Prepared culture media were stored at -20°C until sterility was confirmed.
Thawed media were discarded after 4 weeks at 4°C because the L-glutamine was
unstable (Goding, 1986). All media were warmed to 37°C in a water bath before use.
Multiple cultures of any cell line were fed from different bottles of medium to
decrease the risk of losing all the cells to microbial contamination.
2.2.3.2 Cell Counting
Viable cell numbers were estimated with a vital stain which consisted of
5 pg/ml acridine orange and 5 pg/ml ethidium bromide in Dulbecco'A'PBS (Parks et
al., 1979). The stain solution was stored in the dark at 4°C.
10 pi stain and 10 pi cell suspension were mixed and immediately transferred
to a haemocytometer chamber (improved Neubauer type) for counting. When viewed
under a fluorescence microscope, live cells were green and dead cells were orange.
The ruled area of the haemocytometer contained nine 1 mm2 sections and the
chamber was 0.1 mm deep therefore the volume of each section was 0.1 pi. The viable
cell concentration was calculated from:
X = Y x Z x 104
where X = number of live cells/ml, Y = number of live cells/section and Z = dilution
factor of the cells in stain (usually 2).
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2.2.3.3 Preparation of Mixed-Thvmocvte Culture-Conditioned Medium (MTM)
MTM was kindly prepared by Dr. L. Micklem, according to the method of
Micklem et al. (1987):
A Sprague-Dawley rat and a Wistar rat (5-6-week-old females) were killed
by cranial impact. The fur was soaked with 70% ethanol then the skin was cut open
with sterile scissors. A fresh set of sterile instruments was used to open the thoracic
cavity and remove the thymus from each rat.
A cell suspension was prepared by homogenization of the thymi in
5 ml Dulbecco 'A' PBS. The cells were washed three times with 25 ml aliquots of
Dulbecco 'A' PBS, collected by centrifugation (200 x g for 10 minutes), and finally
resuspended in 15% FCS medium at 5 x 106 cells/ml. After incubation for 48 hours, in
75 cm2 tissue culture flasks, the cells were removed by centrifugation (2000 x g for
10 minutes). The supernatant (MTM) was filtered through a 0.2 pm membrane then
stored in 10 ml aliquots at -20°C.
2.2.3.4 Preparation of Myeloma Cells
The NS-0 myeloma cell line, which was derived from BALB/c mice and does
not express immunoglobulin chains (Galfre and Milstein, 1981), was the fusion partner
used in this work.
Three days before cell fusion, a vial of NS-0 cells was thawed at 37°C and
the contents immediately transferred into a 75 cm2 tissue culture flask containing
30 ml 10% FCS medium. After incubation for 5-6 hours, 20 ml 5% FCS medium was
added. As soon as the cells were confluent (usually by the next day), the culture was
expanded by division. A sharp smack dislodged the cells from the plastic surface,
half of the resulting cell suspension was transferred to a fresh 75 cm flask, then
25 ml 5% FCS medium was added to each flask. This procedure was repeated daily to
ensure that the cells were in exponential growth.
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On the day of cell fusion, NS-0 cells were harvested by centrifugation (100 x g
for 8 minutes) then washed twice by resuspension in sterile Dulbecco 'A' PBS followed
by centrifugation. The final cell pellet was resuspended in 10 ml Dulbecco 'A' PBS then
a 10 pi sample was removed for counting.
2.2.3.5 Preparation of Spleen Cells
Three days after receiving a final intraperitoneal boost of immunogen in PBS,
the immunized mouse was killed by cervical dislocation. Its fur was soaked with
70% ethanol then the abdominal skin was cut open with sterile scissors. A fresh set
of sterile instruments was used to cut open the left side of the peritoneal cavity and
remove the spleen with as little connective tissue as possible.
A cell suspension was prepared by homogenizing the spleen in 5 ml sterile
Dulbecco 'A' PBS. After allowing any undisrupted tissue to settle out, the cells were
transferred into a sterile plastic universal container, washed three times with
25 ml aliquots of Dulbecco 'A' PBS and collected by centrifugation (200 x g for
8 minutes). The final cell pellet was resuspended in 10 ml Dulbecco 'A' PBS then a
10 pi sample was removed for counting.
2.2.3.6 Preparation of 50% PEG 4000
One day before cell fusion, 1 g PEG 4000 was autoclaved in a glass bijou bottle.
While the PEG was still hot, 1 ml RPMI 1640 without HEPES was added and mixed
thoroughly. The resulting solution was stored in the dark at room temperature. Before




This method was a modification of that of Galfre and Milstein (1981):
Spleen and NS-0 cells were mixed together (1.2 x 108 cells, at a spleen : NS-0
ratio of either 2:1 or 4:1) then centrifuged at 200 x g for 5 minutes. The supernatant
was carefully decanted (complete removal was essential) then the cell pellet was
loosened by gentle vibration. 1 ml 50% PEG 4000 was added and the cells were
resuspended by gentle swirling. At this point cell agglutination could be seen. After
centrifugation (80 x g for 5 minutes), 5 ml RPMI 1640 without HEPES was carefully
added over 1-2 minutes without disturbing the cell pellet. Gentle swirling for
3-4 minutes gradually diluted the PEG solution and resuspended the cells, which were
then collected by centrifugation (150 x g for 5 minutes). The supernatant was discarded
then 5 ml HAT/MTM medium (from a mixture of 100 ml HAT medium and 20 ml MTM)
was slowly added without disturbing the cell pellet. After 7 minutes, the cells were
resuspended by gentle swirling, persistent clumps were dispersed by pipetting, and the
remaining 115 ml HAT/MTM medium was added to give a final concentration of
1 x 106 cells/ml. The cell suspension was distributed amongst the central 60 wells
(0.2 ml/well) of each of ten 96-well flat-bottomed tissue culture plates. The outermost
wells were not used because they had a higher risk of contamination and were also
prone to evaporation.
2.2.3.8 Cell Fusion with In Vitro-Boosted Spleen Cells
Spleen homogenates often contained more cells than were required for one
fusion. The surplus cells were boosted in vitro by culture with antigen (Reading, 1982)
because in vitro stimulation of immune spleen cells was reported to enhance the
efficiency of antigen-specific hybridoma production (Erich et al., 1989).
Spleen cells were cultured in MTM/FCS medium (3 parts MTM : 7 parts
15% FCS medium) containing either AVP (2 (ig/ml) or ANP (1 pg/ml), in a
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25 cm2 tissue culture flask (5 x 106 cells/ml), and harvested after 4 days. Any cells
which remained attached to the plastic were collected after EDTA treatment.
5 ml 0.02% EDTA in Dulbecco 'A' PBS was added to the flask, then 30-60 seconds later
the adherent cells could be resuspended by a sharp smack. The in y/'fra-boosted spleen
cells were collected by centrifugation, washed, and fused with NS-0 cells as above.
2.2.3.9 Culture of Nascent Hybridomas
The plates of fused cells were incubated undisturbed for 5 days (by which time
unfused NS-0 cells were dead), then examined for hybridoma growth with an inverted
phase-contrast microscope. One drop of HAT medium was added to each well on day
five and at intervals thereafter as necessary. Exchange feeding (where half of the
culture medium was replaced with fresh HAT medium) was carried out on any wells
which had been undisturbed for more than 21 days.
Antibody screening began 10-14 days after cell fusion when large hybridoma
colonies occupied about 25% of the area of their culture wells. Supernatant samples
were removed aseptically, replaced with fresh HAT medium, and assayed for
anti-peptide antibody by RIA or ELISA (Section 2.2.4). Hybridoma cultures which
produced positive assay results were immediately cloned and also expanded to produce
cells for cryopreservation.
2.2.3.10 Dilution Cloning
Hybridoma cells were resuspended by repeated pipetting of the culture well
contents. A 10 pi sample was diluted to 1 ml in HT medium supplemented with
10% MTM, while a second 10 pi sample was taken for cell counting. The cells in
HT/MTM were further diluted to 25, 5 and 2.5 cells/ml, distributed into a 96-well
tissue culture plate (0.2 ml/well, 30 wells/concentration), incubated undisturbed for
7 days, then examined for clonal growth. The number of clones in each well was
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recorded before feeding (which often dispersed the loosely-adherent cell clusters). One
drop of HT medium was added to each well. Wells containing single clones were
screened for antibody production when they were sufficiently well-grown.
Three positive clones were selected for expansion and cryopreservation. The
best clone was subcloned as described above, except that 15% FCS medium containing
10% MTM was used. Three subclones were selected for expansion and cryopreservation.
The best subclone was used for bulk antibody production, either in culture or in ascites.
2.2.3.11 Expansion of Hybridoma Cultures
Hybridoma cultures from 96-well plates were resuspended by repeated
pipetting then transferred into 0.5 ml medium containing 10% MTM, in a 24-well tissue
culture plate. (Parent hybridomas were transferred into HT medium, clones and
subclones into 15% FCS medium.) The cultures were fed 0.5 ml medium, without MTM,
at 3-4 day intervals. As soon as a culture occupied more than half the area of its
well, the cells were resuspended and transferred into 5 ml 15% FCS medium in a
25 cm2 tissue culture flask, then fed as required with 10% FCS medium.
At least three flasks were set up for each cell line. The cells were either
harvested and stored in liquid nitrogen, or used for bulk antibody production.
2.2.3.12 Crvopreservation of Cell Lines
Cell lines were stored at all stages of preparation (i.e. parent hybridoma,
clones and subclones) to insure against loss resulting from contamination or overgrowth
by non-secreting variants (Galfre and Milstein, 1981).
Exponentially-growing cells were dislodged from the surface of the flask by a
sharp smack, then harvested by centrifugation (100 x g for 8 minutes). The supernatant
was decanted and the cell pellet loosened by gentle vibration. The cells were
resuspended in ice-cold freezing medium (90% FCS, 10% DMSO), at about
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4 x 106 cells/ml, then 0.5 ml aliquots were transferred into chilled freezing vials and
immediately placed in the vapour phase above liquid nitrogen. After 24 hours, the
vials were transferred into the liquid nitrogen for long-term storage (Reading, 1982).
NS-0 myeloma cells were stored in 1 ml aliquots.
2.2.3.13 Recovery of Hybridomas from Liquid Nitrogen
Frozen cells were thawed rapidly in a 37°C water bath then immediately
transferred into 10 ml 15% FCS medium in a 25 cm2 tissue culture flask. Some cell lines
did not readily recover from freezing therefore, as a precaution, 2 ml of the cell
suspension was transferred into a second flask containing 1 ml MTM. Once cell growth
was established the flasks were fed with 10% FCS medium.
2.2.3.14 Bulk Antibody Production in Ascites
Ten-week-old male BALB/c mice were primed by intraperitoneal injection of
0.3 ml pristane (2,6,10,14-tetramethylpentadecane), 10 days and 3 days before injection
of hybridoma cells.
Monoclonal cell lines were grown in 10% FCS medium, harvested by
centrifugation (100 x g for 8 minutes), washed, and resuspended in Dulbecco 'A' PBS
at 2.5 x 106 cells/ml. Each mouse received 5 x 10s cells intraperitoneally. Ascites
tumours developed in 2-3 weeks. The ascitic fluid was tapped at 1-2 day intervals and
collected into heparinized tubes. Cells were removed by centrifugation (1000 x g for
10 minutes) then sodium azide (final concentration 0.1%) was added to the ascitic
fluid, which was stored at 4°C.
2.2.3.15 Bulk Antibody Production in Culture
Monoclonal cell lines were cultured in 10% FCS medium until exponential
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growth was established, then transferred into 75 cm2 (and subsequently 150 cm2) tissue
culture flasks. The culture volume was doubled every 1-2 days, using 5% FCS medium,
then the cells were left to grow to exhaustion, which usually took 10-14 days after
the final addition of medium. The cells were removed by centrifugation (2000 x g for
10 minutes) then sodium azide (final concentration 0.1%) was added to the
supernatant, which was stored at 4°C.
2.2.4 SCREENING ASSAYS
All incubations were carried out at room temperature.
2.2.4.1 AVP-Capture ELISA
Rabbit TGI antiserum (Smith and Mcintosh, 1986) was diluted 1/10,000 in
Buffer T then adsorbed onto MicroELISA Duo-strips (100 pi/well) by overnight
incubation. Each well was rinsed three times with Buffer T, incubated for 30 minutes
with 400 pi 1% BSA in Buffer T to block remaining protein-binding sites, rinsed once
with Buffer T and dried by evaporation. The coated Duo-strips were incubated with
50ng/ml AVP in Buffer L (lOOpl/well) for 16 hours, then sealed and stored at -20°C,
or used immediately, after rinsing with Buffer K.
The wells were incubated with 100 pi hybridoma culture supernatant, HAT
medium (negative control) or immune mouse serum (1/1000 dilution in Buffer L, positive
control) for 16 hours, then with 100 pi rabbit anti-mouse IgG (whole molecule) HRP
conjugate (1 /200 dilution in Buffer L) for 1 hour. Unbound HRP conjugate was removed
by five washes with Buffer D before the addition of 100 pi freshly-prepared substrate
(100 pg/ml 3,3',5,5'-tetramethylbenzidine, 0.002% H202 in Buffer B). Colour development
was stopped after 30 minutes by the addition of 50 pi 2 M H2S04. The absorbance




Either 1 Jig/ml AVP or 0.1 pg/ml ANP, in Buffer K, was adsorbed onto
MicroELISA Duo-strips (100 pi/well) by overnight incubation. Unbound antigen was
removed by three washes with Buffer K then the wells were dried, sealed and stored
at -20°C until required.
Hybridoma culture supernatant, HAT medium (negative control) and immune
mouse serum (positive control) were diluted 1/2, 1/2 and 1/2000, respectively, with
Buffer L then duplicate 100 pi samples were incubated in the wells for 16 hours.
Incubation with rabbit anti-mouse IgG (whole molecule) HRP conjugate, and the
remainder of the assay, was carried out as described for the AVP-capture ELISA.
2.2.4.3 Radioimmunoassay with PEG Separation (PEG-RIA)
Duplicate 100 pi samples of hybridoma culture supernatant, HAT medium or
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immune mouse serum (diluted 1/1000 in Buffer L) were incubated with 50 pi I-AVP
(7 pg, 1700pCi/pg, in Buffer L) in RT30 tubes for 16 hours, then antibody-bound and
free tracer were separated by the method of Desbuquois and Aurbach (1971).
50 pi bovine serum and 500 pi 25% (w/v) PEG 8000, in distilled water, were added to
the incubation mixture, vortexed and immediately centrifuged at 2000 x g for
30 minutes. The supernatant was decanted and the inverted tubes were drained on
tissue paper for at least 30 minutes, then the radioactivity of the precipitate was
determined in a gamma counter.
2.2.4.4 Radioimmunoassay with Second Antibody Separation (SAM-RIA)
100 pi hybridoma culture supernatant, HAT medium or immune mouse serum
(diluted 1/1000 in Buffer L) was incubated with 50 pi 125I-AVP (7 pg, 1700pCi/pg, in
Buffer L) for 16 hours, then 50 pi SAM-S-500 solid phase (25% (settled volume) slurry
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in Buffer R) was added. The mixture was agitated on an orbital shaker for 1 hour
then bound and free tracer were separated by the sucrose layering technique (Wright
and Hunter, 1983). 1 ml Buffer S was added and the solid phase was allowed to settle
for 5 minutes, then 2 ml 10% (w/v) sucrose in Buffer S was pumped beneath the
mixture. The solid phase settled to the bottom of the tube then unbound tracer, and
most of the sucrose, was aspirated. Sucrose layering was repeated once, then the
radioactivity of the solid phase was determined in a gamma counter.
2.3 PREPARATION OF ASSAY REAGENTS
2.3.1 PURIFICATION OF MONOCLONAL ANTIBODIES
Before reagent preparation, MAbs were concentrated and partially purified by
sodium sulphate precipitation from ascitic fluid or by PEG 8000 precipitation from
culture supernatant. When required, highly purified MAb was isolated from culture
supernatant by affinity chromatography on Protein A-Sepharose.
2.3.1.1 Sodium Sulphate Precipitation
The solubility of sodium sulphate is very temperature-dependent (Tijssen, 1985)
therefore antibody precipitation had to be performed at 20°C. Sodium sulphate is
insufficiently soluble to precipitate antibodies at lower temperatures.
Debris was removed from ascitic fluid by centrifugation (2000 x g for 20 minutes)
then anhydrous sodium sulphate was gradually added, to a final concentration of
18% (w/v), whilst stirring. After standing for 30 minutes, the precipitate was
collected by centrifugation (2000 x g for 15 minutes) then washed twice by resuspension
in 10 ml aliquots of 18% (w/v) sodium sulphate followed by centrifugation. The final
precipitate was redissolved in a small volume of Buffer V, dialysed against 5 litres
Buffer V for 16 hours at 4°C, then stored at -20°C.
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2.3.1.2 PEG 8000 Precipitation
Hybridoma culture supernatant was mixed with 30% (w/v) PEG 8000 in
Buffer E, to give a final PEG concentration of 12.5% (for IgG antibodies) or 15% (for
IgA), then incubated at 4°C for 4 days. The precipitate was collected by centrifugation
(2000 x g for 30 minutes), redissolved in a small volume of Buffer V, then stored
at -20°C after removing insoluble particles by centrifugation.
2.3.1.3 Protein A-Sepharose Affinity Chromatography
This protocol, based on the method of Ey et al. (1978), was used to purify
IgGl from spent culture supernatant. All buffers contained 0.1% sodium azide to
prevent microbial growth.
3 g Protein A-Sepharose CL-4B was swollen in 0.01 M sodium phosphate buffer,
pH 8.0, at room temperature for 1 hour. The gel was degassed, packed into an
adjustable column (1.0x13 cm), then equilibrated with 0.1 M Tris/HCl buffer, pH 8.7,
at a flow rate of 40 ml/hour.
Hybridoma culture supernatant was adjusted to pH 8.7 by dropwise addition of
10 M NaOH, then pumped through the Protein A-Sepharose column at 20ml/hour. The
column was washed with 0.1 M Tris/HCl buffer, pH 8.7, until the absorbance of the
effluent at 280 nm decreased to zero, then IgGl was eluted in 1.9 ml fractions by
0.1 M sodium citrate buffer, pH 5.0. Antibody-containing fractions were neutralized by
the addition of 110 (il 2M Tris, then pooled, concentrated to 0.5 ml using an Amicon
Minicon-B15 Concentrator, and stored at -20°C.
2.3.2 PURIFICATION OF POLYCLONAL ANTIBODIES
Several rabbit polyclonal antibody preparations were used in this work. Some
of these were obtained in an affinity-purified form. The others were received as
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unprocessed antisera which, if haemolysed, were purified by PEG 8000 fractionation
followed by Rivanol precipitation. Non-haemolysed antisera were purified by sodium
sulphate precipitation, as described in Section 2.3.1.1.
2.3.2.1 PEG 8000 Fractionation of Antisera
Haemolysed antiserum was centrifuged at 2000 x g for 20 minutes to remove
particulate material. 25 ml 45% (w/v) PEG 8000 in Buffer E was mixed with
200 ml antiserum then, after standing at room temperature for 2 hours, the precipitate
(0-5% PEG cut) was collected by centrifugation (2000 x g for 20 minutes). Another
33 ml 45% (w/v) PEG 8000 was added to the supernatant. A gelatinous precipitate
(5-10% PEG cut) formed immediately and was harvested by centrifugation, as above.
Most of the haemoglobin remained in the supernatant.
The 0-5% and 5-10% PEG precipitates were redissolved in small volumes of
50 mM sodium acetate then dialysed against 5 litres 50 mM sodium acetate for 16 hours
at 4°C, in preparation for Rivanol precipitation.
2.3.2.2 Rivanol Precipitation
The PEG 8000 fractions from haemolysed antisera were further purified by
Rivanol precipitation, which removed contaminants such as albumin and IgM, leaving
relatively pure IgG in solution (Franek, 1986).
3% (w/v) Rivanol (6,9-diamino-2-ethoxyacridine lactate), pH 8.2, was added
dropwise to the antibody preparation (180 pi Rivanol/ml antibody) whilst stirring
with a glass rod. The mixture was left at room temperature for 20 minutes, with
occasional stirring, then the precipitate was removed by filtration through dampened
Whatman No. 1 filter paper. The filtrate was freed of Rivanol by the addition of
NaCl (to a final concentration of 5%) followed by centrifugation (2000 x g for
15 minutes) to remove the yellow precipitate. The IgG-containing supernatant was
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concentrated by PEG 8000 precipitation. An equal volume of 30% (w/v) PEG 8000 in
Buffer E was added then, after incubation at 4°C for 16 hours, the precipitate was
collected by centrifugation, redissolved in 3-5 ml Buffer V, and stored at -20°C.
2.3.3 ESTIMATION OF ANTIBODY CONCENTRATION
The concentrations of purified antibody preparations were estimated from their
absorbances at 280 nm, assuming an extinction coefficient of 14 for a lOmg/ml solution
in a 1 cm optical pathway (Ey et al., 1978).
2.3.4 LABELLING METHODS
2.3.4.1 Radioiodination of AVP
125I-AVP was kindly prepared by Mrs. R. Stephen, using a protocol based on
the Iodogen method of Salacinski et al. (1981):
200 pg/ml Iodogen (l,3,4,6-tetrachloro-3a,6a-diphenylglycoluril), in methylene
chloride, was aliquoted into 1 ml microcentrifuge tubes (25 pi/tube), vortexed, then
dried under a stream of nitrogen gas. Coated tubes were stored in a desiccator at 4°C.
5 pi lmg/ml AVP in 0.2% acetic acid, 5 pi Buffer I and 10 pi lOOmCi/ml Na125I
were added to an Iodogen-coated tube. The mixture was vortexed immediately, and at
2 minute intervals for 10 minutes, then loaded onto a Sephadex G-25 column (fine,
1 x 40 cm) equilibrated with 0.2% acetic acid, 0.2% BSA. The reaction tube was
rinsed with 100 pi Buffer I, which was added to the column, then three peaks of
radioactivity were eluted by 0.2% acetic acid, 0.2% BSA, in 1.75 ml fractions.
Fractions from the second peak, which contained monoiodinated AVP, were stored
in 50 pi aliquots at -20°C.
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2.3.4.2 Radioiodination of Monoclonal Antibodies
MAbs were iodinated by a modification of the chloramine-T method (Hunter
and Greenwood, 1962) using lOpCi Na125I/pg MAb:
1 g Sephadex G-50 (fine) was swollen in Buffer P at room temperature for
4 hours, then packed into a Quickfit column (1.1 x 10.5 cm). Solutions of 2.5 mg/ml
chloramine-T in Buffer O, 0.625 mg/ml cysteine hydrochloride in Buffer J, and 5 mg/ml
KI in Buffer J, were prepared immediately before iodination. MAbs were diluted to
4mg/ml in Buffer O.
5 pi MAb, 5 pi Buffer O, 2 pi 100 mCi/ml Na125I and 5 pi chloramine-T were
vortexed for 15 seconds in an RT30 tube, then 100 pi cysteine hydrochloride was added
to stop the reaction. The mixture was diluted to 1 ml with KI then its radioactivity
was determined in an SR3 Scaler-Ratemeter (Nuclear Enterprises Ltd).
The iodination mixture was carefully loaded onto the Sephadex G-50 column.
The reaction tube was rinsed with two 1 ml aliquots of Buffer P, which were added to
the column, then the residual radioactivity in the tube was determined. (After a
successful iodination, about 10% of the total counts remained in the reaction tube
because iodinated protein adsorbed to the plastic surface.) Two peaks of radioactivity
were eluted from the column by Buffer P. 1 ml fractions were collected until the
radioactivity of the eluate decreased to background levels. Up to three fractions from
the first peak were pooled (rinsing the tubes with 0.5-1.0 ml Buffer P to maximize
antibody recovery), then stored at 4°C until further purified.
The specific activities and yields of 125I-MAb were calculated from:
Specific Activity (pCi/pg) = A x B
C
where A = D + E
E + F
Yield (pg) = G x C
D + E
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where A = fractional incorporation of 125I, B = pCi 12SI in reaction mixture,
C = pg protein in reaction mixture, D = total counts in MAb peak, E = residual counts
in reaction tube, F = total counts eluted from SephadexG-50 column, and G = counts in
MAb fractions selected for pooling.
2.3.4.3 Purification of Iodinated Monoclonal Antibodies
Most unreacted 12SI was removed during the Sephadex G-50 gel filtration step
whereas high molecular weight contaminants co-eluted with 125I-MAb. These
iodinated contaminants, which made an additional purification step necessary, were
removed (along with any remaining free 125I) by gel filtration on a Sephacryl S-300
column (1.8x57 cm) equilibrated with Buffer P containing 0.1% sodium azide.
Up to 2.5 ml 125I-MAb was applied to the column and eluted with Buffer P
containing 0.1% sodium azide, in 2 ml fractions. The radioactivity in a 10 pi sample
from each fraction was determined in a gamma counter. The peak MAb-containing
fractions were pooled, rinsing the tubes with 1 ml Buffer P to maximize antibody
recovery, then stored at 4°C.
Purified 125I-MAb was usable for 4-5 weeks.
2.3.4.4 Preparation of 125I-Streptavidin
Radioiodination of streptavidin was carried out as in Section 2.3.4.2, except
that 10 pg streptavidin was reacted with 500 pCi Na125I. Iodinated streptavidin was
purified by gel filtration on Sephacryl S-300 (Section 2.3.4.3) then stored at 4°C.
2.3.4.5 Biotinvlation of Monoclonal and Polyclonal Antibodies
MAbs and polyclonal antibodies were biotinylated with biotinyl-e-
aminocaproic acid N-hydroxysuccinimide ester (Biotin-X-NHS) at a biotin : antibody
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ratio of 20 :1 as follows :
A Pharmacia PD-10 column was prepared by BSA-blocking its protein-binding
sites. 4 ml 5% (w/v) BSA in Buffer V was applied to the column and eluted with
50 ml Buffer V.
25 pi freshly-prepared 2.42 mg/ml Biotin-X-NHS in DMF was added to 1 ml
1 mg/ml antibody in Buffer V, then incubated at room temperature for 30 minutes
with continuous agitation on a roller-mixer. The reaction mixture was applied to
the BSA-blocked PD-10 column and eluted in 1 ml fractions with Buffer V.
Antibody-containing fractions were stored at 4°C.
2.3.5 PREPARATION OF ANTIBODY-COATED SOLID PHASES
Antibodies were immobilized either by covalent coupling to periodate-oxidized
Sephacryl or by adsorption onto polystyrene MicroELISA strips and nitrocellulose
membrane-bottomed 96-well plates. All incubations were carried out at room
temperature.
2.3.5.1 Oxidation of Sephacryl
Periodate oxidation of Sephacryl S-300 and Sephacryl S-500 was achieved by
the method of Wright and Hunter (1982):
150 ml (settled volume) Sephacryl was thoroughly washed with 10 litres
distilled water, in a sintered glass funnel (No. 2 porosity) attached to a Venturi
pump. The gel was resuspended in 500 ml 5 mM sodium m-periodate in Buffer C, then
agitated on an orbital shaker for 1 hour. 5 ml 10% (v/v) glycerol was added to use up
excess periodate, then agitation continued for another hour. The oxidized Sephacryl
was washed with 10 litres Buffer V, resuspended in Buffer V, then stored at 4°C as a
50% (settled volume) slurry.
Oxidized Sephacryl was stable for at least 6 months.
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2.3.5.2 Covalent Coupling of Antibodies to Sephacrvl S-300
Antibodies were coupled to oxidized Sephacryl S-300, with subsequent
stabilization of the Schiff's base linkage by borohydride reduction, according to the
method of Wright and Hunter (1982):
3 ml (settled volume) oxidized Sephacryl S-300 was washed with
50 ml Buffer V in a sintered glass funnel, resuspended in 4 ml 1 mg/ml MAb or
affinity-purified polyclonal antibody (or 8 mg/ml partially-purified polyclonal
antibody) in Buffer V, then incubated for 16 hours with continuous agitation on a
roller-mixer. Unreacted antibody was removed by filtration then the Sephacryl was
washed with Buffer K, resuspended in 25 ml Buffer K, and allowed to settle for
30 minutes. The buffer was decanted, which removed fines, then the gel was
resuspended in 20 ml Buffer K and reacted with 100 mg sodium borohydride for
30 minutes with occasional stirring. The reduced antibody-S-300 solid phase was
washed four times with Buffer A, five times with Buffer Q, then resuspended in 22 ml
Buffer R to give a 12.5% (settled volume) slurry, and stored at 4°C.
Assessment of antigen-binding ability
Some antibodies were damaged by covalent linkage to Sephacryl therefore all
new antibody-S-300 solid phases were assayed for the ability to bind antigen.
Duplicate 100 pi aliquots of antibody-S-300 solid phase (12.5% (settled volume) slurry
in Buffer R) were incubated with 50 pi 125I-Ag (7 pg 125I-AVP, or 6.4 pg 125I-ANP, in
Buffer P) in RT30 tubes for 1 hour, with agitation on an orbital shaker. Bound and free
125
I-Ag were separated by sucrose layering (Section 2.2.4.4) then the radioactivity of
the solid phase was determined.
Preparation for immunoradiometric assay
Antibody-S-300 solid phase was rinsed before use, to remove any free antibody
which had leaked from the gel (Homsey et al., 1986; Bessos et al., 1991). The buffer
was decanted and replaced with an equal volume of Buffer G. The solid phase was
resuspended and allowed to settle, then the buffer was exchanged once more.
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2.3.5.3 Preparation of SAM-S-500 Solid Phase
Sheep anti-mouse yglobulin (SAM) antiserum was coupled to oxidized
Sephacryl S-500 without prior antibody purification.
15 ml (settled volume) oxidized Sephacryl S-500 was washed with Buffer V,
resuspended in 20 ml 25% (v/v) SAM antiserum in Buffer V, then incubated, washed,
de-fined and reduced (with 500 mg sodium borohydride and 100 ml Buffer K), as
described in Section 2.3.5.2. After washing with Buffers A and Q, the reduced solid
phase was resuspended in 50 ml Buffer R to give a 25% (settled volume) slurry, and
stored at 4°C. The buffer was exchanged at weekly intervals to remove any free
antibody which had leaked from the solid phase.
2.3.5.4 Adsorption of Antibodies onto MicroELISA Strips
Monoclonal and polyclonal antibodies were diluted to 6 pg/ml in Buffer T, then
adsorbed onto MicroELISA strips (200 pi/well) by overnight incubation. Each well was
rinsed three times with Buffer T, incubated for 30 minutes with 400 pi 1% BSA in
Buffer T to block remaining protein-binding sites, then rinsed once with Buffer T and
dried by evaporation. The coated strips were sealed and stored at -20°C.
2.3.5.5 Adsorption of Antibody onto Nitrocellulose Membrane-Bottomed Plates
Monoclonal antibody (5-30 pg/ml, in Buffer T) was incubated in nitrocellulose
membrane-bottomed 96-well plates (100 pi/well) for 1 hour, then drawn through the
membrane by a vacuum manifold attached to a Venturi pump. The wells were washed
four times by drawing Buffer U through the membrane, then blotted on tissue paper
and used immediately in an immunofiltration assay (Section 2.5.3).
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2.4 CHARACTERIZATION OF MONOCLONAL ANTIBODIES
2.4.1 ISOTYPE DETERMINATION
MAbs in hybridoma culture supernatant (diluted 1/3 in 20 mM Tris/HCl
buffer, pH 7.6, 137 mM NaCl, 0.1% Tween20) were isotyped with an Amersham Mouse
Monoclonal Antibody Isotyping Kit, using the protocol supplied.
2.4.2 ESTIMATION OF ANTIBODY AFFINITY
MAb affinity constants were estimated by Scatchard analysis of RIA data
(Scatchard, 1949) :
Serial dilutions of hybridoma culture supernatant in Buffer L (100 pi/tube) were
incubated with 50 pi 125I-Ag (7 pg 125I-AVP or 6.4 pg 125I-ANP, in Buffer L) for 16 hours
inc 19R
at room temperature. MAb-bound I-Ag was separated from free I-Ag by incubation
with SAM-S-500 followed by sucrose layering (Section 2.2.4.4) for IgG isotypes, or by
the PEG separation method (Section 2.2.4.3) for other isotypes. The radioactivity of
the bound fraction was used to estimate the MAb dilution which produced
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half-maximal I-Ag binding. This dilution was then used in an RIA standard curve.
Duplicate 100 pi aliquots of diluted MAb were incubated with 50 pi 125I-Ag and
100 pi 0-1000 ng/ml unlabelled Ag in Buffer L for 16 hours at room temperature, then
separation and counting of the antibody-bound fraction was carried out as above.
Non-specific binding was determined by replacing MAb with 100 pi Buffer L. At each
point on the standard curve,
B = T x M and F = T - B
where B = MAb-bound antigen concentration (moles/litre of assay mixture), T = total
antigen concentration (125I-Ag + Ag, moles/litre), M = MAb-bound fraction of 125I-Ag
(minus non-specific binding) and F = free antigen concentration (moles/litre).
A plot of B/F against B produced a line with a gradient of —K, where K was
the antibody affinity constant (litres/mole).
2.4.3 ASSESSMENT OF ANTIBODY SPECIFICITY
Anti-AVP MAb specificities were determined by RIA (Section 2.4.2). The
inhibition of 125I-AVP binding caused by AVP was compared with that caused by
various peptide analogues, then the cross-reactivity of MAb with each analogue was
calculated from :
Cross-reactivity (%) = [AVP]50 x 100
[Analogue]50
where [ ]50 = peptide concentration causing 50% inhibition of 125I-AVP binding.
2.5 TWO-SITE IMMUNOMETRIC ASSAYS
All incubations were carried out at room temperature.
2.5.1 TWO-SITE ELISA
The assay protocols below were modified in some experiments, as described in
Chapters 6 and 8.
2.5.1.1 Separate Incubation Protocol
Antibody-coated MicroELISA Duo-strip wells (Section 2.3.5.4) were incubated
with duplicate 100 pi aliquots of antigen standard in Buffer L for 20 hours, then with
100 pi 2 pg/ml biotin-antibody in Buffer L containing 1% normal mouse serum for
24 hours. After incubation with 100 pi 2 pg/ml streptavidin-HRP conjugate in Buffer L
for 15 minutes, the wells were washed five times with Buffer D, then incubated
with 100 pi freshly-prepared substrate (100 pg/ml 3,3',5,5'-tetramethylbenzidine,
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0.002% H202 in Buffer B). Colour development was stopped after 30 minutes by the
addition of 50 pi 2 M H2S04. The absorbance at 450 nm was immediately determined in
a Dynatech MR700 automatic microplate reader.
Alternatively, MAb-coated MicroELISA wells were incubated with
100 pi antigen in Buffer L for 20 hours, then with 100 pi 6 pg/ml unlabelled rabbit
polyclonal antibody in Buffer L for 24 hours, and finally with 100 pi donkey
anti-rabbit IgG HRP conjugate (1 /500 dilution in Buffer L) for 1 hour. Plate-washing,
and the remainder of the assay, was carried out as above.
2.5.1.2 Simultaneous Incubation Protocol
Duplicate 100 pi aliquots of antigen standard in Buffer L and 50 pi 2 pg/ml
biotin-antibody in Buffer L containing 4% normal mouse serum were incubated in
antibody-coated MicroELISA wells for 16 hours, then 50 pi 2 pg/ml streptavidin-HRP
conjugate in Buffer L was added. The assay mixture was swirled gently to ensure
homogeneity, then incubated for another 15 minutes. Plate-washing, and the remainder
of the assay, was carried out as described for the separate incubation protocol.
2.5.2 IMMUNORADIOMETRIC ASSAY (IRMA)
IRMA binding was detected directly using 125I-MAb, or indirectly using
125
I-streptavidin as a universal label in combination with biotinylated antibodies.
Assay protocols were modified in some experiments, as described in Chapters 6 and 8.
2.5.2.1 Direct IRMA
Duplicate 100 pi aliquots of antigen standard in Buffer E containing 5% BSA
were incubated with 100 pi 50ng/ml 125I-MAb in Buffer F for 2 hours, then 100 pi
antibody-S-300 solid phase (12.5% (settled volume) slurry in Buffer G) was added.
53
IOC
The mixture was agitated on an orbital shaker for 2 hours then bound I-MAb was
isolated by the sucrose layering technique (Wright and Hunter, 1983). 1 ml Buffer H
was added and the solid phase was allowed to settle for 5 minutes, then 2 ml
10% (w/v) sucrose in Buffer H was pumped beneath the mixture. The solid phase
settled to the bottom of the tube then free 125I-MAb, and most of the sucrose, was
aspirated. Sucrose layering was repeated once then the radioactivity of the solid
phase was determined in a gamma counter.
2.5.2.2 Indirect IRMA
Duplicate 100 pi aliquots of antigen standard in Buffer E containing 5% BSA
were incubated with 100 pi 50ng/ml biotin-antibody in Buffer F for 2 hours, then 100 pi
antibody-S-300 solid phase (12.5% (settled volume) slurry in Buffer G) was added.
The mixture was agitated for 2 hours, then 100 pi 20 ng/ml 125I-streptavidin in Buffer F
was added. After agitation for a further 15 minutes, bound and free 125I-streptavidin
were separated by the sucrose layering technique, as described in Section 2.5.2.1.
2.5.3 IMMUNOFILTRATION ASSAY
A MAb-coated nitrocellulose membrane-bottomed 96-well plate (Section 2.3.5.5)
was incubated with AVP standard in Buffer M (100 pl/well) for 30 minutes, then the
AVP was drawn through the membrane under vacuum. The wells were washed three
times by drawing Buffer N through the membrane, blotted on tissue paper, then
incubated with 100 pi 50 ng/ml 125I-antibody in Buffer M for 30 minutes. The wells were
washed with Buffer N as before, then the membranes were excised and their





Hybridoma screening assays need to be capable of rapidly processing large
numbers of samples, and must be optimized before MAb production can begin. They are
usually set up with serum from the immune spleen donor (Campbell, 1984; Goding,
1986) and, ideally, should detect only those antibodies which are specific for the
antigen of interest. The assay format is determined by the intended use of the
antibodies therefore ELISA and RIA screening are often used when MAbs are required
for immunoassays. Unfortunately, several problems may be encountered.
The radiolabeled antigens used in RIA will have some altered epitopes
which are no longer recognised by the appropriate antibodies. This may be acceptable
for large protein antigens but is a serious problem with small peptides. For example,
iodination of AVP increases its molecular weight by 11% and significantly increases
the risk of obtaining a false negative screening assay result. An anti-AVP MAb which
does not bind well to 125I-AVP has been reported (Hou-Yu et al., 1982; Valiquette et
al., 1986; Valiquette and Neubort, 1989).
ELISA methods avoid this problem. However, if conformational changes occur
when antigens, such as large proteins, adsorb to the solid phase, ELISA may detect
antibodies which cannot recognise the native antigen in solution (Mierendorf and
Dimond, 1983; Vaidya et al., 1985; Schwab and Bosshard, 1992) and may fail to
detect antibodies which are specific for the native antigen (Mierendorf and Dimond,
1983; Brennand et al., 1986; Overall et al., 1989). On the other hand, small peptides
may not bind well to polystyrene ELISA plates (Briand et al., 1985; Presentini et al.,
1989) so they are often conjugated to large carrier molecules to improve adsorption, but
both the coupling agent and carrier must differ from those used in the immunogen if
the assay is to be specific for anti-peptide antibodies and avoid cross-reaction with
anti-carrier and anti-coupling agent specificities (Briand et al., 1985; Edwards et al.,
1989; Peeters et al., 1989). Alternatively, if the antigen is big enough to bind two
antibodies simultaneously, a capture antibody can be used to efficiently immobilize it
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without loss of its native conformation (Smith and Wilson, 1986).
At the start of this project, an anti-ANP screening assay was locally
available (Prowse et al., 1989) whereas an anti-AVP hybridoma screening assay had
to be developed. Immune serum was the only source of mouse anti-AVP antibody so it
was used for assay development. This caused several unexpected problems.
3.2 PRELIMINARY STUDIES
Iodination of the tyrosine residue of AVP masks an important epitope because
the adjacent phenylalanine is the only amino acid which distinguishes the AVP ring
structure from that of oxytocin (Table 5.3). Consequently, hybridoma screening by RIA
is unlikely to detect antibodies specific for this important region of the AVP
molecule. ELISA seemed to be a more appropriate screening assay format because it
does not require labelled peptide.
An AVP-coated-plate ELISA, with BSA-blocking, was used in initial
experiments with tail bleed sera from immunized mice. It seemed to work, because
non-specific binding to BSA-blocked wells was lower than the specific binding to
AVP-coated wells (Figure 3.1) although only one of four mice showed a significant
antibody response. However, antibody binding did not reach equilibrium if serum
dilutions were only incubated in the wells for 1 hour. Longer incubations produced
higher absorbances (Figure 3.2), but the cell culture work was incompatible with
same-day completion of assays requiring more than 1 hour for antibody binding.
Maximal binding would ensure that screening assays were sensitive, so a standard
16 hour first incubation period was selected for routine use with all screening assay
formats because longer or shorter incubations were impractical.
When the same tail bleed sera were assayed by SAM-RIA, in an attempt to
confirm the validity of the ELISA data, no specific anti-AVP binding could be
detected. This result was surprising because immune serum had been expected to




Response of immune mouse serum in an AVP-coated-plate ELISA
Serum dilutions from mouse nos. 3363 (A), 3364 (B), 3365 (C), and 3366 (D),
immunized with AVP-thyroglobulin conjugate, were assayed in AVP-coated (•), and
AVP-free (o), BSA-blocked Microwells.
Nunc Maxisorp Microwells were coated by incubation with 100 pi lOng/ml AVP
in Buffer K for 16 hours, rinsed 3 times with Buffer K, incubated with 400 pi 1% BSA
in Buffer K for 30 minutes, rinsed once with Buffer K, then dried by evaporation.
Serum dilutions (100 pi, in Buffer L) were incubated in the wells for 1 hour, followed
by 100 pi goat anti-mouse 'polyvalent immunoglobulins' HRP conjugate (1/100 dilution







Effect of incubation time on AVP-coated-plate ELISA
Serum from mouse 3365, diluted in Buffer L, was incubated for 1 (a), 2 (o), or
3 (•) hours in Microwells which had been coated with 10 ng/ml AVP and
BSA-blocked. The assay was completed as described in Figure 3.1. Non-specific
binding to BSA-blocked wells has been subtracted from the absorbances shown.
phase, which was used in the RIA, bound mainly to IgG isotypes whereas the goat
anti-mouse 'polyvalent immunoglobulins' HRP conjugate, which had been used in the
ELISA work, was equipotent for IgG, IgA and IgM. When the 'polyvalent' conjugate
was compared with rabbit anti-mouse IgG (whole molecule) HRP conjugate, in an
AVP-coated-plate ELISA, extremely low anti-IgG results were obtained (Figure 3.3).
This suggested that either the immunization schedule had failed to generate a
significant IgG response or, because animals immunized against vasopressin tend to
develop the symptoms of diabetes insipidus (Morton and Waite, 1972; Skowsky and
Fisher, 1972b), that the mouse anti-AVP IgG had bound in vivo to circulating
endogenous AVP, leaving only low affinity IgM antibodies available to bind AVP in
the screening assays. Both interpretations of the data raised doubts about the
validity of the AVP-coated-plate ELISA and the SAM-RIA as hybridoma screening
assays because no suitable positive control samples were available. It could not be






Effect of HRF conjugate specificity on AVP-coated-pIate ELISA
Serum from mouse 3365, diluted in Buffer L, was incubated for 16 hours in
Microwells which had been coated with 10 ng/ml AVP and BSA-blocked, then
antibody binding was revealed with goat anti-mouse 'polyvalent immunoglobulins'
HRP conjugate (1/100 dilution in Buffer L, •) or rabbit anti-mouse IgG (whole
molecule) HRP conjugate (1/200 dilution in Buffer L, o). Non-specific binding to
BSA-blocked wells has been subtracted from the absorbances shown.
3.3 AVP-CAPTURE ELISA
An AVP-capture ELISA, with a polyclonal capture antibody of non-mouse
origin, seemed an ideal alternative to the AVP-coated-plate ELISA and SAM-RIA
screening formats because previous unpublished work had suggested that a two-site
assay was feasible for AVP (N. Mcintosh, personal communication). Theoretically, the
immobilized capture antibody would bind pre-formed antigen-antibody complexes,
whereas free antibodies would only bind after preincubation of the capture antibody
with antigen (Smith and Wilson, 1986).
Rabbit TGI antiserum (Smith and Mcintosh, 1986) was the only source of
non-mouse anti-AVP polyclonal antibody available when the AVP-capture ELISA was
set up. Four plate-coating concentrations of TGI antiserum were compared by assaying
serum from an immunized mouse in coated wells which had been BSA-blocked and
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FIGURE 3.4
Influence of capture antibody coating concentration on the AVP-capture ELISA
TGI antiserum, diluted 1/100 (a), 1/1000 (o), 1/10,000 (•) or 1/100,000 (x) in
Buffer T, was adsorbed onto Nunc Maxisorp Microwells (100 pi/well) by overnight
incubation. The wells were rinsed and BSA-blocked, incubated with 100 pi lOng/ml
AVP in Buffer L for 16 hours, rinsed with Buffer K, then used to assay serum dilutions
from mouse 3365. Antibody binding was revealed with goat anti-mouse 'polyvalent
immunoglobulins' HRP conjugate (1/100 dilution in Buffer L).
preincubated with AVP (Figure 3.4), using the 'polyvalent immunoglobulins' HRP
conjugate to reveal antibody binding because the reason for the low anti-IgG response
of immune serum in the AVP-coated-plate ELISA (Figure 3.3) had not yet been
determined. A 1/10,000 dilution of TGI antiserum produced the highest absorbances
and so was selected for routine use in the AVP-capture ELISA.
3.3.1 ASSESSMENT OF THE AVP-CAPTURE ELISA
When immune mouse serum was analysed in the AVP-capture ELISA, the
'polyvalent immunoglobulins' HRP conjugate produced higher absorbances than the
anti-IgG HRP conjugate (Figure 3.5) which suggested, in agreement with the
AVP-coated-plate ELISA data (Figure 3.3), that the immunized mouse had more




Effect of HRP conjugate specificity on AVP-capture ELISA
Serum dilutions from mouse 3365 were assayed in AVP-capture ELISA wells
(1/10,000 dilution TGI antiserum, BSA-blocked, lOng/ml AVP). Antibody binding was
revealed with goat anti-mouse 'polyvalent immunoglobulins' HRP conjugate (•) or
sheep anti-mouse IgG (whole molecule) HRP conjugate (o). The absorbances caused by
non-specific binding of the HRP conjugates have been subtracted from the values
shown.
to the fact that a higher IgG response was obtained in the AVP-capture ELISA
(Figure 3.5) than in the AVP-coated-plate ELISA (Figure 3.3) because different serum
samples had been used in the two assays.
Immune mouse serum antibodies bound to immobilized TGI antiserum whether
or not it had been preincubated with AVP (Figure 3.6), which gave the impression
that the serum contained both AVP-free and AVP-bound antibodies. In the absence of
added AVP, antibody binding was detected by both the 'polyvalent immunoglobulins'
and the anti-IgG HRP conjugates (Figure 3.7), which was taken to mean that some of
the AVP-bound antibody was IgG. This binding was much higher if BSA-blocking was
omitted (Figure 3.7), but the antibodies did not adsorb to unoccupied sites on unblocked
ELISA wells because the mouse serum had been diluted in Tween 20-containing buffer
which virtually eliminated non-specific binding to polystyrene (Table 3.4), as reported
by Mohammad and Esen (1989). Instead, it seemed that plate-blocking caused steric
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FIGURE 3.6
Effect of omittine AVP from the AVP-capture ELISA
Microwells coated with TGI antiserum, and BSA-blocked, were incubated with
100 jj.1 lOng/ml AVP in Buffer L (•), or 100 til Buffer L (o), for 16 hours, rinsed with
Buffer K, then used to assay dilutions of serum from mouse 3365. Antibody binding was
revealed with goat anti-mouse 'polyvalent immunoglobulins' HRP conjugate.
Serum dilution
FIGURE 3.7
Binding of immune mouse serum to TGI antiserum and BSA
Serum dilutions from mouse 3365 were assayed in Microwells coated with TGI
antiserum only (•), TGI antiserum with BSA-blocking (o), or BSA-blocked wells (a).
Antibody binding was revealed with goat anti-mouse 'polyvalent immunoglobulins'
HRP conjugate (A) or sheep anti-mouse IgG (whole molecule) HRP conjugate (B). The
absorbances caused by non-specific binding of the HRP conjugates have been subtracted
from the values shown.
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hindrance of binding.
Immune mouse serum contained anti-BSA antibody which caused almost half of
the binding response that was detected by the 'polyvalent immunoglobulins' HRP
conjugate in TGl-coated, BSA-blocked, wells (Figure 3.7A). Cell fusion was therefore
expected to generate hybridomas that secreted anti-BSA antibodies, which would bind
to BSA-blocked AVP-capture ELISA wells causing false positive results. However, the
anti-IgG HRP conjugate detected much less anti-BSA activity (Figure 3.7B), indicating
that most anti-BSA antibodies were either IgM or IgA. Fewer anti-BSA specificities
would be detected if an anti-IgG HRP conjugate was used in hybridoma screening.
Non-specific binding of the affinity-isolated anti-IgG HRP conjugate to
AVP-capture ELISA wells caused inconveniently high background absorbances. Despite
the presence of BSA and Tween 20 in the assay buffer, the conjugate bound to BSA,
TGI antiserum, normal rabbit serum, bovine serum (NBCS) and foetal calf serum, but
not to uncoated wells (Table 3.1), which indicated that it bound to the coating
materials and not to polystyrene. The 'polyvalent immunoglobulins' HRP conjugate did
TABLE 3.1
Non-specific binding of the affinity-isolated sheep anti-mouse IgG (whole molecule)
HRP conjugate to coated ELISA wells
Various plate-coating solutions, in Buffer T, were adsorbed onto Immulon 1
MicroELISA wells by overnight incubation, then antigen-coated-plate ELISA was
carried out with 100 pi HAT medium in place of sample. The absorbances shown are
the means of duplicate determinations.








not produce high background readings, but was unsuitable for hybridoma screening
because it would detect IgM and IgA in addition to the desired IgG isotypes.
Preincubation of immobilized TGI antiserum with AVP could not be optimized
when the AVP-capture ELISA was set up, because immune serum was the only source
of mouse anti-AVP antibody available and its binding did not seem to depend on the
addition of AVP (Figures 3.6 and 3.7). Preincubation with 50ng/ml AVP was selected
for hybridoma screening because this concentration was thought certain to saturate the
binding sites of immobilized TGI antiserum and so maximize MAb detection.
Despite these problems, the AVP-capture ELISA was used for hybridoma
screening because it produced higher immune mouse serum absorbances than an
AVP-coated-plate ELISA that used the same amount of AVP (Figure 3.8), so it
appeared to be a more sensitive assay. It also seemed reasonably specific for
anti-AVP IgG because the binding response of immune mouse serum detected by the
anti-IgG HRP conjugate was much higher than that of normal mouse serum
(Figure 3.9).
3.3.2 HYBRIDOMA SCREENING BY AVP-CAPTURE ELISA
The first cell fusion (VP1, Table 4.6) generated hybridomas in 378 culture
wells. Undiluted supernatants from 26 wells were considered antibody-positive because
they produced AVP-capture ELISA absorbances which exceeded 0.3. However, when
antibody dilution analysis was carried out to identify the highest affinity anti-AVP
antibodies (Van Heyningen, 1986), dilution in assay buffer almost eliminated antibody
binding in many culture supernatants, even when the dilution factor was as low as two
(Table 3.2, Experiment 1). Dilution in cell culture medium did not have this drastic
effect (Table 3.2, Experiment 2), which was seen particularly clearly with supernatant
from hybridoma VP1/169 (Figure 3.10). Something in the assay buffer obviously




Comparison of the binding responses of immune mouse serum in the AVP-capture
ELISA and in the AVP-coated-pIate ELISA
Serum dilutions from mouse 3365 were simultaneously assayed in AVP-capture
ELISA wells (1/10,000 dilution TGI antiserum, BSA-blocked, lOng/ml AVP, •) and in
AVP-coated-plate ELISA wells (10 ng/ml AVP, BSA-blocked, o). Antibody binding
















Response of immune mouse serum and normal mouse serum in the AVP-capture ELISA
Dilutions of immune serum from mouse 3365 (•), and normal mouse serum (o),
were assayed by AVP-capture ELISA. Antibody binding was revealed with sheep
anti-mouse IgG (whole molecule) HRP conjugate.
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TABLE 3.2
Response of AVP-capture ELISA-positive culture supernatants to dilution
The AVP-capture ELISA response of undiluted hybridoma culture supernatant
was compared with the response obtained after dilution with an equal volume of
Buffer L (Experiment 1), or 15% FCS medium (Experiment 2). The absorbance caused by
non-specific binding of the sheep anti-mouse IgG (whole molecule) HRP conjugate has
been subtracted from the values shown.
Absorbance at 450 nm
Hybridoma Experiment 1 Experiment 2
Undiluted Diluted 1/2 in Undiluted Diluted 1/2 in
Buffer L 15% FCS medium
VP1/10 0.525 0.441 0.544 0.568
VP1/89 1.005 0.126 1.422 1.193
VP1/121 1.522 0.049 1.869 1.788
VP1/140 >2.050 0.300 >2.050 >2.050
VP1/169 1.620 0.743 1.916 >2.050
VP1/271 1.991 0.040 >2.050 2.028
VP1/367 0.712 0.089 0.469 0.411
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FIGURE 3.10
Effect of diluent composition on the AVP-capture ELISA response of culture
supernatant from hybridoma VP1/169
Culture supernatant was diluted in 15% FCS medium (•), or Buffer L (o), then
assayed by AVP-capture ELISA.
3.3.3 ANALYSIS OF AVP-CAPTURE ELISA-POSITIVE SUPERNATANTS
The immunized mice had produced an anti-BSA response (Figure 3.7) therefore
some AVP-capture ELISA-positive hybridomas were expected to secrete anti-BSA
antibodies. However, the BSA used in plate-blocking, and in the assay buffer, was
only 98% pure and so was likely to contain other substances, such as thyroglobulin, to
which the hybridoma antibodies might bind. Pure BSA was not available therefore
BSA-blocked wells had to be avoided in specificity assays.
Antibody binding to thyroglobulin was assayed in wells blocked with non-fat
dried milk, which was reported to be an effective plate-blocking agent (Vogt et al.,
1987). All AVP-capture ELISA-positive supernatants, except those from hybridomas
VP1/10 and VP1/367, bound equally to thyroglobulin-coated wells and 1% dried
milk-blocked control wells (Table 3.3), giving the impression that 1% milk was
insufficient to provide adequate plate-blocking. However, higher concentrations of
dried milk could not eliminate binding (Figure 3.11), which suggested that most of the
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TABLE 3.3
Binding response of AVP-capture ELISA-positive culture supernatants to thyroglobulin
Nunc Maxisorp Microwells were coated by incubation with 100 pi 10 pg/ml
bovine thyroglobulin in Buffer T for 16 hours, rinsed three times with Buffer T,
incubated for 1 hour with 400 pi 1% non-fat dried milk in Buffer T to block remaining
protein-binding sites, rinsed once with Buffer T, then dried by evaporation.
Undiluted hybridoma culture supernatants were incubated in the coated wells
and in dried milk-blocked control wells for 16 hours, then antibody binding was
revealed with sheep anti-mouse IgG (whole molecule) HRP conjugate. Serum from
mouse 3365, diluted 1 /1000 in Buffer L, was included for comparison. The absorbances
caused by non-specific binding of the HRP conjugate have been subtracted from the
values shown.
Absorbance at 450 nm
Sample









Immune serum >2.050 1.778
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FIGURE 3.11
Binding of AVP-capture ELISA-positive hybridoma culture supernatants to non-fat
dried milk-blocked Microwells
Nunc Maxisorp Microwells were incubated for 1 hour with 400 pi 1-10% non-fat
dried milk in Buffer T, to block protein-binding sites, rinsed with Buffer T, then used
to assay undiluted culture supernatants from hybridomas VP1/89 (o), VP1/140 (■),
VP1/169 (x), and VP1/271 (a). Immune serum from mouse 3365, diluted 1/1000 in
Buffer L (•), was included for comparison. Antibody binding was revealed with sheep
anti-mouse IgG (whole molecule) HRP conjugate.
antibodies bound specifically to a component of the milk preparation. Further
evidence was provided by the fact that immune mouse serum bound strongly to
milk-blocked wells (Tables 3.3 and 3.4, Figure 3.11), despite dilution in Buffer L
which prevented non-specific binding to polystyrene (Table 3.4).
The effect of plate-blocking was checked by comparing antibody binding in
dried milk-blocked, BSA-blocked and unblocked wells (Table 3.4). Immune mouse serum
and AVP-capture ELISA-positive culture supernatants bound to BSA-blocked wells
more strongly than to unblocked wells, which confirmed that there was specific
binding to the BSA preparation. In contrast, most samples bound less strongly to
non-fat dried milk-blocked wells than to unblocked wells, which suggested that milk
had a reasonable plate-blocking effect even though specific binding also occurred.
Non-specific binding to unblocked polystyrene was a measure of the antibody content
of undiluted samples therefore the polyclonal supernatant from in vitro-boosted spleen
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TABLE 3.4
Effect of blocking proteins on the adsorption of antibodies onto uncoated ELISA wells
Uncoated Nunc Microwells were blocked by incubation with 400 j_il 3% dried
milk, or 1% BSA, in Buffer T for 1 hour, rinsed once with Buffer T, dried by
evaporation, and used to assay undiluted culture supernatants from AVP-capture
ELISA-positive hybridomas, in u/fro-boosted spleen cells and ESA 4, an anti-ANP
MAb. Immune serum from mouse 3365, diluted 1/1000 in Buffer L, was included for
comparison. The absorbance caused by non-specific binding of the sheep anti-mouse IgG
(whole molecule) HRP conjugate to the plate-blocking proteins has been subtracted
from the values shown.
Absorbance at 450 nm
Sample
3% Dried Milk 1% BSA Unblocked
VP1/10 0.000 0.713 0.044
VP1/89 0.424 1.689 0.290
VP1/121 0.164 >2.050 1.645
VP1/140 0.033 0.971 0.020
VP1/169 0.907 >2.050 >2.050
VP1/271 0.263 1.376 0.126
ESA 4 0.028 0.000 0.658
Spleen supernatant 0.078 0.266 1.231
Immune serum 1.454 0.187 0.049
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cells contained a lot of antibody, but relatively few anti-BSA and anti-dried milk
specificities, because it bound more strongly to uncoated, unblocked, wells than to
BSA-blocked or dried milk-blocked wells (Table 3.4).
Since the AVP-capture ELISA-positive culture supernatants bound to BSA and
dried milk, they might also have bound to other commonly-used blocking agents
therefore it was essential to carry out specificity assays in unblocked ELISA wells.
However, the Nunc Maxisorp Microwells, which had been used in all previous work,
had a high protein binding capacity so non-specific binding could have been a
problem in unblocked wells. Antibody adsorption to uncoated, unblocked, Nunc
Microwells was therefore compared with that to Immulon 1 and Immulon 2 MicroELISA
wells (Table 3.5). Undiluted culture supematants adsorbed more strongly to Nunc
Microwells than to Immulon 2 MicroELISA wells, while the lowest adsorption was
recorded in Immulon 1 MicroELISA wells whose low binding capacity suggested that
coating proteins might occupy all possible protein-binding sites thus making
plate-blocking unnecessary.
When specificity assays were carried out in unblocked Immulon 1 MicroELISA
wells, most undiluted AVP-capture ELISA-positive hybridoma culture supernatants
bound strongly to BSA, TGI antiserum, normal rabbit serum and bovine serum, while
their response to foetal calf serum was similar to, or lower than, the adsorption to
uncoated wells which occurred during the 16 hour incubation period (Table 3.6). Most
supernatants also seemed to bind to AVP-coated wells but this binding was probably
non-specific because it was much lower than that to TGI antiserum, normal rabbit
serum, bovine serum or BSA, and no anti-AVP antibody could be detected by RIA.
Hybridomas VP1/10 and VP1/367 appeared to secrete anti-BSA antibodies.
Foetal calf serum sometimes contains antibodies (Kniazeff and Rimer, 1967) but
is usually considered to be antibody-free, whereas high antibody concentrations are
present in non-foetal sera. BSA preparations are often contaminated by antibodies
(Boscato and Stuart, 1988) while dried milk, to which many hybridoma supematants
bound (Figure 3.11), was also likely to contain bovine antibodies. Most undiluted
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TABLE 3.5
Comparison of the adsorption properties of three types of polystyrene ELISA well
Undiluted culture supematants from AVP-capture ELISA-positive hybridomas,
in uz'tro-boosted spleen cells and ESA 4, an anti-ANP MAb, were incubated in
uncoated, unblocked, ELISA wells for 16 hours, then antibody adsorption was revealed
with sheep anti-mouse IgG (whole molecule) HRP conjugate. Immune serum from
mouse 3365, diluted 1/1000 in Buffer L, was included for comparison.
ND = not determined.
Absorbance at 450 nm
Sample
Nunc Maxisorp Immulonl Immulon2
VP1/10 0.044 0.000 0.001
VP1/89 0.290 0.026 0.331
VP1/121 1.645 0.034 ND
VP1/140 0.020 0.002 0.087
VP1/169 >2.050 0.207 1.559
VP1/271 0.126 0.032 0.000
ESA 4 0.658 0.141 0.561
Spleen supernatant 1.231 0.365 0.732
Immune serum 0.049 0.000 0.000
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TABLE 3.6
Specificity of AVP-capture ELISA-positive hvbridoma culture supernatants
Undiluted culture supernatants were assayed in Immulon 1 MicroELISA wells
coated with the materials indicated, without any additional plate-blocking agent.
The absorbance caused by non-specific binding of the sheep anti-mouse IgG (whole
molecule) HRP conjugate to each plate-coating material has been subtracted from the
values shown. Immune serum from mouse 3363, diluted 1/1000 in 15% FCS medium, was
included for comparison.
Absorbance at 450 nm
Sample "
Uncoated 2% 2% 1% 0.01% 0.01% lOng/ml
FCS NBCS BSA TGI NRS AVP
VP1/10 0.066 0.123 0.177 0.777 0.040 0.088 0.090
VP1/89 0.190 0.135 0.603 1.658 1.073 1.120 0.410
VP1/121 0.409 0.181 0.717 1.855 1.449 1.609 0.822
VP1/140 0.485 0.256 1.000 >2.050 1.606 >2.050 0.746
VP1/169 1.733 1.843 >2.050 >2.050 >2.050 >2.050 >2.050
VP1/271 0.290 0.378 1.484 >2.050 >2.050 >2.050 1.063
VP1/367 0.045 0.045 0.088 1.083 0.040 0.152 0.073
Immune serum 0.063 0.072 0.799 0.319 0.964 0.971 0.158
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AVP-capture ELISA-positive culture supernatants bound strongly to all of the
antibody-containing materials, but not to foetal calf serum (Table 3.6), therefore it
was concluded that they contained anti-immunoglobulin antibodies which would have
caused false positive results in the AVP-capture ELISA, even in the absence of a
blocking protein, by binding directly to the antibody fraction of TGI antiserum.
Dilution in BSA-containing buffer decreased binding in these samples (Table 3.2)
because the anti-immunoglobulin antibodies bound to antibody contaminants in the
BSA and so were unavailable to bind to the AVP-capture ELISA wells.
3.3.4 FURTHER AVP-CAPTURE ELISA STUDIES
Immune mouse serum contained high concentrations of anti-immunoglobulin and
anti-BSA antibodies. Even after dilution in Buffer L, it bound strongly to AVP-capture
ELISA wells (Figure 3.12A) yet no anti-AVP IgG could be detected by SAM-RIA.
Higher AVP-capture ELISA binding was recorded if the serum was diluted in culture
medium (Figure 3.12A) but the difference was less dramatic than that observed with
AVP-capture ELISA-positive hybridoma culture supernatants (Figure 3.10, Table 3.2).
The anti-immunoglobulin and anti-BSA antibodies had probably been raised in
response to contaminants in the thyroglobulin that was used for immunogen
preparation, because serum from a mouse immunized with PTH 53-84 conjugated to
thyroglobulin (by the method in Section 2.2.1.4) also bound to AVP-capture ELISA
wells (Figure 3.12B). PTH 53-84 is structurally unrelated to AVP so the serum
contained no anti-AVP activity, and its AVP-capture ELISA binding was therefore
attributed to anti-thyroglobulin or anti-contaminant antibodies. Lower AVP-capture
ELISA absorbances were obtained when the PTH-thyroglobulin antiserum was diluted
in Buffer L rather than culture medium (Figure 3.12B), showing that it contained
antibodies which behaved similarly to those raised against AVP-thyroglobulin.
Although the AVP-thyroglobulin antiserum did not seem to contain anti-AVP




Effect of diluent composition on the AVP-capture ELISA response of immune mouse
serum
Serum from mouse 3365, immunized with AVP-thyroglobulin conjugate (A), and
from a mouse immunized with PTH 53-84 conjugated to thyroglobulin (B), was diluted
in 15% FCS medium (•), or Buffer L (o), then assayed by AVP-capture ELISA.
Antibody binding was revealed with sheep anti-mouse IgG (whole molecule) HRP
conjugate.
antiserum (Figure 3.12). This may have been caused by a difference in the
concentration of contaminants in the thyroglobulin preparations used for immunogen
production or, alternatively, the larger size of the PTH 53-84 peptide may have
influenced the immunogenicity of the conjugate so that more of the response was
directed towards the peptide than the carrier. Antiserum against ANP-thyroglobulin
was not available for comparison when these experiments were carried out.
Antibody concentrations in hybridoma culture supernatants are initially low
therefore screening assays must be very sensitive to avoid false negative results, and
supernatants are commonly assayed without dilution (Galfre and Milstein, 1981;
Robert et al., 1985; Vaidya et al., 1985; Smith and Wilson, 1986; Gustafsson, 1990).
However, false positive results were a major problem when undiluted culture
supernatants were assayed by AVP-capture ELISA. Dilution of supernatants with an
equal volume of Buffer L did not always eliminate false positive binding (Table 3.2),
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FIGURE 3.13
Effect of normal rabbit serum on the binding of AVP-capture ELISA-positive culture
supernatants to TGI antiserum
Normal rabbit serum dilutions (10 pi, in 15% FCS medium) were added to
TGI antiserum-coated, BSA-blocked, Microwells, which were immediately used to
assay undiluted culture supernatants (90 pi/well) from hybridomas VP1/103 (•),
VP1/169 (o), VP1/271 (a) and VP1/367 (x). Antibody binding was revealed with
sheep anti-mouse IgG (whole molecule) HRP conjugate.
and higher dilution factors would have increased the risk of false negative results, so
the addition of non-immune serum to the supernatant samples seemed the best way to
remove anti-immunoglobulin antibody interference.
When AVP-capture ELISA-positive culture supernatants were incubated with
normal rabbit serum (NRS) in TGI antiserum-coated BSA-blocked wells, binding tended
to decrease as the NRS concentration increased (Figure 3.13) but a final concentration
of 10% NRS could not eliminate all false positive binding, while the binding of
supernatant from hybridoma VP1/103 actually increased with the NRS concentration.
Similar results were obtained whether NRS was added to the sample or substituted
for BSA in the assay buffer (Table 3.7), even though the buffer was only present
during conjugate incubation. NRS could therefore displace anti-immunoglobulin
antibodies which had already bound to the coated wells. Binding decreased further if
NRS was present in both the sample and the buffer (Table 3.7) but this still did not
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TABLE 3.7
Effect of normal rabbit serum on false positive AVP-capture ELISA results
Undiluted culture supernatants from AVP-capture ELISA-positive hybridomas,
and in uifro-boosted spleen cells, were assayed in AVP-capture ELISA Microwells
(90 pl/well) to which either 10 pi 15% FCS medium or 10 pi NRS had been added.
Antibody binding was revealed with sheep anti-mouse IgG (whole molecule) HRP
conjugate, diluted in either Buffer L (BSA buffer) or Buffer K containing 2% NRS and
0.1% Tween 20 (NRS buffer). Immune serum from mouse 3365, diluted 1/1000 in
15% FCS medium, was included for comparison. The absorbance caused by non-specific
binding of the HRP conjugate has been subtracted from the values shown.
Absorbance at 450 nm
Sample BSA Buffer NRS Buffer
10 pi Medium 10 pi NRS 10 pi Medium 10 pi NRS
VP1/10 0.345 0.207 0.194 0.121
VP1/89 0.265 0.072 0.042 0.013
VP1/103 0.227 0.435 0.089 0.140
VP1/121 0.438 0.079 0.150 0.008
VP1/140 0.865 0.415 0.302 0.216
VP1/169 1.090 0.538 0.533 0.199
VP1/271 1.401 0.799 0.694 0.417
VP1/367 0.120 0.000 0.023 0.003
Spleen supernatant 0.321 0.179 0.137 0.077




Binding specificity of anti-AVP antibody-containing mouse serum
Serum from mouse 3476, immunized with AVP-thyroglobulin conjugate, was
diluted in Buffer K containing 2% bovine serum and 0.1% Tween 20, then assayed in
Immulon 1 MicroELISA wells coated with 10 ng/ml AVP (x), 0.01% normal rabbit
serum (a), 0.01% TGI antiserum (o), or 0.01% TGI antiserum preincubated with
50 ng/ml AVP (AVP-capture ELISA, •), without any additional plate-blocking agent.
Antibody binding was revealed with sheep anti-mouse IgG (whole molecule) HRP
conjugate (A) or goat anti-mouse 'polyvalent immunoglobulins' HRP conjugate (B).
The absorbances caused by non-specific binding of the HRP conjugates to each
plate-coating material have been subtracted from the values shown.
eliminate all false positive results.
When tail bleed sera from other AVP-thyroglobulin-immunized mice became
available, the AVP-capture ELISA was shown to be genuinely capable of detecting
anti-AVP antibodies (Figure 3.14) although low titre sera gave ambiguous results. The
anti-IgG HRP conjugate detected strong binding to AVP-capture ELISA wells and weak
binding to AVP-coated wells (Figure 3.14A), whereas the 'polyvalent immunoglobulins'
HRP conjugate recorded strong binding to both types of well (Figure 3.14B). This
suggested that the AVP-capture ELISA bound all isotypes equally, while the
AVP-coated wells bound anti-AVP IgM more efficiently than IgG.
Immune serum bound equally to TGI antiserum and to normal rabbit serum
(Figure 3.14), which suggested that direct binding to immobilized TGI antiserum had
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been caused by anti-immunoglobulin antibodies and not, as previously thought, by
AVP-bound antibodies. The anti-IgG HRP conjugate detected less anti-immunoglobulin
binding (Figure 3.14A) than did the 'polyvalent immunoglobulins' HRP conjugate
(Figure 3.14B), confirming previous suggestions that many of these antibodies were
either IgM or IgA isotypes (Figure 3.7).
Despite these observations, the problem of preventing false positive binding
remained unresolved therefore the AVP-capture ELISA could not be used for further
hybridoma screening.
3.4 RADIOIMMUNOASSAY
Initial experiments with SAM-RIA failed to detect anti-AVP antibody in
immune mouse serum. There had been no other mouse anti-AVP antibody available so
there was no positive control for the assay and it was impossible to establish
whether the problem had been assay failure or absence of antibody.
In the SAM-RIA, antibody-bound and free tracer were separated by the
SAM-S-500 solid phase which was specific for mouse antibodies and bound mainly to
IgG isotypes. The PEG-RIA was not species-specific because it achieved separation by
PEG 8000 precipitation of antibodies. Consequently, rabbit TGI antiserum could be used
as a positive control in the PEG-RIA but not in the SAM-RIA.
3.4.1 PEG SEPARATION METHOD (PEG-RIA)
When tail bleed sera from eight AVP-thyroglobulin-immunized mice were
assayed by PEG-RIA, all of the sera bound 125I-AVP although a lot of the anti-AVP
antibody might have been IgM because PEG 8000 precipitated all isotypes. None of
the AVP-capture ELISA-positive hybridoma culture supernatants (Section 3.3.2) could
IOC
bind I-AVP, backing up previous data which had suggested that these supernatants
contained only anti-immunoglobulin and anti-BSA antibodies (Section 3.3.3).
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The PEG-RIA was prone to high background readings (5-10% of added tracer)
and poor reproducibility, which was caused by inefficient separation of unbound
125I-AVP although longer tube-drainage times produced better results. The assay was
also unlikely to detect antibodies specific for epitopes close to the tyrosine residue of
AVP. However, despite these problems, the PEG-RIA was used to screen hybridoma
supernatants from the next two groups of cell fusions (Table 4.6).
The PEG-RIA detected 125I-AVP binding in an in vitro-boosted spleen cell
culture supernatant even though unlabelled AVP was present. However, when
51 hybridoma culture supernatants were assayed, only one bound I-AVP. The
antibody in this supernatant was not detected by the AVP-capture ELISA or by an
AVP-coated-plate ELISA (10 ng/ml AVP, unblocked wells) which detected anti-AVP
antibody in immune mouse serum and in the in uifro-boosted spleen cell supernatant.
Nevertheless, the PEG-RIA-positive hybridoma was cloned, and subcloned, to produce
a monoclonal cell line which secreted ESVP 1, an anti-AVP MAb.
3.4.2 SECOND ANTIBODY SEPARATION METHOD (SAM-RIA)
Immune mouse serum, ESVP 1 supernatant and an in vitro-boosted spleen cell
supernatant, which all bound 125I-AVP in the PEG-RIA, were also SAM-RIA-positive.
Although the supernatants produced similar results in both assays, higher immune
serum titres were estimated by PEG-RIA than by SAM-RIA (Table 3.8), which
suggested that the serum contained significant amounts of anti-AVP IgM.
Since the early attempts to assay immune serum by SAM-RIA had been
unsuccessful, two of the original tail bleed sera were compared with serum samples
taken from the same mice after additional boosting (Figure 3.15). Both mice were
SAM-RIA-negative before additional boosting but positive afterwards, which
suggested that the initial sera contained no anti-AVP IgG. Initial serum from
mouse 3365 had produced strong positive AVP-coated-plate ELISA results with the
'polyvalent immunoglobulins' HRP conjugate (Figure 3.1), indicating that the serum
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TABLE 3.8
Comparison of the immune serum anti-AVP antibody titres estimated by PEG-RIA and
by SAM-RIA
Tail bleed sera from mice immunized with AVP-thyroglobulin conjugate were
diluted in Buffer K containing 2% bovine serum and 1% Tween 20, then assayed by
PEG-RIA and by SAM-RIA. Antibody titres were defined as the serum dilutions

















The effect of additional boosting on the SAM-RIA response of serum from immunized
mice
Tail-bleeding was carried out after basic immunization (priming dose of
AVP-thyroglobulin conjugate and two boosts, o) and after additional boosting (•). The
serum was diluted in Buffer K containing 2% bovine serum, then assayed by SAM-RIA.
Mouse 3365 (A) had received three additional boosts of immunogen in alum, while
mouse 3366 (B) had received two additional boosts.
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contained a lot of anti-AVP antibody, but this must all have been IgM.
The SAM-RIA was superior to the PEG-RIA because its background readings
were much lower (0.5-1.0% of added tracer) and it was selective for the desired IgG
isotypes. It was therefore used to screen the next group of cell fusions, using ESVP 1
MAb as a positive control. However, 288 hybridomas were SAM-RIA-negative, even
though the spleen donor (mouse 3476, Table 4.2) was well-immunized and its
in vitro-boosted spleen cell supernatant was SAM-RIA-positive. Some anti-AVP
antibodies might have been missed because they could not bind 125I-AVP therefore
screening by AVP-coated-plate ELISA was investigated as an alternative to RIA.
3.5 AVP-COATED-PLATE ELISA
The original AVP-coated-plate ELISA was set up using rabbit TGI antiserum
as the sample, with donkey anti-rabbit IgG HRP conjugate to detect binding. When
immune mouse serum became available, coating with 10 ng/ml AVP had still seemed
satisfactory because serum from mouse 3365 produced a good dilution curve with the
'polyvalent immunoglobulins' HRP conjugate (Figure 3.1), although poor results were
obtained with the anti-mouse IgG HRP conjugate (Figure 3.3) due to a lack of
anti-AVP IgG (Figure 3.15). However, even when the AVP-capture ELISA identified
immune serum which contained anti-AVP IgG, the AVP-coated-plate ELISA recorded
very low serum IgG binding (Figure 3.14A) and could not detect ESVP 1, an anti-AVP
IgGl MAb, in undiluted culture supernatant.
Investigation of the AVP-coated-plate ELISA revealed that ESVP 1 binding
increased dramatically as the AVP-coating concentration increased (Figure 3.16A). In
contrast, there was a relatively small effect on TGI antiserum (Figure 3.16B) which
bound well at all AVP-coating concentrations. This showed that the high avidity
TGI antiserum had misleadingly suggested that a coating of 10 ng/ml AVP would
detect anti-AVP IgG antibodies, when much higher AVP-coating concentrations were
actually needed for efficient MAb detection.
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Supernatant dilution Serum dilution
FIGURE 3.16
Effect of AVP-coating concentration on antibody binding in the AVP-coated-plate
ELISA
ESVP 1 MAb culture supernatant (A), and rabbit TGI antiserum (B), were
diluted in Buffer L, then assayed in Nunc Microwells coated with lOng/ml (a),
100 ng/ml (o), or 1 pg/ml AVP (•), without any additional plate-blocking agent.
ESVP 1 binding was revealed with rabbit anti-mouse IgG (whole molecule) HRP
conjugate (1/200 dilution in Buffer L), while TGI antiserum binding was revealed with
donkey anti-rabbit IgG HRP conjugate (1/500 dilution in Buffer L). The absorbances
caused by non-specific binding of the HRP conjugates have been subtracted from the
values shown.
An AVP-coated-plate ELISA with a coating of 1 |ig/ml AVP, and using rabbit
anti-mouse IgG (whole molecule) HRP conjugate, seemed appropriate for hybridoma
screening because it recorded strong ESVP 1 MAb binding (Figure 3.16A). It also
produced immune mouse serum titre estimates which were roughly similar to those
produced by SAM-RIA (Table 3.9). A few sera had higher AVP-coated-plate ELISA
titres than SAM-RIA titres (e.g. mouse 3477, Table 3.9) because they contained some
IOC
antibodies that could bind immobilized AVP but not I-AVP. This demonstrated that
the ELISA could detect anti-AVP specificities that the SAM-RIA would miss.
Plate-blocking was omitted from the AVP-coated-plate ELISA because BSA
caused non-specific binding of the anti-mouse IgG HRP conjugate (Table 3.1), allowed
false positive binding of anti-BSA and anti-immunoglobulin antibodies (Table 3.6),
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TABLE 3.9
Comparison of the immune serum antibody titres estimated by AVP-coated-plate
ELISA and bv SAM-RIA
Tail bleed sera from mice immunized with AVP-thyroglobulin conjugate were
diluted in Buffer L then assayed by AVP-coated-plate ELISA (1 pg/ml AVP, unblocked
Immulon 2 MicroELISA wells) and by SAM-RIA. ELISA binding was revealed with
rabbit anti-mouse IgG (whole molecule) HRP conjugate. The antibody titre was defined
as the serum dilution which produced an absorbance of 1.0 at 450 nm










Effect of BSA-blocking on antibody binding in the AVP-coated-plate ELISA
ESVP 2 MAb culture supernatant and immune serum from mouse 3475 (diluted
1/2 and 1/2000, respectively, in Buffer L) were assayed in BSA-blocked, or unblocked,
Immulon 2 MicroELISA wells coated with 1 pg/ml AVP. The absorbance caused by
non-specific binding of the rabbit anti-mouse IgG (whole molecule) HRP conjugate has
been subtracted from the values shown. Colour development occurred rapidly therefore
the absorbance at 630 nm was recorded before H2S04 addition.
Absorbance at 630 nm
Sample
Blocked Unblocked
ESVP 2 1.085 1.297
Immune serum 0.534 0.614
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and decreased anti-AVP antibody binding by steric hindrance (Table 3.10). All
hybridoma culture supernatants were therefore diluted with an equal volume of
Buffer L, which introduced Tween 20 and so prevented non-specific binding to the
unblocked wells during the 16 hour incubation period (Mohammad and Esen, 1989). The
initial hybridoma cultures were so small that only 150 pi supernatant could be taken
for screening but dilution increased the sample volume and so allowed duplicate assay
wells to be set up, which improved the reliability of the result. As an additional
benefit, sample dilution often increased the binding of anti-AVP antibodies
(Table 3.11) so that false negative results were less likely to occur.
Fusion VP12, which generated hybridomas in 466 culture wells (Table 4.6), was
screened by AVP-coated-plate ELISA, AVP-capture ELISA and SAM-RIA. One
monoclonal cell line was established after it was detected by both the
AVP-coated-plate ELISA and the SAM-RIA, but it could not be detected by the
AVP-capture ELISA (ESVP 2 MAb, Table 3.11). Undiluted culture supernatants from
110 hybridomas were AVP-capture ELISA-positive but did not contain anti-AVP
antibody because AVP-coated-plate ELISA binding was prevented by dilution with an
equal volume of Buffer L (Table 3.11) and all were SAM-RIA-negative. Dilution also
decreased the binding of these supernatants to thyroglobulin, BSA, NRS, TGI
antiserum and AVP-capture ELISA wells (Table 3.11). Immune mouse serum and
in yffra-boosted spleen cell supernatants reacted strongly with thyroglobulin even
after dilution in Buffer L because they contained anti-thyroglobulin antibodies, and in
comparison their binding to BSA, NRS and TGI antiserum was weak (Table 3.11).
The remaining cell fusions were screened by AVP-coated-plate ELISA, with
RIA confirmation of positive results, and two further monoclonal cell lines were
established. These secreted ESVP 3 and ESVP 4, which were anti-AVP IgM and IgA
MAbs, respectively, therefore the anti-mouse IgG HRP conjugate was not specific for
mouse IgG. In addition to binding mouse IgM and IgA, the conjugate showed some
cross-reaction with rabbit and bovine sera, even if it was an affinity-isolated
preparation (Table 3.1).
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Effect of BSA-blocking on the ANP-coated-plate ELISA response of immune mouse
serum
Serum from mouse 3478, immunized with ANP-thyroglobulin conjugate, was
diluted in Buffer L then assayed in BSA-blocked (•), or unblocked (o), Immulon 2
MicroELISA wells coated with 100 ng/ml ANP. Antibody binding was revealed with
rabbit anti-mouse IgG (whole molecule) HRP conjugate. Colour development occurred
rapidly therefore the absorbance at 630 nm was recorded before H2S04 addition.
3.6 ANP-COATED-PLATE ELISA
The original ANP-coated-plate ELISA method (Prowse et al., 1989), which
used BSA-blocked wells coated with 100 ng/ml ANP, was likely to cross-react with
the anti-BSA and anti-immunoglobulin antibodies that were expected to be generated
in response to immunization with ANP-thyroglobulin conjugate. This cross-reaction was
avoided by the omission of BSA-blocking, while non-specific binding to the unblocked
wells was prevented by dilution of all samples in Buffer L. Higher anti-ANP
antibody binding was recorded in the absence of BSA-blocking (Figure 3.17) because
BSA caused steric hindrance.
Antibody binding increased with the ANP-coating concentration (Figure 3.18),
but the effect on ESA 4 MAb detection (Figure 3.18A) was less dramatic than that on
ESVP1 MAb detection when the AVP-coating concentration increased (Figure 3.16A).
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Supernatant dilution Serum dilution
FIGURE 3.18
Effect of ANP-coating concentration on antibody binding in the ANP-coated-plate
ELISA
ESA 4 MAb culture supernatant (A), and serum from mouse 3479, immunized
with ANP-thyroglobulin conjugate (B), were diluted in Buffer L then assayed
in Immulon 2 MicroELISA wells coated with 10 ng/ml (a), 100 ng/ml (o), or
1 pg/ml ANP (•), without any additional plate-blocking agent. Antibody binding was
revealed with rabbit anti-mouse IgG (whole molecule) HRP conjugate. Colour
development occurred rapidly therefore the absorbance at 630 nm was recorded before
H2S04 addition.
This may have been due to the difference in binding affinities because ESA 4 had a
much higher affinity constant (Table 7.1) than ESVP 1 (Table 5.1). ESA 4 MAb and
immune mouse serum bound strongly to all of the ANP-coating concentrations which
were tested, but 100 ng/ml ANP produced the best MAb detection because high
absorbances were obtained over a wide range of ESA 4 dilutions (Figure 3.18).
An ANP-coated-plate ELISA with 100 ng/ml ANP-coated, unblocked, wells
was selected for hybridoma screening. Culture supernatants were diluted with an equal
volume of Buffer L, and antibody binding was revealed with rabbit anti-mouse IgG
(whole molecule) HRP conjugate. This assay only detected anti-ANP antibodies,
whose binding was often increased by dilution in Buffer L (Table 3.12).
Some hybridomas which were raised against ANP-thyroglobulin conjugate
secreted antibodies that bound strongly to BSA-blocked, rabbit TGI antiserum-coated
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TABLE 3.12
Effect of sample dilution on ANP-coated-plate ELISA binding response
Culture supernatants from anti-ANP MAbs (ESNP 1 and ESNP 3), an
anti-immunoglobulin hybridoma (NP6/27), and in uffro-boosted spleen cells derived
from mouse 3478, were assayed in Immulon 1 MicroELISA wells coated with the
materials indicated. Serum from mouse 3481, immunized with ANP-thyroglobulin
conjugate, diluted 1/500 in 15% FCS medium, was included for comparison. All
samples were assayed before, and after (figures in parentheses), dilution with an
equal volume of Buffer L. The absorbance caused by non-specific binding of the rabbit
anti-mouse IgG (whole molecule) HRP conjugate to each plate-coating material has





Absorbance at 450 nm








0.868 (2.020) 0.007 (0.000) 0.002 (0.007) 0.005 (0.003)
1.266 (1.765) 0.001 (0.000) 0.004 (0.015) 0.000 (0.004)
0.000 (0.000) 0.066 (0.026) 0.187 (0.075) 0.063 (0.036)
0.006 (0.016) 0.185 (0.061) 0.220 (0.342) 0.087 (0.042)
0.359 (0.766) 0.025 (0.001) 1.819 (>2.050) 0.020 (0.019)
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wells but not to ANP, while an in uitro-boosted spleen cell supernatant which
contained very little anti-ANP antibody could bind to thyroglobulin and to BSA
(Table 3.12), indicating that anti-thyroglobulin, anti-BSA and anti-immunoglobulin
antibodies had been produced in response to the immunogen. In contrast, immune mouse
serum bound strongly to ANP and thyroglobulin yet appeared to contain negligible
anti-BSA and anti-immunoglobulin activity (Table 3.12) even when diluted in culture
medium rather than Buffer L, which suggested that BSA and immunoglobulins were
probably very minor components of the ANP-thyroglobulin immunogen.
RIA was not used to screen for anti-ANP antibodies. 125I-ANP could not be
prepared locally because there were no HPLC facilities for the separation of
unreacted 125I, while purchased 125I-ANP was expensive and had a short shelf-life.
The ANP-coated-plate ELISA was therefore the most cost-effective assay.
3.7 DISCUSSION
A two-site antigen-capture ELISA, using rabbit polyclonal antibodies to
immobilize the antigen (Smith and Wilson, 1986), had seemed ideal for hybridoma
screening because MAbs suitable for two-site immunometric assay development were
required. This type of screening assay was reported to be more sensitive than
antigen-coated-plate ELISA (A1 Moudallal et al., 1984; Brennand et al., 1986) and
was the only ELISA format that could detect all of the antigen-specific MAbs which
were tested by Brennand et al. (1986).
Initial tests had suggested that the AVP-capture ELISA detected anti-AVP
antibodies, despite slight cross-reaction with anti-BSA antibodies (Figure 3.7) and
non-specific binding of the anti-mouse IgG HRP conjugate to the solid-phase
components (Table 3.1). Serum from an AVP-thyroglobulin-immunized mouse produced
much higher AVP-capture ELISA absorbances than normal mouse serum (Figure 3.9) or
serum from a mouse immunized with PTH 53-84-thyroglobulin conjugate (Figure 3.12).
The anti-AVP-thyroglobulin serum bound to TGI antiserum-coated wells whether or
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not they were preincubated with AVP (Figures 3.6 and 3.7), but this was assumed to
indicate the presence of AVP-bound mouse antibodies. However, the AVP-capture
ELISA-positive culture supernatants failed to bind after dilution in Buffer L
(Table 3.2), even though significant adsorption to uncoated wells (Tables 3.5 and 3.6)
had suggested that they contained high concentrations of antibody (Miller et al.,
1983). Investigation of this phenomenon revealed that undiluted AVP-capture
ELISA-positive culture supernatants also bound strongly to rabbit TGI antiserum,
normal rabbit serum, bovine serum and BSA (Table 3.6), while their response to FCS
was the same as to uncoated wells.
Many BSA preparations are contaminated by immunoglobulins (Boscato and
Stuart, 1988), which were also present in all of the sera used in this work, except
FCS, therefore most of the AVP-capture ELISA-positive supernatants probably
contained anti-immunoglobulin antibodies. Since antibodies are raised against all
immunogen components, it is likely that the bovine thyroglobulin used in immunogen
production (and described by Sigma as 'electrophoretically heterogeneous') was
contaminated by immunoglobulins. Anti-immunoglobulin antibodies have often been
reported to cause interference in immunoassays and have been described as
heterophilic antibodies (Boscato and Stuart, 1988; Nahm and Hoffmann, 1990;
Levinson, 1992). The thyroglobulin preparation presumably also contained BSA because
anti-BSA antibodies were detected in immune mouse serum (Figure 3.7) and in some
hybridoma culture supernatants (e.g. hybridoma VP1/367, Table 3.6). When
supernatants were diluted with an equal volume of Buffer L, the anti-BSA and
anti-immunoglobulin antibodies reacted with the BSA and immunoglobulins in the
buffer so that binding to AVP-capture ELISA wells was prevented, although high
titre supernatants could still show some binding due to inadequate neutralization
(Table 3.2). Dilution in cell culture medium did not have this effect (Table 3.2,
Figure 3.10) because it contained no immunoglobulins and relatively little BSA.
Traditional ELISA methods include a blocking step during which an inert
protein is adsorbed onto unoccupied sites on the solid phase to prevent non-specific
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binding of the assay components (Campbell, 1984), although there are reports which
suggest that blocking is unnecessary (Engvall and Perlmann, 1972; Mohammad and
Esen, 1989; Gosling, 1990). The effectiveness of any particular blocking protein seems to
depend on the assay system in which it is used (Kenna et al., 1985; Vogt et al., 1987;
Pruslin et al., 1991) and there is a risk of interference from anti-blocking-protein
antibodies (Schonheyder and Andersen, 1984; Kemeny and Chantler, 1988). BSA is a
commonly-used blocking agent (Reading, 1982; Douillard and Hoffman, 1983;
Gustafsson, 1990; Pruslin et al., 1991) although casein (Kenna et al., 1985; Vogt et al.,
1987) and non-fat dried milk (Vogt et al., 1987; Mohammad and Esen, 1989) have been
suggested as cheaper alternatives and serum has been used occasionally (Hou-Yu et
al., 1982; Campbell, 1984). However, these materials are all likely to contain
immunoglobulins and so will be bound by anti-immunoglobulin antibodies. Campbell
(1984) suggested the use of antigen-free plates to confirm that antibodies are
antigen-specific and do not bind to the blocking protein or the plastic surface, but this
increases the work and expense involved in hybridoma screening and introduces the
risk that antigen-specific antibodies might be overlooked if they are present in
supernatants which also contain anti-blocking-protein antibodies.
Omission of BSA-blocking from the AVP-coated-plate and ANP-coated-plate
ELISAs prevented the binding of anti-BSA and anti-immunoglobulin antibodies,
decreased non-specific binding of the anti-mouse IgG HRP conjugate (Table 3.1), and
increased specific antibody binding (Table 3.10, Figure 3.17) by removing the steric
hindrance (Hobbs, 1989; Mohammad and Esen, 1989) that was caused by the large
BSA molecules (67,000 Daltons) surrounding the small AVP (1,084 Daltons) and ANP
(3,077 Daltons) peptides. The binding of anti-immunoglobulin antibody to TGI
antiserum-coated wells was also increased in the absence of BSA-blocking (Figure 3.7).
Since the Fc portion of IgG is hydrophobic (Ishikawa, 1987) it is likely to be the
part of the molecule which adsorbs to the solid phase. BSA-blocking will sterically
hinder binding to this region therefore many of the anti-immunoglobulin specificities
were probably directed against the Fc portion of the antibody molecule.
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Dilution of hybridoma culture supernatants with an equal volume of Buffer L
introduced Tween 20 which prevented non-specific binding to the unblocked ELISA
wells (Mohammad and Esen, 1989). At the same time, specific antibody binding often
increased (Tables 3.11 and 3.12), probably as a result of buffering the sample because
spent culture supernatants tend to be acidic (Campbell, 1984) while most antibodies
bind optimally at neutral pH values. However, sample dilution may also have
decreased the steric hindrance which occurs when second antibody-enzyme conjugates
bind to high concentrations of solid phase-bound antibody (Koertge and Butler, 1985),
and there may have been a prozone effect because concentrated antibody solutions bind
univalently to immobilized antigen and can then leach off the assay plate during
subsequent incubation and washing steps (Nygren et al., 1985; Vos et al., 1987).
Caution is required when immune sera are used to develop hybridoma screening
assays, because their binding properties differ from those of MAbs so that they may
bind strongly under conditions in which MAbs are undetectable (Al Moudallal et al.,
1984). Normal mouse serum may not be an appropriate negative control because it does
not produce the false positive binding which can be caused by antibodies raised
against contaminants in the immunogen. Serum from an animal immunized with an
unrelated peptide conjugated to the same carrier protein is more likely to give an
indication of possible problems, particularly if it is diluted in culture medium instead
of assay buffer. In this work, serum from a PTH 53-84-thyroglobulin-immunized mouse
bound more strongly to AVP-capture ELISA wells if it was diluted in 15% FCS
medium rather than Buffer L (Figure 3.12B), which showed that it contained some
anti-immunoglobulin or anti-BSA antibodies. However, the PTH 53-84-thyroglobulin
(Figure 3.12B) and ANP-thyroglobulin (Table 3.12) conjugates did not produce such a
strong anti-immunoglobulin response as the AVP-thyroglobulin conjugate (Figure 3.12A,
Table 3.11), which may indicate that there were batch-to-batch variations in the
contaminant concentrations present in the thyroglobulin which was used for immunogen
production.
Immune serum was used to set up the AVP-capture ELISA and the
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AVP-coated-plate ELISA but gave misleading results because two major problems were
concealed. Firstly, the presence of anti-immunoglobulin and anti-BSA antibodies was
masked when immune serum was diluted in Buffer L, and only became obvious when
undiluted culture supernatants were assayed. This problem, which was also
encountered when screening hybridomas raised against thyroglobulin-conjugated
peptides derived from PTH (unpublished observation) and HIV (J. Boyd, personal
communication), might have been prevented by using an alternative carrier protein in
the immunogen. However, Skowsky and Fisher (1972b) showed that the choice of
carrier is important in determining the immune response to small peptides. Bovine
thyroglobulin was used because it was known to be a good carrier for AVP and had
been successfully used in anti-AVP antibody production by many research groups
(Baylis and Heath, 1977; Hou-Yu et al., 1982; Jones et ah, 1985; Robert et ah, 1985;
Work et ah, 1985; Smith and Mcintosh, 1986).
Secondly, the anti-AVP MAbs were undetectable by AVP-capture ELISA
(Table 3.11) and difficult to detect at low AVP-coating concentrations in the
AVP-coated-plate ELISA (Figure 3.16A), even though the polyclonal anti-AVP
antibodies of immune serum produced high absorbances under these conditions
(Figure 3.16B). MAbs bind poorly at low epitope densities (Lew, 1984), especially
when they have low binding affinities (Nimmo et ah, 1984; Nygren et ah, 1985;
Peterman et ah, 1985), whereas the high affinity antibodies in immune serum bind
strongly and give the impression that an appropriate screening assay has been
developed even though much higher antigen-coating concentrations may be needed for
efficient MAb detection.
All of the anti-AVP MAbs, and many anti-ANP MAbs, reported by other
workers were raised against AVP-thyroglobulin and ANP-thyroglobulin conjugates,
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respectively. The anti-AVP MAbs were detected by liquid-phase RIA with I-AVP
(Hou-Yu et ah, 1982; Robert et ah, 1985) or 3H-AVP (Jurzak et ah, 1990), by
solid-phase RIA using 125I-anti-mouse F(ab)2 (Hou-Yu et ah, 1982), by ELISA (Robert
et ah, 1985; Jurzak et ah, 1990) and by an immunohistochemical method (Robert et
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al., 1985). Most workers screened for anti-ANP MAbs by liquid-phase RIA with
125I-ANP (John et al., 1986; Naomi et al., 1987; Mukoyama et al., 1988a; Rathinavelu
and Isom, 1989; Prowse et al., 1989) although solid-phase RIA with 125I-anti-mouse
IgG (Glembotski et al., 1987; Milne et al., 1987) and ELISA (Prowse et al., 1989)
screening methods have also been reported.
Liquid-phase RIA with 125I-Ag is unlikely to produce false positive screening
results but can give false negative results if antibodies are directed to parts of the
antigen into which 125I has been incorporated. This is a particular problem with AVP
because of its small size, and one anti-AVP MAb which does not readily bind to
125I-AVP has been reported (Hou-Yu et al., 1982; Valiquette et al., 1986). On the
other hand, solid-phase screening methods, in which the binding of antibodies to
unlabelled, immobilized, antigen is revealed by a second antibody, can easily give
rise to false positive results especially when blocking proteins are present. Several
workers used BSA-blocking (Robert et al., 1985; Prowse et al., 1989; Jurzak et al.,
1990), serum-blocking (Hou-Yu et al., 1982), or an immobilized antigen-BSA conjugate
(Glembotski et al., 1987; Milne et al., 1987; Jurzak et al., 1990) in their solid-phase
anti-AVP and anti-ANP screening assays, so interference from anti-BSA and
anti-immunoglobulin antibodies could be expected. However, false positive binding was
not reported even though undiluted culture supernatants were assayed, although
problems may have occurred because Robert et al. (1985) and Jurzak et al. (1990)
suggested that supernatants should be screened with more than one type of assay.
This is a wise precaution, particularly with small peptide antigens, because no
screening assay is entirely problem-free. In this work, anti-AVP MAbs were screened
by AVP-coated-plate ELISA and positive results were confirmed by RIA. Anti-ANP
MAbs were only screened by ANP-coated-plate ELISA but anti-ANP activity was
confirmed if the addition of liquid-phase ANP decreased antibody binding to
immobilized ANP.
Early screening of hybridoma supernatants is important because cultures often
contain more than one colony of cells and non-producers are liable to overgrow
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antibody-secreting cells (Goding, 1986). Screening assays must be sensitive to avoid
false negative results therefore supernatants are often assayed without prior dilution.
This is acceptable in liquid-phase RIA screening because buffer is introduced with the
labelled antigen and only specific binding is detected, but ELISA screening of
undiluted supernatants is prone to many problems. Hybridoma culture supernatants,
particularly those raised against thyroglobulin-conjugated peptides, should therefore
be diluted in buffer which contains BSA and Tween 20 prior to ELISA screening. This
simple step will prevent non-specific binding and so make plate-blocking unnecessary,
maximize specific binding by buffering the sample, and neutralize most of the
anti-immunoglobulin and anti-BSA antibodies which are produced in response to
contaminants in the thyroglobulin preparation.
Hybridomas are usually cloned as soon as positive screening results are
obtained (Goding, 1986), at which time there is often insufficient supernatant
available for repeat assays or specificity testing. If cloning is delayed until these
results are known, valuable cell lines may be lost because of overgrowth by
non-secreting variants. Valiquette et al. (1986) considered that false positive results
were more acceptable than false negatives, but a lot of time can be wasted cloning
hybridomas which are unsuitable because they secrete antibodies that bind to the
wrong antigen. The screening assay therefore needs to be specific for the antigen of
interest. This is particularly important if a successful cell fusion produces so many
positive hybridomas that they cannot all be handled. Hybridomas which produce the
highest initial screening results are generally selected for further study, so if false
positive results are higher than genuine positive binding, as happened with the
AVP-capture ELISA, there is a danger that cultures containing antigen-specific
antibodies will be rejected in favour of those which contain irrelevant antibodies.
Consequently, it is important to select hybridoma screening assays which minimize





The supply of any polyclonal antiserum is ultimately limited by the size and
lifespan of the immunized animal, while the properties of antisera vary between
bleeds (Campbell, 1984; Tijssen, 1985). Antibody-secreting plasma cells will not grow
in culture and can only survive for a few days, but after fusion with myeloma cells to
produce hybridomas (Kohler and Milstein, 1975) they can be cultured indefinitely to
yield unlimited quantities of monoclonal antibodies which, in contrast to polyclonal
antisera, have uniform properties. Hybridomas are usually prepared from spleen cells
but other tissues such as lymph nodes (Galfrfe and Milstein, 1981) can also be used.
The immune system can synthesize antibodies against an almost infinite
number of antigens before antigen contact occurs, each B cell secreting antibody which
is specific for a single epitope. Antibody-secreting hybridomas can therefore be
prepared from the cells of non-immunized animals (Campbell, 1984; Westerwoudt,
1985) although immunization produces better results because it induces clonal expansion
of antigen-specific B cells and so increases the number available for fusion. The
primary antibody response, which occurs after the first exposure to antigen, is
dominated by relatively low affinity IgM antibodies. Subsequent antigen contact
produces a much higher secondary antibody response which consists mainly of IgG
isotypes, and the average antibody affinity is increased as a result of the selective
expansion of high affinity antibody-secreting clones, a process known as affinity
maturation (Roitt et al., 1985; Tijssen, 1985). Immunization therefore increases the
probability that a cell fusion will produce hybridomas which secrete the high
affinity antibodies that are necessary for the development of sensitive immunoassays.
4.2 IMMUNIZATION OF MICE
Although immunization with unconjugated AVP has been reported (Roth et al.,
1966b; Wu and Rockey, 1969), small peptides tend to be poor immunogens so they are
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usually conjugated to large carrier molecules to induce a better antibody response.
However, antibodies raised against the carrier and the coupling agent (Briand et al.,
1985; Edwards et al., 1989; Peeters et al., 1989) can cause problems with some
screening assay formats. The AVP-capture ELISA, for example, produced false positive
results (Section 3.3.3) because it detected antibodies that had been raised against
components of the carrier preparation. Assays therefore need to be very carefully
selected when immunization has been carried out with a peptide-carrier conjugate.
Bovine thyroglobulin, which is highly immunogenic (Skowsky and Fisher,
1972b), is the most commonly-reported carrier molecule for AVP and ANP, but BSA
(Freisenhausen et al., 1976; Jiippner et al., 1986), KLH (Reilly and Root, 1986;
Rosmalen et al., 1987), IgG (Wu and Rockey, 1969), IgA (Rougon-Rappuzi et al., 1977;
Nishiuchi et al., 1986), polyvinylpyrillidone (Reilly and Root, 1986) and succinylated
poly-L-lysine (Vallotton, 1971) have also been used. All of the reported anti-AVP
MAbs (Hou-Yu et al., 1982; Jones et al., 1985; Robert et al., 1985; Work et al., 1985;
Jurzak et al., 1990), and several anti-ANP MAbs (Milne et al., 1987; Mukoyama et
al., 1988c; Prowse et al., 1989; Watanabe et al., 1989), were produced following
immunization with thyroglobulin-conjugated peptides. ANP-KLH conjugate has also
been used to produce some anti-ANP MAbs (John et al., 1986; Glembotski et al., 1987;
Naomi et al., 1987).
Bovine thyroglobulin was the main carrier molecule used in this project but
KLH was also tested as an alternative carrier for AVP.
4.2.1 AVP-THYROGLOBULIN
The first batch of AVP-thyroglobulin conjugate was prepared by the technical
staff, and immunization begun, so that immune mice would be available at the
start of this project. The conjugate was accidentally prepared with cyanamide
(carbodiimide, mol. wt. 42.04) rather than EDC (l-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide hydrochloride, mol. wt. 191.7) so the reaction conditions were incorrect,
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which would have affected the composition of the final product. Mouse nos. 3363-3366
were primed and boosted twice with cyanamide-coupled conjugate then tail-bled
for antibody titre estimation. Serum from mouse 3365 produced moderate
AVP-coated-plate ELISA binding but the other sera contained very little anti-AVP
antibody (Figure 3.1, Table 4.1) and all of them were SAM-RIA-negative (Table 4.1).
Mouse 3365 was boosted with a larger dose of the cyanamide-coupled conjugate in
week 12 of the immunization schedule but its serum antibody titre did not improve.
All subsequent work was carried out with EDC-coupled conjugate. The first
batch was prepared without the neutralization step (Section 2.2.1.1) and, as a result,
the acidic conditions caused immediate thyroglobulin precipitation which may have
hindered conjugation to AVP. Boosting with this material, in week 16, had only a
minor effect on the serum antibody titres estimated by AVP-coated-plate ELISA, and
mouse 3366 was still SAM-RIA-negative (Table 4.1). Nevertheless, mouse 3363 was
used in fusion VP1 (Table 4.6) which produced no anti-AVP MAbs but revealed that
the AVP-capture ELISA (Section 3.3) was unsuitable for screening hybridomas raised
against AVP-thyroglobulin conjugate.
After boosting with correctly-prepared conjugate (Section 2.2.1.1), in week 36,
mouse nos. 3364-3366 became SAM-RIA-positive (Table 4.1). It was concluded that the
anti-AVP response during the first four months of the immunization schedule had
consisted entirely of IgM antibodies, which could be detected by the goat anti-mouse
'polyvalent immunoglobulins' HRP conjugate but not by the SAM-S-500 solid phase
which bound mainly to IgG isotypes. The mice began to produce anti-AVP IgG after
boosting with the correctly-prepared conjugate, but only mouse 3365 responded
sufficiently well to be used in a cell fusion.
The next group of mice (nos. 3470-3477) was primed and boosted once with
EDC-coupled conjugate prepared without the neutralization step, then boosted with
correctly-prepared conjugate. All of the initial tail bleed sera were PEG-RIA-positive
(Table 4.2). After a boost in week 18, the SAM-RIA titres of sera from mouse
nos. 3474-3477 were less than 10% of their PEG-RIA titres (Table 4.2), which showed
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TABLE 4.1
Immunization with AVP-thvroglobuIin conjugate
Mouse nos. 3363-3366 were immunized by intraperitoneal injection of
AVP-thyroglobulin conjugate at the intervals shown below. The indicated dose
corresponds to the amount of AVP in the immunogen. Serum samples were assayed by
AVP-coated-plate ELISA (lOng/ml AVP, BSA-blocked wells, binding revealed by goat
anti-mouse 'polyvalent immunoglobulins' HRP conjugate) or by SAM-RIA (results in
parentheses). The antibody titre was defined as the serum dilution which produced an
absorbance of 1.0 at 450 nm (AVP-coated-plate ELISA) or half-maximal 125I-AVP
binding (SAM-RIA). ND = not determined.
During the first 12 weeks of the immunization schedule a cyanamide-coupled
conjugate was used. Subsequent boosting was carried out with a conjugate prepared by













































Immunization with AVP-thyroglobulin conjugate (EDC preparation)
Mouse nos. 3470-3477 were immunized by intraperitoneal injection of
AVP-thyroglobulin conjugate prepared by the EDC method, the dose indicating the
amount of AVP in the immunogen. Serum dilutions were assayed by PEG-RIA
(asterisked results), by SAM-RIA, or by AVP-coated-plate ELISA (1 pg/ml AVP,
unblocked wells, results in parentheses). ELISA binding was revealed with rabbit
anti-mouse IgG (whole molecule) HRP conjugate. The antibody titre was defined as
the serum dilution which produced an absorbance of 1.0 at 450 nm (AVP-coated-plate
ELISA) or half-maximal 125I-AVP binding (PEG-RIA and SAM-RIA). ND = not
determined. A dash indicates an occasion when a mouse was not boosted.
Serum antibody titre
Week Dose
3470 3471 3472 3473
0 10 pg ND ND ND ND
5 10 pg ND ND ND ND
10 10 pg *1/600 *<1/100 *1/1000 *1/4000
14 10 pg - - - Cell fusion
24 50 pg 1/160 <1/100 1/100
30 50 pg ND ND ND
32 50 pg 1/230 1/1000 1/240
42 50 pg 1/1600 (1/4000) 1/440 (1/300) 1/2400 (1/2400)
69 50 pg Cell fusion — —
3474 3475 3476 3477
0 20 pg ND ND ND ND
5 20 pg ND ND ND ND
10 20 pg *1/600 *1/1300 *1/9000 *1/500
18 50 pg *1/2000 <1/100 *1/3500 ND *1/35,000 1/3200 *1/2700 1/160
21 60 pg - - 1/32,000 -
24 50 pg 1/400 1/560 Cell fusion 1/130
30 50 pg ND ND ND
32 50 pg 1/560 1/1000 1/125
42 50 pg - 1/3200 (1/4200) 1/400 (1/3500)
54 40 pg — — Cell fusion
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that the anti-AVP IgG response was much smaller than the IgM response. The
SAM-RIA titres gradually increased with additional boosting, but the later samples
were not assayed by PEG-RIA so it is not known whether the ratio of anti-AVP
IgG : IgM increased. Four of the mice were eventually used in cell fusions (Table 4.6).
One batch of AVP-thyroglobulin conjugate was prepared by the enhanced EDC
method (Section 2.2.1.2). The inclusion of 5 mM N-hydroxysulphosuccinimide in
the reaction mixture was reported to enhance the coupling of peptides to carrier
molecules (Staros et al., 1986) so a stronger immune response was expected with this
preparation. However, mouse nos. 3542-3549 produced such low anti-AVP IgG responses
to the enhanced EDC-coupled conjugate, as determined by SAM-RIA (Table 4.3), that
their serum antibody titres could not be estimated, whereas mouse nos. 3470-3477 had
produced moderate anti-AVP IgG responses to the normal EDC-coupled conjugate
(Table 4.2). This suggested that the enhanced EDC-coupled conjugate was actually less
immunogenic than the normal EDC-coupled material, but there was no time available
to carry out further study of this phenomenon.
4.2.2 AVP/LVP-KLH
Initial hybridoma screening results had shown that immunization with
AVP-thyroglobulin conjugate generated anti-BSA and anti-immunoglobulin antibodies
which caused false positive ELISA results if undiluted culture supernatants were
assayed in wells coated with antibodies or BSA (Section 3.3.3). KLH was therefore
investigated as an alternative carrier molecule because it was less likely to generate
antibodies that would cross-react with mammalian proteins, so ELISA screening of
undiluted culture supernatants might have been possible. This would have had the
advantage of decreasing the workload, whilst minimizing the risk that antibody
would be lost by adsorption onto equipment surfaces (Campbell, 1984), because the
supernatant samples could have been transferred directly into the assay wells.
KLH was coupled to a mixture of AVP and LVP by m-maleimidobenzoic acid
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TABLE 4.3
Immunization with AVP-thvroglobulin (enhanced EDC preparation)
Mouse nos. 3542-3549 were immunized by intraperitoneal injection of
AVP-thyroglobulin conjugate prepared by the enhanced EDC method (Section 2.2.1.2).
The dose shows the amount of AVP in the immunogen. Serum dilutions were assayed
by SAM-RIA but low binding prevented antibody titre estimation. Non-specific binding
has been subtracted from the values shown, which indicate the % 125I-AVP bound by
serum diluted 1/100 in Buffer L. ND = not determined.
% 125I-AVP bound
Week Dose
3542 3543 3544 3545 3546 3547 3548 3549
0 50 pg ND ND ND ND ND ND ND ND
5 48 pg ND ND ND ND ND ND ND ND
11 50 pg 6.6 0.3 1.5 6.4 0.0 0.6 0.7 5.1
36 50 pg 15.3 1.2 1.6 1.0 4.6 13.3 0.9 18.4
TABLE 4.4
Immunization with AVP/LVP-KLH conjugate
Mouse nos. 3538-3541 were given intraperitoneal injections of AVP/LVP-KLH
conjugate (Section 2.2.1.3), where the dose indicates the total amount of AVP and LVP
in the immunogen. Serum dilutions were assayed by SAM-RIA but low binding
prevented antibody titre estimation. Non-specific binding has been subtracted from the
values shown, which indicate the % 12 I-AVP bound by serum diluted 1/100 in
Buffer L. ND = not determined.
Week Dose
% 125I-AVP bound
3538 3539 3540 3541
0 50 pg ND ND ND ND
5 40 pg ND ND ND ND
11 50 pg 0.5 0.4 0.5 0.7
36 50 pg 0.3 0.3 0.0 0.2
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N-hydroxysuccinimide ester (MBS), a heterobifunctional reagent which links primary
amine groups to free sulphydryl groups. AVP and LVP do not contain free sulphydryl
groups so these were introduced by 2-iminothiolane (Traut et alv 1973; Jue et alv 1978)
which acted on the N-terminal a-amino groups of AVP and LVP, and the lysine
e-amino group of LVP. The thiolated peptides were expected to react with
MBS-modified KLH in such a way that both the AVP tail tripeptide and the LVP
ring structure (which is identical to that of AVP) would be presented for antibody
recognition on the surface of the KLH molecule. Although some LVP molecules would
have coupled to KLH through their a-amino groups, so that antibodies would also
have been raised against the LVP tail region, immunization with the AVP/LVP-KLH
conjugate was expected to maximize the probability of raising antibodies against
opposite ends of the AVP peptide and, therefore, of developing two-site AVP assays.
However, when mouse nos. 3538-3541 were immunized with the AVP/LVP-KLH
conjugate, no significant anti-AVP IgG responses were detected either by SAM-RIA
(Table 4.4) or by AVP-coated-plate ELISA (data not shown) so none of these mice
could be used in cell fusions.
4.2.3 ANP-THYROGLOBULIN
Mouse nos. 3478-3481 were immunized with a batch of EDC-coupled
ANP-thyroglobulin conjugate which had been successfully used in previous
immunizations (Prowse et al., 1989). After four injections of this immunogen, all of the
mice produced reasonable anti-ANP IgG responses, as determined by ANP-coated-plate
ELISA (Table 4.5), so all of them were used in cell fusion experiments (Table 4.8).
104
TABLE 4.5
Immunization with ANP-thvroglobulin conjugate
Mouse nos. 3478-3481 were immunized by intraperitoneal injection of
ANP-thyroglobulin conjugate (Section 2.2.1.4) as indicated, each dose of immunogen
containing 5 pg ANP. Serum dilutions were assayed by ANP-coated-plate ELISA
(100 ng/ml ANP, unblocked wells). The antibody titre was defined as the serum
dilution which produced an absorbance of 1.0 at 450 nm. ND = not determined.
A dash indicates an occasion when a mouse was not boosted.
Serum antibody titre
Week Dose
3478 3479 3480 3481
0 5Mg ND ND ND ND
5 ND ND ND ND
10 5gg 1/1000 1/2800 1/1000 1/700
40 1/19,000 1/10,500 1/5300 1/5000
62 5gg - Cell fusion - -
76 5Pg Cell fusion - -
81 5pg Cell fusion -




Fifteen cell fusions were carried out in an attempt to produce anti-AVP MAbs
(Table 4.6). Ten of these fusions were done with freshly-prepared spleen cells from
AVP-thyroglobulin-immunized mice, and the remainder were carried out after surplus
spleen cells had been boosted in vitro (Section 4.3.3).
Fusion VP1 generated hybridomas in 378 culture wells (Table 4.6). Undiluted
supernatants from 26 wells were AVP-capture ELISA-positive but investigation
revealed that they did not contain anti-AVP antibodies (Section 3.3.3). Although the
AVP-capture ELISA bound the anti-AVP antibody from high titre serum samples
(Figure 3.14), it was unsuitable for hybridoma screening because it also bound
anti-BSA and anti-immunoglobulin antibodies but did not bind anti-AVP MAbs
(Table 3.11). No other screening assay was available at that time so if any anti-AVP
antibody-secreting hybridomas were present they remained undetected.
Fusion VP1 was carried out by the standard method (Section 2.2.3.7) whereas
fusion VP2, which used spleen cells from the same mouse, was done with NS-0 cells
which had been adapted to grow in serum-free medium, and the fused cells were
cultured in serum-free HAT/MTM medium. Fusion VP2 produced a few hybridomas but
they were weak and did not survive. Their frailness was probably caused by the
serum-free-adapted NS-0 cells, which were less robust than those grown in FCS
medium, so no further serum-free fusions were attempted.
Fusions VP3 and VP4 were distributed into 25 cm2 tissue culture flasks
(5 ml/flask) so that large volumes of supernatant would be available for screening by
PEG-RIA. (Replicate samples were essential because inefficient separation of unbound
125 I-AVP caused poor reproducibility in this assay.) The concentration of anti-AVP
antibody in the supernatant was expected to be low therefore large samples (450 pi)
were assayed to maximize sensitivity. All of the cultures were PEG-RIA-negative but
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this might have been caused by excessive antibody dilution if the cultures contained
only a few anti-AVP antibody-secreting cells.
Fusions VP6 and VP7 were distributed into 1 ml cultures, which still allowed
duplicate sampling for the PEG-RIA but decreased the dilution factor of any antibody
in the supernatant. Fusion VP6 generated hybridomas in 23 cultures but only one was
PEG-RIA-positive. This hybridoma was cloned, and subcloned, to produce a monoclonal
cell line which secreted ESVP 1 MAb (Table 4.7). Fusion VP7 produced 12 hybridoma
cultures but they were all PEG-RIA-negative.
The remaining cell fusions were distributed into 0.2 ml cultures.
Fusions VP9 and VP10 generated hybridomas in 282 culture wells. These were
all SAM-RIA-negative, even though the spleen donor (mouse 3476, Table 4.2) had
produced a high serum anti-AVP antibody titre in response to immunization, but some
anti-AVP antibodies might have been missed because they could not bind ~ I-AVP.
Fusion VP12 generated hybridomas in 466 culture wells. One hybridoma
secreted anti-AVP antibody but was difficult to clone because it was unstable. The
first cloning plate became contaminated, and by the time a second cloning plate was
set up, 10 days after first identifying the hybridoma, non-secreting cells were rapidly
taking over the parent culture so the clones were all antibody-negative. Although
cells were stored before the parent hybridoma stopped secreting antibody, most of
them were non-secretors therefore hundreds of cloning wells had to be seeded to
maximize the probability of isolating antibody-secreting cells. The stored cells
produced clones in 2535 culture wells, 11 of which were SAM-RIA-positive but only
one clone, from a well which contained multiple cell colonies, was sufficiently stable
to produce antibody-positive subclones. The best subclone was cloned again to produce
the final monoclonal cell line which secreted ESVP 2 MAb (Table 4.7).
Fusion VP14 generated hybridomas in 531 culture wells, four of which were
anti-AVP antibody-positive. Two hybridomas were lost because they stopped secreting
antibody before the parent cells could be stored, and all of their clones were
antibody-negative. The other two hybridomas were cloned, and subcloned, to produce
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TABLE 4.7
Monoclonal cell lines produced in AVP fusions





monoclonal cell lines which secreted ESVP 3 MAb and ESVP 4 MAb (Table 4.7).
4.3.2 ANP FUSIONS
Three anti-ANP MAbs (ESA 4, ESA 5 and ESA 9) were available at the start
of this project. In an attempt to produce additional anti-ANP MAbs, six cell fusions
were carried out (Table 4.8), four of which were done with freshly-prepared spleen
cells from ANP-thyroglobulin-immunized mice, while two fusions were done with
in uifro-boosted spleen cells (Section 4.3.3).
Fusion NP1 had a disappointingly low fusion efficiency (Table 4.8). It produced
only three hybridoma cultures, which were all ANP-coated-plate ELISA-negative.
In contrast, fusion NP2 generated hybridomas in 553 culture wells, four of
which were ANP-coated-plate ELISA-positive. Two hybridomas soon stopped secreting
antibody, while another was abandoned because it always produced low assay results
and was found to secrete an IgM antibody. The remaining hybridoma was cloned, and
subcloned, to produce a monoclonal cell line which secreted ESNP 1 MAb (Table 4.9).
Fusion NP4 produced hybridomas in 416 culture wells, three of which were
ANP-coated-plate ELISA-positive. Two hybridomas were easy to clone, and subclone,




Suspensions of fused cells were diluted to 1 x 106 cells/ml and seeded into
0.2 ml cultures. The fusion efficiency was the number of cultures which contained
hybridomas, expressed as a percentage of the total number of cultures seeded. Culture
supernatants were screened by ANP-coated-plate ELISA, and were considered
antibody-positive if they produced absorbances which exceeded 0.3. Some hybridomas
subsequently ceased to secrete antibody.
In vitro-boosted spleen cells were used in fusions NP3 and NP6.
Mouse Fusion Spleen : NS-0 Cultures Hybridoma Fusion Ab-positive MAbs
no. no. ratio seeded cultures efficiency, % cultures produced
3479 NP1 2:1 600
3478 NP2 2:1 607
NP3 2:1 180
3480 NP4 2:1 600
3481 NP5 2:1 558
NP6 1:1 280
3 0.5 0 0
553 91.1 4 1
1 0.5 0 0
416 69.3 3 3
44 7.9 0 0
31 11.1 0 0
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TABLE 4.9
Monoclonal cell lines produced in ANP fusions





(Table 4.9). The third hybridoma initially produced positive clones but they soon
stopped secreting antibody, and 73 subclones were all antibody-negative. The
parent hybridoma was still strongly positive so it was recloned but no further
antibody-positive clones were obtained. However, the antibody-secreting cells released
so much antibody that cultures which contained few cells could generate high ELISA
absorbances. Non-secreting cells were therefore concealed until they had taken over a
culture, because the ELISA readings decreased only when exchange feeding diluted the
residual antibody. The parent hybridoma eventually stopped secreting antibody but
cells had been stored before this happened. The stored cells produced clones in
1185 culture wells, six of which were ANP-coated-plate ELISA-positive although only
two clones continued to secrete antibody. One of these was subcloned to produce the
final monoclonal cell line which secreted ESNP 3 MAb (Table 4.9).
Fusion NP5 had a low fusion efficiency and produced only 44 hybridoma
cultures, all of which were ANP-coated-plate ELISA-negative.
4.3.3 FUSIONS WITH IN V7TRO-BOOSTED SPLEEN CELLS
Most spleen homogenates contained more cells than were required for a cell
fusion. The surplus cells were boosted in vitro then used in additional cell fusions
111
because it was reported that memory B cells, generated by in vivo immunization, can
be activated in vitro (De Boer et al., 1988) to produce an increase in both the fusion
efficiency and the production of antigen-specific antibodies (Erich et al., 1989).
Many workers favour serum-free medium for in vitro immunization (Reading,
1982; Van Ness et al., 1984; Darfler, 1987; De Boer et al., 1989), but when spleen cells
from mouse 3473 were in u/fro-boosted in serum-free medium only 16% of the cells
survived the 4 day culture period (Table 4.10). In contrast, there was a 46% survival
rate when spleen cells from mouse 3365 were in vitro-boosted in 15% FCS medium. All
other in vitro boosts were therefore done in 15% FCS medium, and cell survival rates
of 34-60% were recorded (Table 4.10).
In vitro-boosting did not produce the expected increase in fusion efficiency.
Instead, it seemed to decrease the ability of spleen cells to undergo successful cell
fusion, because most fusions which were carried out with in wfro-boosted cells had
lower efficiencies than those done with freshly-prepared cells from the same mouse
(Tables 4.6 and 4.8). Fusion NP6 was the exception because it had a higher efficiency
than fusion NP5 which was done with freshly-prepared spleen cells (Table 4.8), but
this difference occurred because the cells from fusion NP5 had a low viability as a
result of an unusually long exposure to PEG 4000.
Five cell fusions were carried out with in vitro-boosted spleen cells from
AVP-thyroglobulin-immunized mice (Table 4.6). Fusions VP5 and VP15 did not produce
any hybridomas at all. Fusions VP8, VP11 and VP13 generated hybridomas in 9, 6 and
34 culture wells, respectively, but no anti-AVP antibodies were detected.
Two cell fusions were carried out with in vitro-boosted spleen cells from
ANP-thyroglobulin-immunized mice (Table 4.8). Fusion NP3 generated one hybridoma




Survival rate of in u/fro-boosted spleen cells
Immune mouse spleen cells were boosted in vitro by culture in the presence of
antigen (Section 2.2.3.8). Cells from mouse 3473 were cultured with EDC-coupled
AVP-thyroglobulin conjugate in serum-free medium containing 30% serum-free MTM
(Section 2.2.3.3, prepared using serum-free medium instead of 15% FCS medium), while
those from mouse nos. 3365, 3470, 3476 and 3477 were cultured with unconjugated AVP
in MTM/FCS medium. Spleen cells from mouse nos. 3478 and 3481 were cultured with
unconjugated ANP in MTM/FCS medium.
Mouse No. cells No. cells % cells Fusion
no. cultured surviving surviving no.
3473 15 x 106 2.4 x 106 16.0 VP5
3365 30 x 106 14 x 106 46.7 VP8
3476 50x 106 17 x 106 34.0 VP11
3477 50xl06 27 x 106 54.0 VP13
3470 55 x 106 23 x 106 41.8 VP15
3478 73 x 106 28 x 106 38.4 NP3
3481 50 x 106 30xl06 60.0 NP6
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4.4 BULK PRODUCTION OF MONOCLONAL ANTIBODIES
Large quantities of MAbs were required for the two-site immunometric assay
work (Chapters 6 and 8). The monoclonal anti-AVP and anti-ANP cell lines were
therefore either injected into pristane-primed mice for ascitic fluid production
(Section 2.2.3.14) or grown in bulk culture (Section 2.2.3.15).
4.4.1 MONOCLONAL ANTIBODIES TO AVP
Ascitic fluid production was attempted with all four anti-AVP MAb-secreting
cell lines (Table 4.7) but only three of them induced ascites tumours.
Hybridoma VP6/7.1.4 was injected into ten mice, all of which produced ascitic
fluid containing ESVP 1 MAb (Table 4.11). Ascitic fluid tapping began 10-21 days after
injection of the cells and was completed by day 25 (total volume 65.5 ml), no mouse
surviving for more than 7 days after the start of tapping. Despite some fluctuation,
the ESVP 1 MAb titres of the ascitic fluid tended to increase over the tapping period
and titres ranging from 1/6200 to 1/125,000 were recorded (Table 4.11).
Five mice, which had been injected with hybridoma VP14/247.6.1, produced
34.5 ml ESVP 3 MAb-containing ascitic fluid (Table 4.12). The tapping period was
similar to that for ESVP 1 MAb-containing fluid (Table 4.11) but the ESVP 3 MAb
titres were lower, ranging from 1/2200 to 1/18,000 (Table 4.12).
In contrast, hybridoma VP14/308.1.1 was slow to produce ascites tumours. It
was injected into five mice but only one produced ESVP 4 MAb-containing ascitic fluid,
on day 39 (Table 4.13). When the other four mice were given a second injection of
cells, three of them produced ascitic fluid although one mouse was not ready for
tapping until 62 days after the second injection. A total of 37 ml ascitic fluid was
eventually collected. The ESVP 4 MAb titres were lower than expected (maximum
titre 1/540) and could not be estimated in ascitic fluid from two of the mice
(Table 4.13), therefore hybridoma VP14/308.1.1 was also grown in bulk culture to
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TABLE 4.11
ESVP 1 MAb production in ascitic fluid
Mouse nos. 3504-3513 were pristane-primed then given intraperitoneal injections
of hybridoma VP6/7.1.4 (5 x 105 cells/mouse). Ascitic fluid was collected whenever
abdominal distension was evident. Antibody titres were defined as the ascitic fluid
dilutions which produced half-maximal 12 I-AVP binding in the SAM-RIA. A dash
indicates an occasion when fluid was not collected.
Ascitic fluid antibody titre
Day
3504 3505 3506 3507 3508 3509 3510 3511 3512 3513






16 - - - 1/58,000 1/21,000 1/20,000 1/62,000
17 1/40,000 1/28,000
18 - 1/6600 - 1/18,000 - -
19 - 1/11,000
20 1/14,000 1/100,000 1/23,000 1/16,000 1/6200
21 1/23,000 1/20,000 - - - - -
22 - 1/27,000 1/47,000 1/125,000 1/100,000 - 1/114,000
23 1/8000 1/11,000 1/70,000
24 - 1/18,000
25 1/45,000
1/6200 - - 1/10,000
1/10,000 -
1/11,000 - - 1/35,000
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TABLE 4.12
ESVP 3 MAb production in ascitic fluid
Pristane-primed mice (nos. 3584-3588) were given intraperitoneal injections of
hybridoma VP14/247.6.1 (5 x 105 cells/mouse). Ascitic fluid was collected whenever
abdominal distension was evident. The antibody titre was defined as the ascitic fluid
dilution which produced an absorbance of 1.0 at 450 nm (AVP-coated-plate ELISA,
using sheep anti-mouse IgG (whole molecule) HRP conjugate to reveal binding). A
dash indicates an occasion when fluid was not collected.
Ascitic fluid antibody titre
Day






















ESVP4 MAb production in ascitic fluid
Pristane-primed mice (nos. 3589-3593) were given intraperitoneal injections of
hybridoma VP14/308.1.1 (5 x 105 cells/mouse), but only mouse 3592 produced ascitic
fluid in response. The other mice were given a further dose of pristane on day 39,
followed by 1 x 106 hybridoma VP14/308.1.1 cells/mouse on day 44. Ascitic fluid was
collected whenever abdominal distension was evident, and was assayed by PEG-RIA
but low binding prevented antibody titre estimation in some samples. Non-specific
binding has been subtracted from the values shown, which indicate the % 125i-avp
bound by ascitic fluid diluted 1/100 in Buffer L. The antibody titres which could be
estimated are shown in parentheses, and were defined as the ascitic fluid dilutions
which produced half-maximal 125I-AVP binding.
No ascitic fluid was produced by mouse 3591. Dashes indicate occasions when
fluid was not collected.
% 125I-AVP bound
Day
3589 3590 3592 3593
39 - - 60.5 (1/400)
60 - 9.6
68 - 46.0 (1/180)
70 - 53.0 (1/300)
71 - 60.0 (1/400)









Anti-AVP MAb production in culture
When monoclonal anti-AVP cell lines were grown to exhaustion in FCS
medium, the antibody titres obtained were typically as shown below. Antibody titres
were defined as the culture supernatant dilutions which produced half-maximal
125I-AVP binding in the SAM-RIA (for ESVP 1 and ESVP 2) or the PEG-RIA (for
ESVP3 and ESVP 4).





produce 500 ml ESVP 4 MAb-containing culture supernatant (Table 4.14).
Hybridoma VP12/339.5.3.2 would not grow in ascites. It was injected into five
mice, which had not responded by day 46 so they were given an additional dose of
pristane followed, 4 days later, by 1 x 106 hybridoma VP12/339.5.3.2 cells/mouse. No
ascites tumours formed so the cells were grown in bulk culture instead, to produce
1 litre ESVP 2 MAb-containing culture supernatant (Table 4.14).
Hybridomas VP6/7.1.4 and VP14/247.6.1 were not grown in bulk culture, but
the ESVP 1 and ESVP 3 MAb titres attainable in spent culture supernatant have been
included in Table 4.14 for comparison.
4.4.2 MONOCLONAL ANTIBODIES TO ANP
The cause of the poor ascites response of hybridomas VP12/339.5.3.2 and
VP14/308.1.1 (Section 4.4.1) was unknown so no attempt was made to grow the
anti-ANP MAb-secreting cell lines (Table 4.9) in ascites. They were instead grown in
bulk culture, each producing 500 ml anti-ANP MAb-containing supernatant (Table 4.15).
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TABLE 4.15
Anti-ANP MAb production in culture
Bulk production of anti-ANP MAbs was achieved by culturing the monoclonal
cell lines to exhaustion in FCS medium. The antibody titre was defined as the culture
supernatant dilution which produced an absorbance of 1.0 at 450 nm in the
ANP-coated-plate ELISA.





4.5 PURIFICATION OF MONOCLONAL ANTIBODIES
4.5.1 MONOCLONAL ANTIBODIES TO AVP
4.5.1.1 Sodium Sulphate Precipitation
ESVP 1 and ESVP 3 MAbs were partially purified and 5-fold concentrated from
ascitic fluid by sodium sulphate precipitation (Section 2.3.1.1). 370 mg ESVP 1 and
137 mg ESVP 3 were obtained from 65.5 ml and 34.5 ml ascitic fluid, respectively.
However, ascitic fluid also contains endogenous mouse antibodies which co-precipitate
with MAbs (Galfr6 and Milstein, 1981; Baines et al., 1990) so the ESVP 1 and ESVP 3
preparations would have been contaminated by these antibodies. Few other
components were present, because iodinated ESVP 1 eluted from Sephacryl S-300 as one
major peak of radioactivity corresponding to IgG (Figure 4.1A), while iodinated
ESVP 3 eluted as two peaks (Figure 4.IB) which corresponded to a major peak of IgM




Elution of 125I-ESVP 1 and 125I-ESVP 3 from Sephacrvl S-300
ESVP 1 (A) and ESVP 3 (B) were prepared from ascitic fluid by sodium
sulphate precipitation, then radioiodinated (Section 2.3.4.2) and purified by gel
filtration on a Sephacryl S-300 column (Section 2.3.4.3). The radioactivity of each
fraction is expressed as a percentage of the total applied to the column.
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4.5.1.2 PEG 8000 Precipitation
ESVP 2 and ESVP 4 MAbs were concentrated from spent culture supernatant by
PEG 8000 precipitation (Section 2.3.1.2) because sodium sulphate was reportedly
unsuitable for precipitating MAbs from culture supernatants (Baines et al., 1990).
In a preliminary study, the ESVP 2 MAb precipitated by 10% (w/v) PEG 8000
was collected after a 2 hour incubation period but the antibody titre of the
supernatant indicated that a significant amount of ESVP 2 remained in solution
(Table 4.16, Experiment 1). The bulk culture supernatant (450 ml) was therefore
incubated with PEG 8000 for 16 hours before collection of the precipitate, but even
this was insufficient to achieve maximal precipitation because a second ESVP 2
MAb-containing precipitate formed during storage of Supernatant I (Table 4.16,
Experiment 2) and the antibody titre of Supernatant II suggested that it still contained
about half of the original ESVP 2 activity. Precipitate II was purer than Precipitate I
because it had a higher antibody titre despite a lower protein concentration
(Table 4.16).
IgA precipitation requires higher PEG concentrations than are needed for IgG
precipitation (Cripps et al., 1983) therefore 15% (w/v) PEG 8000 was selected for the
preparation of ESVP 4 MAb from culture supernatant. In contrast to ESVP 2 MAb, a
preliminary experiment showed that more than 90% of ESVP 4 activity was
precipitated after a 2 hour incubation period (Table 4.17). For convenience, however,
the ESVP 4 MAb-containing bulk culture supernatant (450 ml) was incubated with
PEG 8000 for 4 days before collection of the precipitate (86.6 mg).
4.5.1.3 Protein A-Sepharose Affinity Chromatography
Highly purified ESVP 2 MAb was prepared from spent culture supernatant by
affinity chromatography on Protein A-Sepharose (Section 2.3.1.3). ESVP 3 and ESVP 4
could not be purified in this way because mouse IgM and IgA antibodies do not bind
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TABLE 4.16
PEG 8000 precipitation of ESVP 2 from culture supernatant
ESVP 2 MAb-containing culture supernatant was mixed with 30% (w/v)
PEG 8000 in Buffer E, to give a final PEG concentration of 10% (w/v), then incubated
at room temperature for 2 hours (Experiment 1) or at 4°C for 16 hours (Experiment 2)
before collection of the precipitate (Section 2.3.1.2). Further precipitation occurred
during storage, at 4°C, of Supernatant I from Experiment 2. Precipitate II formed within
24 hours but was not collected until day 4.
The antibody titre was defined as the sample dilution which produced an
absorbance of 1.0 at 450 nm in the AVP-coated-plate ELISA. ND = not determined.














Starting material 35 1/135 ND 450 1/56 ND
Supernatant I 52.5 1/64 ND 675 1/35 ND
Precipitate I 3.5 1/500 2.2 8.0 1/420 6.6
Supernatant II _ 675 1/28 ND
Precipitate II — — — 2.0 1/1800 4.2
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TABLE 4.17
PEG 8000 precipitation of ESVP 4 from culture supernatant
ESVP4 MAb-containing culture supernatant was mixed with an equal volume of
30% (w/v) PEG 8000 in Buffer E, then incubated at room temperature for 2 hours before
collection of the precipitated protein.
The antibody titre was defined as the sample dilution which produced an








Culture supernatant 44 1/10 ND
PEG supernatant 88 <1/2 ND
PEG precipitate 4.4 1/90 3.0
to protein A (Ey et al., 1978).
Mouse IgGl was reported to have a weak affinity for Protein A-Sepharose
(Underwood et al., 1983; Jiskoot et al., 1991), binding at high pH values and eluting
in the pH range 6.0-7.0 (Ey et al., 1978). However, an initial trial showed that there
was still some interaction between protein A and ESVP 2 at pH 6.0 because elution was
retarded in 0.1 M sodium citrate buffer, pH 6.0, so that ESVP 2 emerged in a broad
peak of fifteen fractions (data not shown). In contrast, pH 5.0 buffer eluted ESVP 2 in
a sharp peak of only three fractions (Figure 4.2). Elution at pH 5.0 was therefore
selected for bulk purification of ESVP 2 because it produced the most concentrated
antibody solution.
The Protein A-Sepharose column (bed volume 10 ml) was expected to bind about
50 mg IgG (Ey et al., 1978) but it failed to bind all of the ESVP 2 from 390 ml culture
supernatant, even though only 4.07 mg protein could be eluted at pH 5.0. The column
initially extracted about 99% of ESVP 2 from the culture supernatant but became less
efficient as loading progressed, so that the final drops of supernatant to pass through




Elution of ESVP 2 MAb from Protein A-Sepharose
ESVP 2 MAb-containing culture supernatant (390 ml, pH 8.7) was loaded onto a
Protein A-Sepharose column as described in Section 2.3.1.3. Fraction collection began
when all of the supernatant had been applied. Bound antibody was eluted by 0.1 M
sodium citrate buffer, pH5.0.
also continual SAM-RIA-detectable leakage of ESVP 2 activity during the washing
step, which suggested that ESVP 2 did not bind tightly to protein A at pH 8.7 despite
a report that IgGl was fully retained at pH 8.0 (Ey et al., 1978). However,
Underwood et al. (1983) showed that MAbs of the same isotype could have widely
differing affinities for protein A and that the concentration of IgG bound by a
Protein A-Sepharose column was dependent on the binding affinity. ESVP 2 may
therefore have had a particularly low affinity for protein A.
Iodination of ESVP 2, followed by gel filtration (Figure 4.3), revealed that
protein A-purified MAb was much purer than PEG-precipitated MAb since the latter
contained a large quantity of high molecular weight material which was unable to
bind to the SAM-S-500 solid phase (Figure 4.3A). This result was confirmed when
1 ml PEG-precipitated ESVP 2 (6.6 mg protein) was protein A-purified and only 0.5 mg
protein was retained on the column, which implied that more than 90% of the
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FIGURE 43
Elution of 125I-ESVP 2 from Sephacrvl S-300
ESVP 2 MAb was prepared from spent culture supernatant by PEG 8000
precipitation (A; Precipitate I (Experiment 2), Table 4.16) or Protein A-Sepharose
affinity chromatography (B), then radioiodinated (Section 2.3.4.2) and purified by gel
filtration on a Sephacryl S-300 column (Section 2.3.4.3). Iodinated material (•) was
eluted in 2.3 ml (A) or 1.95 ml (B) fractions. The radioactivity of each fraction is
expressed as a percentage of the total applied to the column.
The eluate was assayed for 125I-IgG (o) by agitating a mixture of 50 pi column
fraction and 50 pi SAM-S-500 solid phase (25% (settled volume) slurry in Buffer R) on
an orbital shaker for 1 hour at room temperature. Bound 125I-IgG was separated from
unbound 12SI-proteins by the sucrose layering technique (Section 2.2.4.4).
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PEG-precipitated preparation consisted of non-IgG substances. In contrast, there were
no high molecular weight materials in the protein A-purified ESVP 2 preparation,
although it seemed to contain two IgG components which were partially separated by
gel filtration on Sephacryl S-300 (Figure 4.3B).
4.5.2 MONOCLONAL ANTIBODIES TO ANP
ESNP 1, ESNP 2, ESNP 3 and ESNP 4 MAbs were each concentrated from 500ml
spent culture supernatant by precipitation with 12.5% (w/v) PEG 8000 (Section 2.3.1.2),
yielding 101.9, 69.4, 108.5 and 104.0 mg protein, respectively. A preliminary study had
shown that significant amounts of MAb remained in solution after protein
precipitation with 10% (w/v) PEG 8000 (Table 4.18, Experiment 1), as previously seen
with ESVP 2 MAb (Table 4.16). Increasing the PEG 8000 concentration to 12.5% (w/v)
decreased the residual antibody titre of the supernatant (Table 4.18, Experiment 2) but
still did not precipitate all of the MAb. Centrifugation at 40,000 x g, rather than
2000 x g, made no difference to the antibody titre of the supernatant (data not shown)
so the failure to collect all of the MAb was not due to inadequate centrifugation.
Samples of ascitic fluid containing ESA 4, ESA 5 and ESA 9 (2.5 ml each),
which were a gift from Dr. C. Prowse, were purified by sodium sulphate precipitation
(Section 2.3.1.1), yielding 33.0, 23.1 and 15.3 mg protein, respectively.
4.6 PURIFICATION OF POLYCLONAL ANTIBODIES
4.6.1 ANTI-AVP SERUM
The anti-AVP serum was a pool of rabbit antisera which had been raised
against both unconjugated AVP and AVP-BSA. Insoluble material was removed by
centrifugation at 2000 x g then the antibody was partially purified by sodium sulphate
precipitation (Section 2.3.1.1), yielding 6.956 g protein from 476 ml antiserum.
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TABLE 4.18
Effect of PEG 8000 concentration on anti-ANP MAb precipitation
Anti-ANP MAbs were precipitated from culture supernatant by PEG 8000 in
Buffer E, at a final PEG concentration of 10% (w/v) (Experiment 1) or 12.5% (w/v)
(Experiment 2), and collected after incubation at room temperature for 30 minutes
(Experiment 1) or at 4°C for 4 days (Experiment 2). The supernatants were assayed by
ANP-coated-plate ELISA before, and after, PEG 8000 precipitation. The antibody titre
was defined as the sample dilution which produced an absorbance of 1.0 at 450 nm.
MAb
Antibody titre









ESNP 1 1/150 1/45 1/440 1/40
ESNP2 1/470 1/250 1/840 1/70
ESNP 3 - - 1/3000 1/400
ESNP 4 1/1100 1/240 1/530 1/24
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4.6.2 ANTI-PAG SERUM
The haemolysed rabbit anti-PAG serum, which had been raised against a
PAG-thyroglobulin conjugate, was purified by PEG 8000 precipitation, a method which
was reportedly more suitable for haemolysed sera than was salt precipitation
(Tijssen, 1985). Cripps et al. (1983) showed that half of the IgM in human serum was
precipitated by 4% (w/v) PEG 8000 while most of the IgG was precipitated by
4-8% (w/v) PEG 8000, therefore the anti-PAG serum was fractionated by 0-4%, 4-8%
and 8-13% (w/v) PEG 8000. When the fractions were assayed (Table 4.19), most of the
antibody activity was found in the 4-8% PEG cut while almost none remained in the
13% PEG supernatant, which contained most of the haemoglobin.
Iodination of ESVP 2 MAb had shown that PEG precipitates were very impure
(Figure 4.3) therefore the PEG cuts were further purified by Rivanol precipitation
(Section 2.3.2.2), which removes most serum proteins leaving relatively pure IgG in
solution (Franek, 1986). The PEG cuts were not dialysed before Rivanol precipitation
because PEG fractionation was expected to have decreased the concentration of
chloride ions, in which Rivanol is insoluble. However, the Rivanol formed a yellow
precipitate from the PEG cuts, rather than the expected sticky brown paste, and the
4-8% and 8-13% PEG cuts were still reddish-brown after filtration. This was thought
to indicate that some of the Rivanol had been precipitated by residual NaCl in the
PEG cuts, particularly as a second volume of Rivanol, added to the 4-8% and 8-13%
PEG cuts, precipitated an orange-brown paste and produced a clear yellow filtrate.
The 0-4% PEG cut was expected to consist mostly of IgM (Cripps et al., 1983),
which is precipitated by Rivanol (Franek, 1986), so the large decrease in antibody
titre produced by Rivanol precipitation (Table 4.19) had been anticipated. However,
Rivanol precipitation also produced an unexpectedly large decrease in the antibody
titres of the 4-8% and 8-13% PEG cuts (Table 4.19), which should have consisted
mainly of IgG (Cripps et al., 1983). Rivanol was not expected to precipitate IgG
(Franek, 1986) but the extra Rivanol which was added to the 4-8% and 8-13% PEG
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TABLE 4.19
Preparation of IgG from anti-PAG serum
Haemolysed anti-PAG serum (400 ml) was purified by PEG 8000 fractionation
followed by Rivanol precipitation (Section 4.6.2). Antibody titres were defined as the
sample dilutions which produced half-maximal 125I-AVP binding in the PEG-RIA.
spnt = supernatant.














0-4% 25 1/26,000 16.1 24 1/170 53.0 48
4-8% 45 1/70,000 78.2 47 1/65 39.7 62
8-13% 25 1/9000 5.6 28 1/20 7.3 38
13% spnt 600 <1/4 <0.1 - - - -
TABLE 4.20
Preparation of IgG from anti-ANP serum
Antibody was collected from 200 ml haemolysed anti-ANP serum by PEG 8000
fractionation (Section 2.3.2.1). Each PEG cut was dialysed against 50 mM sodium
acetate then purified by Rivanol precipitation (Section 2.3.2.2). The antibody titre
was defined as the sample dilution which produced an absorbance of 1.0 at 450 nm in
the ANP-coated-plate ELISA, using donkey anti-rabbit IgG HRP conjugate to reveal
binding, spnt = supernatant.
After PEG fractionation After Rivanol precipitation
PEG cut
Volume Antibody % Antibody Volume Antibody % Antibody Protein
(ml) titre activity (ml) titre activity (mg)
0-5% 10 1/14,500 22.0 12.5 1/2000 9.3 24
5-10% 22 1/21,000 70.0 25.5 1/8000 75.9 257
10-15% 26 1/2000 7.9 33 1/1200 14.7 359
15% spnt 300 <1/2 <0.1 — — — -
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cuts must have significantly affected the solubility of the IgG because more antibody
activity remained in the 0-4% PEG cut than in either the 4-8% or 8-13% PEG cuts
(Table 4.19). The 0-4% PEG cut was therefore selected for use in the two-site
immunometric assay work (Section 6.3.2).
4.6.3 ANTI-ANP SERUM
The haemolysed rabbit anti-ANP serum was purified by PEG 8000
fractionation, using 0-5%, 5-10% and 10-15% (w/v) PEG cuts (Section 2.3.2.1). When
the PEG cuts were assayed by ANP-coated-plate ELISA, using donkey anti-rabbit IgG
HRP conjugate to detect binding, most of the antibody activity was found in the
5-10% PEG cut (Table 4.20) which would have consisted mainly of IgG (Cripps et al.,
1983). The 10-15% PEG cut contained relatively little antibody activity (Table 4.20)
and was very impure because most of the haemoglobin was precipitated from the
antiserum by 15% (w/v) PEG 8000.
The anti-ANP serum PEG cuts were dialysed against 50 mM sodium acetate
then further purified by Rivanol precipitation (Section 2.3.2.2). A yellow-brown
precipitate was removed from the PEG cuts, rather than the expected sticky brown
paste, and almost none of the haemoglobin was precipitated from the 10-15% PEG cut
which was still dark red after filtration.
The 0-5% PEG cut contained most of the IgM, and some IgG (Cripps et al.,
1983), so the large decrease in antibody titre produced by Rivanol (Table 4.20) was
due to IgM precipitation. This also showed that the anti-rabbit IgG HRP conjugate
was not specific for rabbit IgG, but cross-reacted with IgM. The 5-10% PEG cut may
also have contained some IgM because more antibody was lost during Rivanol
precipitation than expected, although this fraction still contained the largest portion
of antibody activity (Table 4.20) and was therefore selected for use in two-site
immunometric assay work (Section 8.3). Relatively little antibody was lost from the
10-15% PEG cut, which would have contained mainly IgG (Cripps et al., 1983).
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4.7 DISCUSSION
Anti-AVP and anti-ANP MAb-secreting hybridomas were generated by the
fusion of NS-0 myeloma cells with spleen cells from immunized BALB/c mice.
However, immunization against AVP was difficult because AVP is present in almost
all mammals, including mice, and it was only weakly immunogenic even after
conjugation to a carrier molecule. Immunization against ANP was easier because human
ANP differs from mouse ANP in one amino acid residue, so moderate anti-ANP
antibody titres were obtained after four doses of ANP-thyroglobulin conjugate
(Table 4.5).
The cyanamide-coupled AVP-thyroglobulin conjugate was a particularly poor
immunogen which produced a weak anti-AVP response that consisted entirely of IgM
antibodies (Table 4.1). A peptide : thyroglobulin : cyanamide molar ratio of 118 :1 :1400
had been used to prepare this conjugate, although Skowsky and Fisher (1972b)
reported that optimal conjugation occurred with a peptide : thyroglobulin : EDC ratio
of 118:1 :200. Both the quantity and the type of carbodiimide used in the conjugation
procedure had therefore been incorrect, which would have influenced the composition
of the final product. The correctly-prepared EDC-coupled AVP-thyroglobulin conjugate
was more immunogenic than the cyanamide-coupled material and so produced
anti-AVP IgG, although good responses were obtained only after many injections
(Tables 4.1 and 4.2).
The enhanced EDC conjugation method was expected to produce a better
immunogen by increasing the incorporation of AVP onto thyroglobulin (Staros et al.,
1986) but the enhanced EDC-coupled AVP-thyroglobulin conjugate actually generated a
weaker anti-AVP IgG response (Table 4.3) than the normal EDC-coupled material
(Table 4.2). Peeters et al. (1989) reported that conjugate immunogenicity decreased
with increasing peptide incorporation, and suggested that peptide antigenic
determinants are masked by close-packing on the carrier, so the low immunogenicity of
the enhanced EDC-coupled conjugate might have resulted from epitope masking.
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However, the compositions of the AVP-thyroglobulin conjugates were not analysed so
it is not known whether there was a correlation between AVP incorporation and
immunogenicity.
Carbodiimides catalyse the formation of amide bonds between carboxyl groups
and amino groups (Skowsky and Fisher, 1972b; Staros et al., 1986). Proteins contain
many such groups therefore carbodiimide conjugation generates many different products
(Peeters et al., 1989), including self-coupled proteins (Liu et al., 1979). In contrast,
heterobifunctional reagents, such as MBS, can be used in a step-wise manner to produce
specific cross-linking of peptides and proteins with minimal self-coupling (Liu et al.,
1979). The N-hydroxysuccinimidyl group of MBS reacts with the primary amino
groups of a sulphydryl-free protein in the first step, then the MBS maleimido group
reacts with a sulphydryl-containing peptide to produce a conjugate in which the
peptide and protein are linked by a spacer arm. In this project, KLH was reacted
with MBS by the method of Lerner et al. (1981) then mixed with thiolated AVP and
LVP to produce the final conjugate. The composition of the product was not analysed
so it is not known whether the thiolation and conjugation procedures were successful,
but the failure of the AVP/LVP-KLH preparation to produce a significant anti-AVP
IgG response (Table 4.4) suggests that very little peptide had conjugated to KLH. The
anti-AVP IgM response to this material was not determined.
KLH is often used as a carrier molecule because it is strongly immunogenic
(Goding, 1986). An EDC-coupled AVP-KLH conjugate was reported to generate
anti-AVP IgG in BALB/c mice, although eight injections produced a maximum serum
antibody titre of only 1/2500 (Reilly and Root, 1986). However, the EDC-coupled
AVP-thyroglobulin conjugate could generate anti-AVP IgG titres of more than 1/30,000
(Tables 4.1 and 4.2) which suggested that thyroglobulin was superior to KLH as a
carrier for AVP. The absence of an anti-AVP IgG response to the AVP/LVP-KLH
preparation may therefore have been only partly due to poor conjugation and partly
due to the KLH carrier because Skowsky and Fisher (1972b) showed that the choice
of carrier is important in determining the immune response to small peptides.
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Thyroglobulin was better than BSA, ovalbumin or amino acid polymers as a carrier
for LVP and PTH (Skowsky and Fisher, 1972b), and it was better than either BSA or
KLH as a carrier for ANP (Prowse et al., 1989).
Despite conjugation to thyroglobulin, however, the antibody responses to AVP
and ANP were still relatively low. Recently, Fiori and Rappelli (1991) showed that
intravenous injection of PPD tuberculin, a polyclonal B cell activator (Sultzer and
Nilsson, 1972), stimulated mouse spleen cells so that the specific antibody response to
soluble antigens increased dramatically and subsequent cell fusions generated a higher
frequency of antigen-specific hybridomas. PPD tuberculin treatment of mice, prior to
immunization, might therefore be of value in future attempts to generate anti-AVP
and anti-ANP MAbs.
Alternatively, in vitro immunization can be used to raise antibodies against
highly conserved and weakly immunogenic antigens, including 'self-antigens (Reading,
1982; Van Ness et al., 1984; Borrebaeck and Moller, 1986). Successful in vitro
immunizations have been achieved under a wide range of culture conditions. Many
workers used serum-free medium because it contained fewer competing antigens than
FCS medium (Ossendorp et al., 1986; Darfler, 1987; De Boer et al., 1989), in which
only the most immunogenic antigens produced specific antibody responses (Van Ness et
al., 1984), and because some batches of serum were reported to inhibit in vitro
immunizations (Reading, 1982). However, serum proteins are often considered essential
for B cell division so some workers added FCS to their in vitro immunization cultures
after a serum-free induction period (Van Ness et al., 1984; Erich et al., 1989), while
others used culture medium containing either FCS (Takahashi et al., 1987;
Rathinavelu and Isom, 1989) or rabbit serum (Borrebaeck and Moller, 1986) throughout
the procedure. The minimum antigen concentration required to produce an antibody
response varied between antigens (Van Ness et al., 1984; Borrebaeck and Moller, 1986;
Ossendorp et al., 1986; Takahashi et al., 1987), with the highest concentrations being
necessary for the most highly conserved antigens (Van Ness et al., 1984), while a
range of stimulation periods (3-8 days) have all been reported as optimal (Borrebaeck
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and Moller, 1986; Takahashi et al., 1987; De Boer et al., 1989; Erich et al., 1989).
However, a comparison of reported in vitro immunizations is difficult because most
workers used different cell concentrations and different culture medium supplements,
which would have affected the final result, and the optimum conditions for in vitro
immunization may well prove to be different for each antigen.
In vitro immunization tends to produce only a primary immune response so the
hybridomas generated in subsequent cell fusions usually secrete IgM antibodies (Van
Ness et al., 1984; Darfler, 1987; De Boer et al., 1989). A few IgG-secreting hybridomas
occasionally arise (Ossendorp et al., 1986; Rathinavelu and Isom, 1989) although
optimized stimulation conditions can produce them at higher frequencies (Takahashi
et al., 1987). Alternatively, memory B cells which have been generated by in vivo
immunization can be activated in vitro to produce a secondary immune response
(Reading, 1982; De Boer et al., 1988), increasing both the fusion efficiency and the
antigen-specific IgG-secreting hybridoma production of subsequent cell fusions (De Boer
et al., 1988; Erich et al., 1989). In uifro-boosting was therefore carried out whenever
surplus immune spleen cells were available.
Comparatively few spleen cells survived in uifro-boosting in serum-free
medium (Table 4.10) even though B cell survival was reported to be higher in
serum-free medium than in serum-containing medium (Iscove and Melchers, 1978).
However, no optimization work had been carried out so the antigen concentrations
chosen for in u/tra-boosting may have been too low. Cell survival was reportedly
higher in antigen-stimulated cultures than in control cultures (Ossendorp et al., 1986),
and increased as the antigen concentration increased (Van Ness et al., 1984), so the
higher survival rate in FCS medium (Table 4.10) may have been caused by the serum
proteins acting as additional antigens.
The fusion efficiencies of the in vitro-boosted spleen cells were usually much
lower than those of freshly-prepared cells (Tables 4.6 and 4.8), which was surprising
because higher fusion efficiencies had been expected (Erich et al., 1989). However,
hybridomas tend to be generated from immature, actively-dividing B cells (Reading,
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1982) since fully differentiated cells do not fuse efficiently (Tijssen, 1985). The mice
were boosted 3 days before splenectomy, then the spleen cells were in p/fro-boosted for
4 days so B cell maturation may have progressed too far. The final in vivo boost could
not be omitted because most fusions used freshly-prepared cells and only the surplus
cells were boosted in vitro, but a shorter in pifro-boosting period might have
produced better results. However, the memory B cells may not have responded to
in vitro-boosting because most in vitro-boosts were done with unconjugated peptides
(Table 4.10) whereas the donor mice had been immunized with thyroglobulin
conjugates (Section 4.2). Small peptides produce optimal secondary responses only if
they are conjugated to the carrier molecule that was used in an earlier antigen
challenge (the 'carrier effect'; Roitt et al., 1985). The in vitro antibody responses
to AVP and ANP may also have been inhibited by FCS proteins in the culture
medium (Van Ness et al., 1984), although Rathinavelu and Isom (1989) were able
to generate an anti-ANP IgG-secreting hybridoma from spleen cells which had been
in pifro-immunized in FCS medium.
AVP and ANP are such weak antigens that immunization produced few
antigen-specific B cells therefore subsequent cell fusions could not generate many
antigen-specific hybridomas (Erich et al., 1989), although high fusion efficiencies
increase the probability of hybridoma generation from rare B cells. All of the fusions
that produced antigen-specific MAbs were done with freshly-prepared spleen cells
and, with the exception of fusion VP6 (Table 4.6), had efficiencies of more than 69%
and generated more than 400 hybridomas, less than 1% of which were antigen-specific
(Tables 4.6 and 4.8). Fusion VP6 was done with spleen cells from mouse 3365, which
had responded exceptionally well to immunization (Table 4.1). Many AVP-specific
B cells would have formed so an anti-AVP MAb-secreting hybridoma was generated
despite the low efficiency of fusion VP6 (Table 4.6), and culture supernatant from the
in uffro-boosted surplus cells was strongly PEG-RIA-positive even though unlabelled
AVP was present. Surplus spleen cells from other mice failed to secrete significant
amounts of antigen-specific antibody into the culture medium.
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The AVP and ANP cell fusions (Tables 4.6 and 4.8) generated 2796
hybridoma-containing cultures, thirteen of which were originally antigen-specific
although four were lost at an early stage. Hybridomas VP12/339 and NP4/213 would
also have been lost if stored cells had not been available for re-cloning. Some
antigen-specific hybridomas are lost because they are overgrown by unrelated cells.
Hybridoma NP4/213 (Section 4.3.2, Table 4.9) came from a culture well which
contained two hybridoma colonies so the antibody-secreting cells were probably
overgrown by the second hybridoma, although they were eventually isolated from
frozen cell stocks. In contrast, hybridoma VP12/339 (Section 4.3.1, Table 4.7) came from
a culture well which contained only a single hybridoma colony. The non-secreting cells
which rapidly overgrew the culture were therefore derived from hybridoma
VP12/339, and a stable MAb-secreting clone was difficult to obtain.
Hybridomas have two sets of chromosomes and are genetically unstable,
tending to lose chromosomes until a more stable genotype is achieved (Galfre and
Milstein, 1981; Goding, 1986). Loss of antibody chain expression occurs frequently
(Kohler and Milstein, 1976). Although the genes which code for the heavy and light
antibody chains are located on different chromosomes, there is preferential loss of the
heavy chain because free heavy chains seem to be toxic for the cells (Kohler, 1980).
Hybridomas which stop secreting antibody have therefore lost the chromosome which
controls heavy chain synthesis, but may continue to produce light chains.
Both the spleen cells and the NS-0 myeloma cells (Galfrb and Milstein, 1981)
were derived from BALB/c mice so the anti-AVP and anti-ANP hybridomas could
theoretically be grown as ascites tumours in BALB/c mice (Kohler and Milstein, 1976).
Hybridomas VP6/7.1.4 and VP14/247.6.1 produced high titre ascitic fluid containing
ESVP 1 and ESVP 3 MAbs, respectively (Tables 4.11 and 4.12). Fluid tapping began
10-21 days after injection of the cells and the antibody titres increased over the
tapping period as reported by Brodeur et al. (1984). In contrast, hybridoma
VP14/308.1.1 produced ascitic fluid only after a long delay (Table 4.13) and its low
antibody titre suggested that the ascites tumours contained few ESVP 4 MAb-secreting
136
cells, although the average fluid volume collected per mouse was similar to that
obtained from hybridomas VP6/7.1.4 and VP14/247.6.1 (Section 4.4.1). However,
myelomas are induced in 40% of BALB/c mice within one year of receiving three
intraperitoneal pristane injections (Goding, 1986). The slow ascitic fluid response to
hybridoma VP14/308.1.1 may therefore have been largely due to pristane-induced
myeloma formation, particularly in the case of mouse 3589 (Table 4.13) which
produced exceptionally low titre ascitic fluid and did not do so until 62 days after a
second dose of hybridoma cells.
Hybridoma VP12/339.5.3.2, however, would not grow in ascites at all. Some
hybridomas lose the ability to grow as tumours after long periods of in vitro culture
(Hoogenraad and Wraight, 1986; Mattes et al., 1991), presumably because they have
lost a myeloma-derived gene which confers tumorigenicity since Mattes et al. (1991)
showed that backcrossing these cell lines with the parent myeloma restored their
ability to produce ascites. The parent hybridoma, VP12/339, had been difficult to
clone (Section 4.3.1) because it was unstable and tended to stop secreting antibody,
which seemed to be a result of chromosome loss. It is therefore quite likely that
stabilization of the final ESVP 2 MAb-secreting cell line was achieved by the loss of
a chromosome which carried the gene for tumorigenicity.
Ascitic fluid usually contains 2-20 mg MAb/ml (Goding, 1986). It also contains
high concentrations of non-MAb proteins which, if not removed, would compete with
the MAb during labelling reactions and solid phase preparation (Neoh et al., 1986).
Spent culture supernatant, on the other hand, has lower concentrations of non-MAb
proteins but typically contains only 5-50 fig MAb/ml (Goding, 1986) and so needs to be
concentrated to allow for efficient MAb labelling. MAbs were therefore partially
purified from ascitic fluid by sodium sulphate precipitation (Tijssen, 1985), and
concentrated from hybridoma culture supernatant by PEG 8000 precipitation (Baines et
al., 1990) or Protein A-Sepharose affinity chromatography (Ey et al., 1978).
Baines et al. (1990) recommended a final concentration of 10% (w/v) PEG 8000
for IgG MAb precipitation from hybridoma culture supernatant because Neoh et al.
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(1986) had reported that maximal precipitation occurred within the range
5-10% (w/v) PEG 8000, at a concentration that was characteristic for each MAb,
although this information was obtained with ascitic fluid. However, 10% (w/v)
PEG 8000 produced inefficient precipitation of ESVP 2 (Table 4.16), ESNP 1, ESNP 2
and ESNP 4 MAbs (Table 4.18, Experiment 1) because it left about half of the MAb
activity in the PEG supernatant. IgG precipitation was improved by increasing the
PEG 8000 concentration to 12.5% (Table 4.18, Experiment 2) but the concentration of
FCS-derived contaminants also rose because increasing amounts of non-antibody protein
precipitated from serum and ascitic fluid as the PEG 8000 concentration was raised
above 7% (Cripps et al., 1983; Neoh et al., 1986). Recently, Brooks et al. (1992)
reported that 15% (w/v) PEG 8000 was optimal for IgG MAb precipitation from culture
supernatant, so the exact composition of the MAb-containing sample may influence
PEG 8000 precipitation even though it was supposedly insensitive to the solution
conditions (Ingham, 1984). However, high PEG concentrations precipitate large
amounts of contaminating protein and so produce very impure MAb preparations.
Towards the end of this project, 8% (w/v) PEG 8000 was shown to precipitate a lot of
protein but relatively little ESVP 2 activity from ESVP 2 MAb-containing culture
supernatant, while more than half of the total ESVP 2 activity was present in an
8-12.5% PEG cut which contained less protein (Table 4.21). PEG fractionation was
therefore a better way to concentrate MAbs from spent culture supernatant because a
large portion of the non-MAb protein was removed from the final product.
PEG precipitation was reported to be a rapid procedure, requiring only a short
equilibration period of up to 1 hour before centrifugation (Ingham, 1984; Neoh et al.,
1986; Baines et al., 1990). However, PEG precipitation of IgG MAbs from culture
supernatant was slow and continued for more than 16 hours, because further ESVP 2
MAb-containing precipitates formed during storage of the PEG supernatants that
remained after collection of ESVP 2 MAb Precipitate I (Table 4.16, Experiment 2) and
8-12.5% PEG cut I (Table 4.21). In contrast, IgA precipitation by 15% (w/v) PEG 8000
occurred rapidly so that more than 90% of ESVP 4 MAb activity was precipitated
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TABLE 4.21
Preparation of ESVP 2 MAb by PEG 8000 fractionation of culture supernatant
ESVP 2 MAb-containing culture supernatant was mixed with 40% (w/v)
PEG 8000 in Buffer E, to give a PEG concentration of 8% (w/v), then incubated at 4°C
for 24 hours before collection of the precipitate (0-8% PEG cut) as described in
Section 2.3.1.2. Additional 40 % (w/v) PEG 8000 in Buffer E was added to the
8% supernatant, to give a final PEG concentration of 12.5% (w/v), then the mixture
was incubated at 4°C for 16 hours before the precipitate (8-12.5% PEG cut I) was
collected. Further precipitation occurred during storage of 12.5% supernatant I at 4°C,
although the 8-12.5% PEG cut II was not collected until day 3. Even after this, an
additional ESVP 2 MAb-containing precipitate formed, and was harvested, from
12.5% supernatant II (data not shown).
The antibody titre was defined as the sample dilution which produced an








Starting material 450 1/56 ND
8% supernatant 565 1/44 ND
0-8% PEG cut 5.5 1/100 12.1
12.5% supernatant I 650 1/15 ND
8-12.5% PEG cut I 5.5 1/2900 8.4
12.5% supernatant II 650 1/10 ND
8-12.5% PEG cut II 3.5 1/475 1.9
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within 2 hours (Table 4.17), although this material was very impure because 30% of
total serum proteins were reported to precipitate in 14% (w/v) PEG 8000 (Cripps et
al., 1983).
Protein A-Sepharose affinity chromatography was an inefficient purification
method for ESVP 2 MAb (Section 4.5.1.3) because mouse IgGl antibodies do not bind
strongly to protein A (Underwood et ah, 1983; Jiskoot et ah, 1991) and the binding
capacity of the Protein A-Sepharose column for ESVP 2 was low, although the eluted
MAb was relatively pure (Figure 4.3B). ESVP 2 was produced by bulk culture in FCS
medium, and although FCS is usually considered to be antibody-free (Goding, 1986)
it often contains a low concentration of bovine IgG (Kniazeff and Rimer, 1967;
Underwood et ah, 1983; Jiskoot et ah, 1991) which was reported to co-purify with
mouse IgGl on Protein A-Sepharose (Underwood et ah, 1983; Jiskoot et ah, 1991).
Bovine IgG may therefore have been a contaminant of protein A-purified ESVP 2,
-i o r
which seemed to contain two I-IgG components after radioiodination and gel
filtration on Sephacryl S-300 (Figure 4.3B). The SAM-S-500 solid phase, which
detected the 125I-IgG (Figure 4.3), was supposed to be specific for mouse antibodies but
was shown to cross-react with a sheep antiserum (unpublished observation) and might
therefore also cross-react with bovine IgG.
MAbs prepared from ascitic fluid by sodium sulphate precipitation were
contaminated by endogenous mouse antibodies (Galfrfe and Milstein, 1981; Baines et ah,
1990) but relatively few other components (Figure 4.1). In contrast, MAbs prepared
from spent culture supernatant by PEG 8000 precipitation were very impure and
contained large quantities of high molecular weight materials (Figure 4.3A) which
were not present in protein A-purified ESVP 2 (Figure 4.3B) and which interfered with
reagent preparation for the two-site immunometric assay work (Chapters 6 and 8).
The specific activities attainable for 125I-MAbs were decreased by impurities in the
MAb preparations (Table 4.22) because different proteins have different iodination
efficiencies (Goding, 1986). Monoiodinated IgG has a specific activity of 10 pCi/pg
(Hunter et ah, 1983) but protein A-purified ESVP 2 was the only material that could
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TABLE 4.22
Effect of MAb purification method on the specific activity of 125I-MAb
MAbs were partially purified from ascitic fluid by sodium sulphate
precipitation, and concentrated from hybridoma culture supernatant by PEG 8000
precipitation or Protein A-Sepharose affinity chromatography, then radioiodinated.
The specific activities of the 1 5I-MAbs were calculated as described in Section 2.3.4.2.
The Sephacryl S-300 column profiles of 125I-ESVP 1, 125I-ESVP 3 and the 125I-ESVP 2
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Effect of MAb purification method on the binding of I-streptavidin to biotin-MAbs
ESVP 1 (•) and ESVP 3 (x) MAbs were partially purified from ascitic fluid by
sodium sulphate precipitation, while ESVP 2 (o) and ESVP 4 (a) were concentrated
from hybridoma culture supernatants by PEG 8000 precipitation, then the MAbs were
biotinylated as described in Section 2.3.4.5.
-IOC
The biotin-MAbs were assayed for I-streptavidin binding by incubation of
100 pi biotin-MAb in Buffer L with 100 pi 20 ng/ml 125I-streptavidin in Buffer R for
15 minutes at room temperature, then 100 pi SAM-S-500 solid phase (25% (settled
volume) slurry in Buffer R) was added. The mixture was agitated on an orbital shaker
for 1 hour, then bound and free 125I-streptavidin were separated by the sucrose
layering technique (Section 2.2.4.4).
be iodinated to a specific activity which approached this figure (Table 4.22). Low
specific activities were obtained with the very impure PEG 8000-precipitated MAbs,
while sodium sulphate preparations iodinated to an intermediate specific activity
(Table 4.22). The impurities decreased the efficiency of MAb biotinylation such that
IOC
less I-streptavidin bound to biotin-MAbs prepared from PEG 8000 precipitates than
to those prepared from sodium sulphate precipitates (Figure 4.4), and lower two-site
ELISA binding occurred with biotin-ESVP 2 prepared from a PEG 8000 precipitate than
with that prepared from protein A-purified material (Figure 6.13). The impurities
also interfered with solid phase preparation by binding to sites which MAbs would
otherwise have occupied, although this effect was less noticeable because of the high
binding capacity of the solid phases (Chapter 6). These problems could have been
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avoided by further purification of the MAbs but there was no time available to
investigate suitable methods.
Purification of the rabbit polyclonal antibodies (Section 4.6) also presented
difficulties because the antisera contained irrelevant antibodies in addition to the
anti-AVP and anti-ANP specificities, while two of the antisera were badly
haemolysed. The anti-AVP serum (Section 4.6.1) was purified by sodium sulphate
precipitation only, so the product consisted of a mixture of IgM and IgG antibodies.
The haemolysed anti-PAG and anti-ANP sera (Sections 4.6.2 and 4.6.3), on the other
hand, were purified firstly by PEG 8000 fractionation then by Rivanol precipitation,
so the final preparations consisted mainly of IgG antibodies (Franek, 1986).
PEG 8000 precipitation acted more efficiently on antisera (Tables 4.19 and 4.20)
than it did on hybridoma culture supernatants (Tables 4.16, 4.18 and 4.21). As reported
by Cripps et al. (1983), more than 90% of polyclonal antibody activity was rapidly
precipitated from serum by 8% (w/v) PEG 8000 (Table 4.19), a concentration which
had little effect on ESVP 2 MAb (Table 4.21), while IgG MAb precipitation from
culture supernatant by 10% or 12.5% (w/v) PEG 8000 was slow (Tables 4.16 and 4.21,
respectively) and left up to half of the MAb in the PEG supernatant (Tables 4.16,
4.18 and 4.21). A PEG 8000 concentration of 10% (w/v) did not improve polyclonal
antibody precipitation (Table 4.20) but merely increased the precipitation of
impurities (Cripps et al., 1983).
Rivanol precipitation of the anti-PAG serum PEG cuts did not proceed as
expected (Sections 4.6.2) so a second volume of Rivanol was added to the 4-8% and
8-13% PEG cuts. This increased the final Rivanol concentration from 0.46% (w/v) to
0.79% (w/v) and, surprisingly, precipitated most of the antibody activity (Table 4.19).
Rivanol precipitates negatively-charged proteins (Franek, 1986) so at neutral pH
values it should, for example, precipitate serum albumin but not IgG (which have
isoelectric pH values of 4.9 and 6.6, respectively; Lehninger, 1975). However, the
anti-PAG serum PEG cuts had neither been dialysed nor had their pH values checked
so the pH was probably higher than expected. The extra volume of Rivanol (pH 8.2)
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would have raised the pH further so that IgG, and the traces of haemoglobin
(isoelectric pH 6.8) that were precipitated by 13% (w/v) PEG 8000, became negatively
charged and were therefore precipitated by the Rivanol. In contrast, the anti-ANP
serum PEG cuts were dialysed before Rivanol precipitation and only one volume of
Rivanol was added, so the pH was correct and most of the IgG activity therefore
remained in solution (Table 4.20). The nature of the Rivanol precipitate was still not
as expected, however, but this was due to the low serum albumin content of the
PEG cuts (Cripps et al., 1983). Albumin is a major component of the material
precipitated from whole serum or ascitic fluid by Rivanol (Franek, 1986) and is the
main contributor to the sticky precipitate which had been expected.
The polyclonal antibody preparations could have been further purified by
affinity chromatography on immobilized antigen (Goding, 1986) which would have
removed the irrelevant antibodies. However, this was not deemed worthwhile because
the polyclonal antibodies were mainly used in feasibility studies (Chapters 6 and 8)




CHARACTERIZATION OF MONOCLONAL ANTIBODIES
TO VASOPRESSIN
5.1 INTRODUCTION
Anti-AVP MAbs were difficult to produce because AVP is only weakly
immunogenic, even after conjugation to a carrier molecule. The AVP fusions
(Section 4.3.1) generated 1748 hybridoma-containing cultures but only six of these were
anti-AVP antibody-positive. Four hybridomas were eventually cloned, and subcloned,
to produce monoclonal cell lines which secreted anti-AVP MAbs (Table 4.7).
Antibody purification was not necessary for the MAb characterization work,
which was done with samples of spent culture supernatant.
5.2 ANTIBODY ISOTYPES AND AFFINITIES
The isotypes of the anti-AVP MAbs, determined using an Amersham Mouse
Monoclonal Antibody Isotyping Kit, are shown in Table 5.1. All of the MAbs had
k light chains.
Affinity constants were determined by Scatchard analysis (Scatchard, 1949) of
solution-phase RIA binding (Section 2.4.2). The mean values shown in Table 5.1 were
calculated from the results of seven (ESVP 1), five (ESVP 2) and two (ESVP 3 and
ESVP 4) experiments.
TABLE 5.1
Isotvpes and affinities of the anti-AVP MAbs
MAb Isotype Affinity (1/mole)
ESVP 1 IgGl 2.8 x 108
ESVP 2 IgGl 2.2 x 108
ESVP 3 IgM 1.1 x 107
ESVP 4 IgA 1.9 x 107
145
5.3 ANTIBODY SPECIFICITIES
ESVP 1 MAb bound to the AVP ring structure. It cross-reacted strongly with
LVP, Hep, dDAVP and tGLVP (Table 5.2), which have similar ring structures to AVP
but different tail regions (Table 5.3). The ESVP 1 epitope was unlikely to include the
N-terminal cysteine residue of AVP because deamination (in dDAVP) had little effect
on binding, while the addition of three glycine residues (in tGLVP) produced a
4.7-fold increase in cross-reactivity, relative to LVP (Table 5.2), which was
presumably caused by conformational changes that allowed greater access to the ring
structure. In comparison, cross-reactivity with dNMeAVP was low, even though it has
an identical ring structure to dDAVP (Table 5.3), therefore the N-methylarginine
residue in its tail region must have caused steric hindrance of ESVP 1 binding. The
ring structures of OT, AVT and dCDAVP differ from that of AVP, so ESVP 1 bound
poorly to these peptides and did not bind at all to the isolated tail tripeptide
(PAG).
ESVP 2, ESVP 3 and ESVP 4 MAbs all bound to the AVP tail region. They
cross-reacted strongly with AVT, which has the same tail tripeptide as AVP, and
bound poorly to analogues which have different tail structures (Tables 5.2 and 5.3).
However, the ring structure is important in maintaining the correct conformation of
the tail tripeptide therefore cross-reactivity with isolated PAG was low.
5.4 DISCUSSION
The result of isotyping the anti-AVP MAbs (Table 5.1) was surprising. The
MAbs were all expected to be IgG antibodies because they were all bound strongly by
the anti-mouse IgG (whole molecule) HRP conjugate in the AVP-coated-plate ELISA,
and were also bound by the SAM-S-500 solid phase which had only ever detected IgG
MAbs in previous (unpublished) hybridoma screening work. However, while the
AVP-coated-plate ELISA and the SAM-RIA produced similar results with ESVP 1 and
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TABLE 5.2
Cross-reactivity of the anti-AVP MAbs with some AVP analogues
Cross-reactivity was calculated from RIA data, as described in Section 2.4.3.
The structures of the AVP analogues are shown in Table 5.3.
Cross-reactivity (%)
Peptide
ESVP 1 ESVP 2 ESVP 3 ESVP 4
AVP 100.0 100.0 100.0 100.0
LVP 66.6 <0.1 1.9 0.4
OT 6.7 <0.1 <0.1 <0.1
AVT 10.4 59.0 65.8 80.0
Hep 37.6 <0.1 <0.1 <0.1
PAG <0.1 2.3 0.4 0.3
dDAVP 70.8 8.7 6.8 4.5
dCDAVP 0.6 6.2 1.6 1.5
dNMeAVP 2.3 13.9 15.6 6.9
tGLVP 317.4 0.2 4.7 0.6
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TABLE 5.3
Amino acid sequences of AVP and AVP analogues
The sites at which the AVP analogues differ from AVP are shown in bold























ESVP 2, the binding obtained with ESVP 3 and ESVP 4 was always much lower in the
SAM-RIA than in the AVP-coated-plate ELISA (data not shown). This was originally
thought to indicate that ESVP 3 and ESVP 4 bound near to the tyrosine residue of the
AVP ring structure, because an anti-AVP MAb which did not bind well to 125I-AVP
had been reported (Hou-Yu et al., 1982; Valiquette et alv 1986), but high PEG-RIA
binding later showed that these MAbs bound strongly to 125I-AVP. The low SAM-RIA
binding of ESVP 3 and ESVP 4 was therefore the result of a weak cross-reaction of the
SAM-S-500 solid phase with IgM and IgA isotypes. The anti-mouse IgG HRP
conjugate, on the other hand, bound strongly to IgM and IgA MAbs and so was clearly
not specific for mouse IgG, particularly as it had also shown some cross-reaction with
rabbit and bovine sera (Table 3.1).
The affinity constants of ESVP 1 and ESVP 2 were disappointingly low, even
though they were an order of magnitude higher than those of ESVP 3 and ESVP 4
(Table 5.1), because MAbs with much higher affinities were needed if sensitive
two-site immunometric assays, which could measure physiological AVP concentrations,
were to be developed. However, the cell fusions had been unlikely to produce high
affinity anti-AVP MAbs because the weak immunogenicity of AVP made immunization
difficult, so that most of the mice produced low titre antisera (Sections 4.2.1 and
4.2.2) which were unlikely to contain high affinity anti-AVP antibodies. Cell fusions
produce MAbs with a range of binding affinities that reflect the affinity distribution
of the antibodies generated by the immunized animal, so affinities which are rare
in vivo will also be rare amongst the MAbs that are subsequently produced (Goding,
1986).
AVP consists of a hexapeptide ring and a C-terminal tripeptide tail
(Table 5.3), which folds back over the ring structure (Jurzak et al., 1990) and seems to
be stabilized by hydrogen bonding between the side chains of the asparagine residue
in the ring and the arginine residue in the tail (Langs et al., 1986). The aromatic side
chains of the tyrosine and phenylalanine residues interact with each other and are
directed away from the AVP ring structure. In contrast, the side chains of the tyrosine
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residues in OT and AVT cannot form this type of interaction with isoleucine, so they
lie over the ring structures of these peptides which therefore have an entirely
different conformation from the AVP ring structure (Langs et alv 1986).
ESVP 1 was specific for the AVP ring so it did not bind well to OT or AVT,
and bound even less well to dCDAVP (Table 5.2) which has a distorted ring structure
due to the absence of a sulphur atom from residue 6 (Table 5.3). The ESVP 1 epitope
probably contained the phenylalanine, glutamine and asparagine residues of AVP, and
possibly also the cysteine residue at position 6, but did not include tyrosine because
ESVP 1 bound strongly to 125I-AVP. The slightly decreased cross-reactivity of LVP and
dDAVP (Table 5.2), which have similar ring structures to AVP (Table 5.3), was
probably caused by steric hindrance from their altered tail tripeptides which would
have interacted differently with the side chain of asparagine. However, this steric
hindrance was small compared with that caused by the N-methylarginine residue in
the tail of dNMeAVP (Table 5.2), so the N-methyl group must be orientated towards
the hexapeptide ring, blocking the access of ESVP 1 to its epitope. The hexapeptide
ring of Hep has the same sequence as that of AVP, but residues 8 and 9 are absent
from the Hep tail (Table 5.3). The asparagine side chain of the Hep ring is therefore
likely to assume the conformation which occurs in pressinoic acid, where it lies over
the ring structure and hydrogen bonds to the nitrogen atom of the tyrosine residue
(Langs et al., 1986). The decreased cross-reactivity of Hep, relative to AVP
(Table 5.2), was therefore likely to be caused by the different conformation of the
Hep ring. Pressinoic acid, which consists of the hexapeptide ring of AVP without the
tail tripeptide, was not available for comparison so the influence of the proline
residue on ESVP 1 binding could not be determined. There were also no analogues
available in which glutamine was replaced by another residue, but its position
between the important phenylalanine and asparagine residues make it a probable
component of the ESVP 1 epitope.
ESVP 2, ESVP 3 and ESVP 4 were all specific for the AVP tail region but had
different patterns of cross-reactivity (Table 5.2) and so bound to overlapping, but not
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identical, epitopes. The arginine residue was an important component of these
epitopes because the anti-tail MAbs cross-reacted strongly with AVT but did not bind
either to the truncated tail of Hep or to OT (Table 5.2), in which a leucine residue
replaces arginine (Table 5.3). Cross-reactivity with LVP and tGLVP was also very
low, while the D-arginine residues of dDAVP and dCDAVP produced large decreases
in cross-reactivity, relative to the L-arginine residue of AVP (Table 5.2). Surprisingly,
dNMeAVP cross-reacted more strongly with the anti-tail MAbs than with the
ring-specific ESVP 1 MAb (Table 5.2), so the N-methylarginine side chain of the
dNMeAVP tail is probably located between the tail and the ring structure, where the
N-methyl group would cause decreased cross-reactivity, relative to AVP, by altering
the tail conformation rather than by directly blocking the epitopes of the anti-tail
MAbs. The conformation of the tail tripeptide was stabilized by the ring structure
(Jurzak et al., 1990), which was important for MAb binding, so the cross-reactivity of
the anti-tail MAbs with isolated PAG was low (Table 5.2). Unfortunately, there were
no analogues available with an alteration at position 9, so the importance of the
glycine residue to the anti-tail MAb epitopes could not be determined.
The ESVP 2 epitope was probably closer to the C-terminal of AVP than the
epitopes of ESVP 3 and ESVP 4. ESVP 2 cross-reacted less well with AVT than did
the other anti-tail MAbs (Table 5.2), possibly because the different conformation of
the AVT ring, relative to AVP, altered the orientation of the glycine residue. It also
bound to isolated PAG more readily than the other MAbs, while the altered residue
at position 6 of dCDAVP produced only a small decrease in cross-reactivity relative to
dDAVP, which has the same tail tripeptide (Table 5.3). The cysteine residue at
position 6 was therefore unlikely to be part of the ESVP 2 epitope.
The ESVP 3 and ESVP 4 epitopes seemed to be closer to the ring structure
because ESVP 3 and ESVP 4 cross-reacted more strongly with AVT, and less strongly
with PAG, than ESVP 2, while the distorted ring structure of dCDAVP produced a
larger decrease in cross-reactivity with these MAbs than with ESVP 2. The ESVP 3
and ESVP 4 epitopes may therefore have included the cysteine residue at position 6.
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However, these epitopes were not identical, because the cross-reactivity of ESVP 3
with dNMeAVP was stronger than that of ESVP 4 (Table 5.2) so the MAbs probably
bound to different sides of the AVP tail.
Despite the low affinities of the anti-AVP MAbs (Table 5.1), ESVP 1 and
ESVP 2 were interesting because they were IgGl antibodies which bound to different
parts of the AVP molecule and so could potentially be used in two-site immunometric
assays. ESVP 4 was also interesting because IgA MAbs are rare (Komisar et al., 1982;
Campbell, 1984) and only one other anti-AVP IgA MAb has been reported (Jurzak et
al., 1990), but ESVP 3 was unlikely to be useful because IgM antibodies are not usually






At the start of this project, there were no published reports of two-site
immunometric assays for AVP. However, unpublished work had suggested that
two-site assays were feasible (N. Mcintosh, personal communication) even though AVP
consists of only nine amino acids.
Four anti-AVP MAbs (Chapter 5) were generated in this project, and four
polyclonal antisera were available in sufficient quantity for immunometric assay
studies. ESVP 1 MAb was generated several months before the other anti-AVP MAbs
therefore a large portion of the two-site assay work was carried out using ESVP 1 in
combination with the polyclonal antibodies. However, the aim of the project was to
develop an assay with a pair of MAbs and, therefore, to avoid the problems caused
by the variable quality and limited supplies of polyclonal antisera.
6.2 TWO-SITE ELISA
Preliminary experiments produced poor results but suggested that ESVP 1 MAb
and polyclonal anti-AVP antibodies could bind simultaneously to AVP in a two-site
ELISA (data not shown). Two-site binding to AVP seemed to occur with liquid-phase
anti-AVP serum in ESVP 1 MAb-coated ELISA wells, but there was no evidence of
two-site binding when liquid-phase ESVP 1 was tested in ELISA wells coated with
unpurified anti-AVP serum. Non-specific binding of the liquid-phase antibody caused
inconveniently high background absorbances that increased as the concentration of
anti-AVP serum increased, irrespective of whether it was in the liquid phase or
coated onto the solid phase. Non-specific binding of the donkey anti-rabbit IgG HRP
conjugate, or the rabbit anti-mouse IgG (whole molecule) HRP conjugate, made a much
smaller contribution to the background absorbances.
Further studies were conducted after partial purification of the anti-AVP




Effect of antibody orientation on a two-site ELISA with ESVP 1 MAb and anti-AVP
serum
Serial dilutions of AVP in Buffer L were incubated in ESVP 1 MAb-coated (A),
or partially-purified anti-AVP serum-coated (B), BSA-blocked, Immulon 2 MicroELISA
wells for 22 hours. The wells were washed once with Buffer L, then incubated with
either biotinylated (2 pg/ml, •) or unlabelled (6 pg/ml, o) partially-purified anti-AVP
serum (A), or ESVP 1 (B), in Buffer L for 19 hours. The remainder of the assay was
carried out as described in Section 2.5.1.1, using 2 (ig/ml streptavidin-HRP conjugate (•),
1/500 dilution donkey anti-rabbit IgG HRP conjugate (A, o) or 1/200 dilution rabbit
anti-mouse IgG (whole molecule) HRP conjugate (B, o) to reveal binding. Colour
development occurred rapidly therefore the absorbance at 630 nm was recorded before
H2S04 addition. The symbols show the mean of duplicate estimates, and the vertical
bars show the difference between those estimates.
biotinylation (Section 2.3.4.5) to be carried out. Initial results with partially-purified
anti-AVP serum confirmed the previous observation that detectable binding occurred
only when anti-AVP serum was in the liquid phase (Figure 6.1). Antigen-specific
antibodies usually comprise less than 5% of the immunoglobulin fraction of an
antiserum (Baker et al., 1985) therefore the failure to detect two-site binding in
anti-AVP serum-coated ELISA wells was probably caused by the adsorption of high
concentrations of irrelevant antibodies, and very little AVP-specific antibody, onto the
polystyrene surface. The epitope density of the AVP that subsequently bound to
immobilized anti-AVP antibody was therefore too low to efficiently bind ESVP 1 MAb
(Figure 3.16A; Lew, 1984), particularly as some anti-AVP antibodies would have
recognized the same epitope as ESVP 1 and, thus, have been unable to participate in
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two-site binding with the MAb.
Non-specific binding of unlabelled anti-AVP serum antibodies to ESVP 1
MAb-coated, BSA-blocked, ELISA wells was much higher than that of biotinylated
anti-AVP serum (Figure 6.1A). The anti-AVP serum was a pool of antisera that had
been raised against both unconjugated AVP and AVP-BSA, so it contained both
anti-AVP and anti-BSA antibodies. Unlabelled anti-AVP serum therefore bound
directly to BSA-blocked ELISA wells despite the presence of BSA in the assay buffer.
Biotinylated anti-AVP serum contained few anti-BSA antibodies because unreacted
biotin was removed by gel filtration on a BSA-blocked PD-10 column which absorbed
most of the anti-BSA activity, therefore similar background binding occurred in both
BSA-blocked (Figure 6.1) and unblocked (Figure 6.2) ESVP 1 MAb-coated ELISA wells.
Biotinylated anti-AVP serum also produced a slightly steeper dose-response curve
than the unlabelled material (Figure 6.1A) and was therefore selected for further
two-site ELISA studies.
Increasing the ESVP 1 MAb-coating concentration from 6 pg/ml to 12, 18 or
24 |ig/ml had no effect on either specific or non-specific binding to unblocked wells
(data not shown), which suggested that a coating of 6 pg/ml ESVP 1 filled most of
the protein-binding sites and that reagent adsorption onto polystyrene was unlikely to
cause the remaining non-specific binding. However, AVP adsorbed onto uncoated,
BSA-blocked, wells causing a dose-dependent increase in biotinylated anti-AVP serum
binding (Figure 6.2). This was lower than the binding recorded in ESVP 1 MAb-coated
unblocked wells (Figure 6.2), which was presumed to be genuine two-site binding, but
implied that considerable assay interference could result from non-specific binding of
liquid-phase reagents to solid phase-bound ELISA components.
Higher background absorbances occurred in ESVP 1 MAb-coated, unblocked,
ELISA wells than in uncoated, BSA-blocked, wells (Figure 6.2), which suggested that
the biotinylated anti-AVP serum contained anti-mouse IgG specificities that bound
directly to ESVP 1 MAb. This was confirmed when the absorbance recorded in
AVP-free ESVP 1 MAb-coated ELISA wells was shown to increase as the concentration
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FIGURE 62
Comparison of the binding of AVP and biotinvlated anti-AVP serum to ESVF 1 MAb
and to BSA
Serial dilutions of AVP in Buffer L were incubated in ESVP 1 MAb-coated,
unblocked, MicroELISA wells (•), or in uncoated, BSA-blocked, wells (o), for 20 hours.
The wells were washed once with Buffer L, then incubated with biotinylated
partially-purified anti-AVP serum (2 pg/ml in Buffer L) for 19 hours. Biotin-antibody
binding was revealed with streptavidin-HRP conjugate. Colour development occurred
rapidly therefore the absorbance at 630 nm was recorded before H2S04 addition.
Vertical bars show the difference between duplicate estimations.
[Biotin-anti-AVP serum] gg/ml
FIGURE 63
Binding of biotinylated anti-AVP serum to ESVP 1 MAb
Duplicate 100 (il aliquots of biotinylated partially-purified anti-AVP serum in
Buffer L were incubated in ESVP 1 MAb-coated, BSA-blocked, MicroELISA wells for
18 hours, then biotin-antibody binding was revealed with streptavidin-HRP conjugate
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Effect of incubation protocol on a two-site ELISA with biotinvlated anti-AVP serum
and ESVP 1 MAb
Serial dilutions of AVP in Buffer L were assayed in ESVP 1 MAb-coated,
BSA-blocked, MicroELISA wells, using the separate (Section 2.5.1.1, A) or
simultaneous (Section 2.5.1.2, B) incubation protocols with biotinylated partially
purified anti-AVP serum in the presence (•) or absence (o) of normal mouse serum.
Biotin-antibody binding was revealed with streptavidin-HRP conjugate. Vertical bars
show the difference between duplicate estimations.
of biotinylated anti-AVP serum increased (Figure 6.3), and to decrease when normal
mouse serum was added to the assay buffer (Figure 6.4). A final concentration of
1% (v/v) normal mouse serum was therefore routinely added to all liquid-phase
antibodies in subsequent two-site AVP ELISA work.
The incubation protocol had a significant effect on the magnitude of the
binding recorded with biotinylated anti-AVP serum in ESVP 1 MAb-coated ELISA
wells (Figure 6.4). Reasonable dose-dependent binding was obtained with the separate
incubation protocol (Figure 6.4A), in which each reagent was added to the wells after
the unbound fraction of the previous reagent had been removed and maximal specific
binding occurred because there was no competition between reagents. In contrast,
specific binding was barely noticeable with the simultaneous incubation protocol
(Figure 6.4B), in which AVP and biotinylated anti-AVP serum were preincubated in
the coated wells then streptavidin-HRP conjugate was added so that all of the assay
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components were in the well simultaneously. Partially-purified anti-AVP serum
contained irrelevant antibodies that could not take part in two-site binding to AVP
but were biotinylated and therefore competed with anti-AVP antibodies for binding of
the streptavidin-HRP conjugate, while anti-AVP antibodies competed with ESVP 1
MAb for AVP binding if their epitope specificities overlapped with that of ESVP 1.
Consequently, minimal specific, and non-specific, binding was recorded (Figure 6.4B)
because the streptavidin-HRP conjugate was more likely to react with unbound
biotinylated antibodies than with solid phase-bound assay components.
Although the simultaneous incubation protocol was unsuitable for partially
purified polyclonal antibodies, it could significantly decrease the total assay time if
competition between reagents was eliminated. Two affinity-purified antisera were
therefore compared with partially-purified anti-AVP serum to determine whether the
removal of irrelevant antibodies would improve two-site ELISA binding. Initial results
obtained with unlabelled polyclonal antibodies in ESVP 1 MAb-coated, BSA-blocked
wells, using the separate incubation protocol, showed that affinity-purified anti-PAG
produced a steeper dose-response curve and lower non-specific binding than either
affinity-purified anti-AVP-thyroglobulin or the partially-purified anti-AVP serum
(Figure 6.5). The high non-specific binding of unlabelled anti-AVP serum was largely
due to anti-BSA antibodies, despite the presence of BSA in the assay buffer.
Affinity-purified anti-AVP-thyroglobulin was not expected to contain anti-BSA
antibodies, but the cause of its high non-specific binding (Figure 6.5) was not
investigated because affinity-purified anti-PAG produced superior results.
The non-specific binding of biotinylated affinity-purified anti-PAG was
unexpectedly high compared with that of biotinylated anti-AVP serum (Figure 6.6),
which may indicate that the harsh conditions needed to elute antibodies from an
immunoaffinity matrix had caused structural damage that increased the probability of
non-specific adsorption onto coated ELISA wells. Nevertheless, the signal-to-noise
ratio was higher than that obtained with biotinylated anti-AVP serum (Figure 6.6)
because affinity-purified anti-PAG contained a higher concentration of anti-AVP
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FIGURE 6.5
Comparison of three polyclonal antibody preparations in a two-site ELISA
ESVP 1 MAb-coated, BSA-blocked, Immulon 2 MicroELISA wells were incubated
with serial dilutions of AVP in Buffer L, then with unlabelled affinity-purified
anti-PAG (•), affinity-purified anti-AVP-thyroglobulin (a) or partially-purified
anti-AVP serum (o) in Buffer L containing 1% normal mouse serum, as described in
Section 2.5.1.1. Antibody binding was revealed with donkey anti-rabbit IgG HRP




Comparison of two biotinvlated polyclonal antibody preparations in a two-site ELISA
ESVP 1 MAb-coated, BSA-blocked, MicroELISA wells were incubated with
serial dilutions of AVP in Buffer L, then with biotinylated affinity-purified
anti-PAG (•) or partially-purified anti-AVP serum (o) in Buffer L containing 1%
normal mouse serum (Section 2.5.1.1). Biotin-antibody binding was revealed with
streptavidin-HRP conjugate. Vertical bars show the difference between duplicate
estimations, although most bars are smaller than the symbols used in this Figure.
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antibodies than the partially-purified anti-AVP serum and was less likely to compete
with the ring-specific ESVP 1 MAb (Section 5.3) for AVP binding because it consisted
mainly of anti-tail antibodies. However, no two-site binding was detected when the
simultaneous incubation protocol was used with biotinylated affinity-purified
anti-PAG and ESVP 1 MAb-coated, unblocked, wells (data not shown). This suggested
that the anti-PAG epitopes were so close to the ESVP 1 epitope that steric hindrance
between the antibodies severely limited two-site binding to AVP, therefore unbound
biotinylated anti-PAG antibodies successfully competed for streptavidin-HRP conjugate
binding. Affinity purification had therefore failed to eliminate competition between
reagents so the separate incubation protocol, which maximized specific binding, was
used in all subsequent ELISA work with polyclonal antibody preparations.
Sephadex G-25 gel filtration of radioiodinated AVP separates 125I-AVP from
unreacted 125I and AVP (Roth et al., 1966a), eluting three peaks of radioactivity
(Figure 6.7) which correspond to unreacted 125I, monoiodinated and diiodinated AVP,
respectively (Sadler et al., 1986). When the elution profile was analysed in a
two-site ELISA with biotinylated affinity-purified anti-PAG and ESVP 1 MAb-coated,
BSA-blocked wells (Figure 6.7), 28% of detectable AVP was shown to elute just before
unreacted 125I, presumably as BSA-bound peptide (Sadler et al., 1986), 34% eluted in
two overlapping peaks of cold AVP and only 38% coincided with monoiodinated AVP.
A similar result was obtained when the elution profile of a second radioiodinated
preparation was analysed (data not shown). Diiodinated AVP was not recognized by
the two-site ELISA. Tyrosine was not a component of the epitopes bound by either
ESVP 1 (Section 5.4) or affinity-purified anti-PAG, but the addition of two 125I atoms
increased the molecular weight of AVP by 23% and so caused significant steric
hindrance. The ability of the individual antibody preparations to bind diiodinated
AVP was not tested but it was reportedly bound by tail-specific antisera (Sadler et
al., 1986) therefore its failure to react in the two-site ELISA was probably caused by
distortion of the ESVP 1 epitope.










Two-site ELISA analysis of 125I-AVP elution from Sephadex G-25
Radioiodinated AVP was purified on a Sephadex G-25 column as described in
Section 2.3.4.1. A sample from each fraction was diluted in 3 volumes Buffer L, then
assayed in a two-site ELISA using ESVP 1 MAb-coated, BSA-blocked, MicroELISA
wells, biotinylated affinity-purified anti-PAG and the separate incubation protocol
(Section 2.5.1.1). Standard AVP was prepared in a mixture of 3 volumes Buffer L and
1 volume 0.2% acetic acid, 0.2% BSA.
two-site assay but was roughly estimated with a Geiger counter after each step of the
separate incubation protocol. Although the monoiodinated AVP peak comprised 72%
of the radioactivity eluted from the column (Figure 6.7), only 25% of the original
radioactivity remained in the ELISA wells after sample incubation and plate-washing
with Buffer L to remove loosely-adherent material, which suggested that the ESVP 1
MAb-coated wells had a low AVP-binding capacity. Incubation with biotinylated
affinity-purified anti-PAG removed another 20% of the radioactivity because some of
the anti-PAG antibodies displaced 125I-AVP that had already bound to ESVP 1 MAb,
but no further radioactivity was lost after incubation with the streptavidin-HRP
conjugate. Less than 5% of the original radioactivity remained in the ELISA plate at
the end of the assay period, adding to the evidence which suggested that steric
hindrance caused competition between the antibodies that severely limited two-site
binding to AVP.
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The radioactivity of column fraction 33 (Figure 6.7), which was selected for use
as a RIA tracer, was 115 pCi/ml (assuming 2.2 x 106 disintegrations/min/pCi and an
80% counting efficiency) while the two-site ELISA data suggested that it contained
70 ng AVP/ml. The specific activity of the 125I-AVP in fraction 33 was therefore
1643 pCi/pg, which is close to the theoretical maximum for monoiodinated AVP of
1861 pCi/pg (Czernichow et al., 1975) and to the previously reported values of
1710 ± 155 Ci/mmol (Baylis and Heath, 1977) and 1756±98Ci/g (Sadler et al., 1986).
ESVP 3 was the next anti-AVP MAb to become available for immunometric
assay work. It bound the AVP tail tripeptide (Section 5.3) and so could theoretically
substitute for affinity-purified anti-PAG in a two-site ELISA with ESVP 1 MAb.
However, no detectable two-site binding occurred between ESVP 1 and ESVP 3,
irrespective of whether ESVP 3 was in the liquid phase (Figure 6.8A) or coated onto
the solid phase (Figure 6.8B). This was probably due to the IgM isotype of ESVP 3,
which would have caused much greater steric hindrance than an IgG antibody,
although the high non-specific binding of the biotinylated MAbs possibly obscured a
specific binding response that might have been revealed under different solution
conditions (Wadsley and Watt, 1987).
Unexpectedly, dose-dependent binding of biotinylated affinity-purified
anti-PAG occurred in both ESVP 1 MAb-coated (Figure 6.8A) and ESVP 3 MAb-coated
(Figure 6.8B), BSA-blocked, ELISA wells. ESVP 3 and affinity-purified anti-PAG had
similar epitope specificities so they were unlikely to bind to AVP simultaneously,
which suggested that the observed binding response was caused by non-specific
adsorption of AVP onto the solid phase. This was confirmed when" further
investigation (Figure 6.9) revealed that similar dose-dependent binding occurred
whether the ELISA wells were coated with ESVP 1, ESVP 3 or ESA 5, an anti-ANP
MAb that did not bind dDAVP (Prowse et al., 1989) and was unlikely to bind AVP
although its cross-reactivity with AVP was not tested. The same dose-dependent
binding also occurred in uncoated BSA-blocked wells (Figure 6.9A) but not in uncoated
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Comparison of ESVP 1 and ESVP 3 MAbs in a two-site ELISA
BSA-blocked Immulon 2 MicroELISA wells, coated with ESVP 1 (A) or
ESVP 3 (B), were incubated with duplicate 100 pi aliquots of AVP in Buffer L for
26 hours, then with biotinylated affinity-purified anti-PAG (•), biotin-ESVP 3 (o) or
biotin-ESVP 1 (a) for 17 hours (separate incubation protocol). Biotin-antibody binding
was revealed with streptavidin-HRP conjugate. Colour development occurred rapidly
therefore the absorbance at 630 nm was recorded before H2S04 addition.
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FIGURE 6.9
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Comparison of the binding of AVP and biotinylated anti-PAG to MAbs and to BSA
BSA-blocked (A) or unblocked (B) MicroELISA wells, coated with ESVP 1 (•),
ESVP 3 (o), ESA 5 (a) or nothing (■), were incubated with serial dilutions of AVP in
Buffer L for 23 hours, then with biotinylated affinity-purified anti-PAG for 18 hours.
Biotin-antibody binding was revealed with streptavidin-HRP conjugate. Vertical bars
show the difference between the absorbances recorded in duplicate wells.
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adsorption onto MAb-coated ELISA wells (Figure 6.9B). This implied that AVP
adsorbed equally onto MAbs and onto BSA, although AVP adsorption onto BSA had
previously been lower than the two-site binding response (Figure 6.2).
The signal-to-noise ratio in these experiments (Figures 6.8 and 6.9) was much
lower than in previous work that had suggested that two-site binding to AVP
occurred with biotinylated affinity-purified anti-PAG in ESVP 1 MAb-coated ELISA
wells (Figure 6.6). However, several months had elapsed between the two sets of
experiments, during which time the affinity-purified anti-PAG preparation was stored
at -20°C. Some antibodies are labile to freeze-thawing (Goding, 1986) therefore
antibody deterioration had probably occurred, particularly as affinity purification and
subsequent lyophilization were likely to have caused structural damage that increased
the lability of some specificities. Affinity-purified anti-PAG contained antibodies
against a range of overlapping epitopes on the AVP tail tripeptide, some of which
were unable to form a two-site assay with ESVP 1 MAb. Antibodies whose epitopes
were too close to the ESVP 1 epitope to allow two-site binding would nevertheless
recognize non-specifically adsorbed AVP if it was orientated in such a way that their
epitopes were accessible. If the ESVP 1 MAb-compatible anti-PAG specificities were
the most labile, antibody deterioration would inhibit two-site binding yet the more
robust antibodies would still detect non-specifically adsorbed AVP. Unfortunately, this
phenomenon could not be investigated because no other batches of affinity-purified
anti-PAG were available.
ESVP 2 and ESVP 4 MAbs, which also bound to the AVP tail tripeptide
(Section 5.3), produced no evidence of two-site ELISA binding with ESVP 1 in initial
studies (data not shown). However, these MAbs were very impure because they were
prepared from spent culture supernatant by PEG 8000 precipitation (Section 4.5.1.2) and
so contained high concentrations of non-MAb protein (Figure 4.3A) that could not take
part in two-site binding to AVP but which decreased the potential signal-to-noise
ratio of the assay system (Figure 4.4). ESVP 4 MAb was not used in any further ELISA




Effect of MAb orientation and post-coating treatment on two-site ELISA binding with
ESVP 1 and ESVP 2 MAbs
BSA-blocked (a) or unblocked (• and o) Nunc Maxisorp Microwells, coated
with protein A-purified ESVP 2 (A) or ESVP 1 (B) and rinsed with Buffer T (a and o)
or with Tween buffer (•, 0.01 M Tris/HCl, pH 7.8, 0.9% NaCl, 0.01% Tween 20),
were incubated on a plate-shaker with serial dilutions of AVP in Buffer L for 2 hours,
then with biotin-ESVP 1 (A) or biotinylated protein A-purified ESVP 2 (B) for 2 hours.
The remainder of the assay was carried out as described in Section 2.5.1.1. Colour
development occurred rapidly therefore the absorbance at 630 nm was recorded before
H2S04 addition. The symbols show the mean of duplicate estimates, while the
vertical bars show the difference between those estimates.
format (Section 6.3.1).
When protein A-purified ESVP 2 became available, ESVP 1 and ESVP 2 MAbs
were shown to bind simultaneously to AVP in a two-site ELISA (Figure 6.10) although
the magnitude of the binding response was unexpectedly dependent on the post-coating
treatment of the MAb-coated wells. Most of the two-site ELISA work in this project
was done with antibody-coated wells that were Buffer T-washed then BSA-blocked,
as described in Section 2.3.5.4. BSA-blocking decreased the non-specific binding of
biotin-ESVP 1 to ESVP 2 MAb-coated Buffer T-washed wells (Figure 6.10A) and so
increased the signal-to-noise ratio, but it had no effect on either the specific or
non-specific binding of biotin-ESVP 2 to ESVP 1 MAb-coated Buffer T-washed wells
(Figure 6.10B). In contrast, a post-coating Tween buffer wash dramatically increased
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the dose-dependent binding response in unblocked wells compared with that obtained
in Buffer T-washed wells, regardless of the MAb orientation (Figure 6.10), therefore
assay sensitivity was increased. (The sensitivity, or detection limit, of an assay was
defined as the analyte concentration that produced a binding response equal to the
sum of the mean zero analyte response plus three standard deviations of that
response.) Interestingly, the augmentative effect of Tween buffer on dose-dependent
binding in MAb-coated wells was not unique to ESVP 1 and ESVP 2 because it also
occurred in a microtitre plate-based immunometric assay for proinsulin (unpublished
observation). However, the binding response failed to increase if MAb-coated wells
were BSA-blocked before the Tween buffer wash, which suggested that Tween buffer
altered the conformation of the adsorbed MAb in such a way that subsequently-bound
antigen was more readily accessible to the liquid-phase MAb and that BSA-blocking
caused steric hindrance which inhibited the conformational change.
Irrespective of the post-coating treatment, a more sensitive assay was obtained
with biotinylated protein A-purified ESVP 2 in ESVP 1 MAb-coated wells
(Figure 6.10B) than with biotin-ESVP 1 in ESVP 2 MAb-coated wells (Figure 6.10A).
Further investigation showed that the dose-dependent binding response resulted from
specific interaction of AVP with the binding sites of ESVP 1 and ESVP 2 MAbs, and
not from non-specific adsorption of AVP onto the coated ELISA wells. No significant
dose-dependent binding of biotin-ESVP 2 occurred in unblocked wells coated with
ESNP 2, an anti-ANP IgGl MAb (Chapter 7), or in uncoated BSA-blocked wells, while
the adsorption of AVP onto uncoated unblocked wells was negligible compared with
the specific binding response in ESVP 1 MAb-coated wells (Figure 6.11). Short
incubation periods were used in these experiments because a plate-shaker became
available, whereas long incubations had been used in the earlier work with
polyclonal antibody preparations (Figures 6.1 to 6.9) to ensure that binding equilibrium
was reached in the unshaken wells. The previously-observed non-specific adsorption of
AVP onto wells coated with BSA (Figures 6.2 and 6.9A) or with MAbs (Figure 6.9B)




Effect of plate-coating protein on ELISA binding of biotin-ESVP 2
Unblocked Microwells, coated with ESVP 1 (•), ESNP 2 (o) or nothing (a),
were rinsed with Tween buffer (Figure 6.10) then incubated on a plate-shaker
with serial dilutions of AVP in Buffer L for 2 hours, followed by biotinylated
protein A-purified ESVP 2 MAb for 2 hours. Biotin-ESVP 2 binding was revealed with
1 pg/ml streptavidin-HRP conjugate. Uncoated, BSA-blocked, wells (■) were included
for comparison. Colour development occurred rapidly therefore the absorbance at
630 nm was recorded before H2S04 addition. Vertical bars showing the difference
between duplicate estimations are smaller than the symbols used in this Figure.
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FIGURE 6.12
Comparison of the binding of AVP and biotin-ESVP 2 to ESVP 1 MAb and to ESVP 2
MAb
Unblocked Microwells, coated with ESVP 1 (•) or protein A-purified ESVP 2 (o)
then rinsed with Tween buffer (Figure 6.10), were incubated on a plate-shaker with
duplicate 100 pi aliquots of AVP in Buffer L for 2 hours, then with biotinylated
protein A-purified ESVP 2 for 2 hours (separate incubation protocol). Biotin-ESVP 2
binding was revealed with 0.1 pg/ml streptavidin-HRP conjugate.
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Unexpectedly, dose-dependent binding of biotin-ESVP 2 was recorded in ESVP 2
MAb-coated wells (Figure 6.12), although extremely high non-specific binding of
biotin-ESVP 1 to ESVP 1 MAb-coated wells obscured any dose-dependent response that
might have occurred when ESVP 1 was on both sides of the 'sandwich' (data not
shown). AVP is too small to bind two molecules of the same MAb simultaneously but
it binds to BSA (Sadler et al., 1986) therefore the 'pseudo-two-site' binding of
biotin-ESVP 2 to ESVP 2 MAb-coated wells probably resulted from MAb cross-linkage
by an AVP-BSA complex in which several AVP molecules were attached to each BSA
molecule. Nevertheless, the 'pseudo-two-site' binding response was less than 2% of
the genuine two-site response recorded with biotin-ESVP 2 in ESVP 1 MAb-coated
wells (Figure 6.12), which suggested that only a small proportion of the AVP was
complexed to BSA.
The incubation protocol had a significant effect on the magnitude of the
dose-dependent binding recorded with biotin-ESVP 2 in ESVP 1 MAb-coated ELISA
wells (Figure 6.13). However, unlike partially-purified anti-AVP serum and
affinity-purified anti-PAG, which produced no significant evidence of two-site binding
with ESVP 1 MAb in the simultaneous incubation protocol because they contained
antibodies whose epitope specificities overlapped with that of ESVP 1, ESVP 2 MAb
recognized a completely different epitope from ESVP 1 (Section 5.4) so there was no
competition between the MAbs for AVP binding. Reasonable dose-response curves were
therefore obtained with biotinylated protein A-purified ESVP 2 in all incubation
protocols (Figure 6.13A). The partial simultaneous incubation protocol, in which AVP
and biotin-ESVP 2 were incubated together in the coated wells then unbound material
was removed before addition of the streptavidin-HRP conjugate, produced the most
sensitive assay (with a detection limit of 200 pg AVP/ml; Figure 6.13A) because it
maximized the recorded signal by preventing competition between bound and unbound
biotin-ESVP 2 for binding of the streptavidin-HRP conjugate. The much shallower
dose-response curve and decreased sensitivity (500 pg AVP/ml) recorded with




Effect of incubation protocol and ESVP 2 MAb purity on two-site ELISA bindine with
biotin-ESVP 2 and ESVP 1 MAb
Serial dilutions of AVP in Buffer L were assayed in ESVP 1 MAb-coated,
unblocked, Tween buffer-washed Microwells on a plate-shaker, using the separate (o),
partial simultaneous (•) or simultaneous (a) incubation protocols with biotinylated
protein A-purified ESVP 2 (A) or biotinylated PEG 8000-precipitated ESVP 2 (B;
Precipitate I (Experiment 2), Table 4.16).
In the separate incubation protocol, the coated wells were incubated with
100 pi AVP for 2 hours, then with 100 pi 2pg/ml biotin-ESVP 2 for 2 hours, followed
by 100 pi 0.1 pg/ml streptavidin-HRP conjugate for 15 minutes, before plate-washing
and incubation with 100 pi substrate. In the partial simultaneous incubation protocol,
100 pi AVP and 100 pi 2 pg/ml biotin-ESVP 2 were incubated together for 2 hours, then
the wells were incubated with 200 pi 0.1 pg/ml streptavidin-HRP conjugate before
plate-washing and incubation with 200 pi substrate. In the simultaneous incubation
protocol, 100 pi AVP and 50 pi 4 pg/ml biotin-ESVP 2 in Buffer L containing 2% normal
mouse serum were incubated together for 2 hours, before the addition of 50 pi 0.4 pg/ml
streptavidin-HRP conjugate. After 15 minutes, the wells were washed and incubated
with 200 pi substrate.
The symbols show the mean of duplicate estimates, and the vertical bars
show the difference between those estimates. Bars which are not shown are smaller
than the symbols used in this Figure.
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the desensitizing effect of competition for binding of the conjugate (Figure 6.13A)
because the simultaneous and partial simultaneous protocols differed only in their
conjugate incubation conditions. The dose-response curve produced by the separate
incubation protocol was intermediate between those of the simultaneous and partial
simultaneous protocols (Figure 6.13A), and had a sensitivity of 250 pg AVP/ml.
The purity of the ESVP 2 MAb preparation had a major influence on the
signal-to-noise ratio and thus the sensitivity of two-site ELISA binding in ESVP 1
MAb-coated wells (Figure 6.13). PEG 8000-precipitated ESVP 2 contained a lot of
non-MAb protein (Figure 4.3A) that decreased the effective MAb concentration of
biotinylated PEG 8000-precipitated ESVP 2 so that it produced lower dose-dependent
binding in the partial simultaneous and separate incubation protocols (Figure 6.13B)
than biotinylated protein A-purified ESVP 2 (Figure 6.13A), while the impurities
increased non-specific binding and limited the assay sensitivity to 1 ng AVP/ml. No
dose-dependent response was observed with the simultaneous incubation protocol
(Figure 6.13B) because the streptavidin-HRP conjugate was more likely to bind to
biotinylated impurities than to solid phase-bound biotin-ESVP 2.
Interestingly, initial studies with biotinylated PEG 8000-precipitated ESVP 2
had failed to detect two-site binding in ESVP 1 MAb-coated wells with the separate
incubation protocol, whereas the above experiment clearly showed dose-dependent
binding with both the separate and partial simultaneous incubation protocols
(Figure 6.13B). However, the initial work was done in Buffer T-washed wells while
the more recent studies used Tween buffer-washed wells, which were shown to produce
higher dose-dependent binding responses (Figure 6.10). Further investigation confirmed
that biotinylated PEG 8000-precipitated ESVP 2 produced no detectable dose-dependent
binding in ESVP 1 MAb-coated Buffer T-washed wells (data not shown), and so
emphasized the importance of the post-coating treatment in determining the
sensitivity of two-site ELISA binding.
The concentration of streptavidin-HRP conjugate used in these experiments was
much lower than in earlier work because the conjugate was in short supply. The lower
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FIGURE 6.14
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Effect of streptavidin-HRP concentration on two-site ELISA binding with biotin-ESVP 2
and ESVP1 MAb
Serial dilutions of AVP in Buffer L were assayed in ESVP 1 MAb-coated,
unblocked, Tween buffer-washed Microwells on a plate-shaker, using the separate (A)
or partial simultaneous (B) incubation protocols as described in Figure 6.13. Binding of
biotinylated protein A-purified ESVP 2 was revealed with either 100 pi (A) or
200 pi (B) of 0.05pg/ml (a), 0.1 pg/ml (•) or 0.2 pg/ml (o) streptavidin-HRP
conjugate. The difference between duplicate estimations was smaller than the symbols
used in this Figure.
concentration caused an 8-fold molar excess of biotin-ESVP 2 over streptavidin-HRP
conjugate and was therefore responsible for the competition that occurred between
bound and unbound biotin-ESVP 2 for binding of the conjugate in the simultaneous
incubation protocol (Figure 6.13). However, reasonable dose-response curves were still
obtained with the separate and partial simultaneous incubation protocols because the
total amount of two-site binding was relatively low. All incubation protocols used the
same mass of sample and biotin-ESVP 2, but the separate incubation protocol had an
assay volume of only 100 pi and used half as much streptavidin-HRP conjugate as the
other protocols, which had 200 pi assay volumes (Figure 6.13). Lower dose-dependent
binding of biotinylated protein A-purified ESVP 2 was recorded with the separate
incubation protocol than with the partial simultaneous protocol (Figure 6.13A) but
this was only partly caused by the difference in conjugate mass (Figure 6.14). If the
conjugate concentration was adjusted so that both protocols used the same conjugate
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mass, the partial simultaneous protocol still produced higher dose-dependent binding
(Figure 6.14) because its larger assay volume allowed a larger area of the ESVP 1
MAb-coated ELISA well to take part in two-site binding with AVP and biotinylated
protein A-purified ESVP 2, which suggested that ESVP 1 MAb availability limited
the binding response. In contrast, biotinylated PEG 8000-precipitated ESVP 2 produced
similar dose-response curves with both the separate and partial simultaneous
incubation protocols (Figure 6.13B) because the low ESVP 2 content of the impure
preparation limited the amount of two-site binding that could occur.
The amount of ESVP 1 MAb that adsorbed onto the surface of the ELISA wells
was not determined but Sorensen and Brodbeck (1986) reported that 350-375 ng rabbit
IgG adsorbed onto Nunc Microwells from 100 pi of a 6pg/ml solution. If ESVP 1
adsorbed in a similar manner, the coated wells would have contained an excess of
ESVP 1 MAb over AVP, irrespective of the assay volume, therefore the separate and
partial simultaneous incubation protocols should have produced identical dose-response
curves with any given mass of conjugate. The higher binding that occurred with
biotinylated protein A-purified ESVP 2 in the partial simultaneous incubation protocol
(Figure 6.14) was therefore evidence of steric hindrance between ESVP 1 and ESVP 2
MAbs, particularly as the percentage increase in binding at high AVP concentrations
was exactly matched by the percentage increase in surface area available for binding
when compared with the separate incubation protocol.
The low conjugate concentration also limited the recorded binding response but
this was less important than the effect of steric hindrance between the MAbs because
doubling the conjugate mass did not double the recorded signal (Figure 6.14). However,
the large size of the streptavidin-HRP conjugate was likely to cause steric hindrance
that limited the amount of conjugate binding to biotin-ESVP 2 (Koertge and Butler,
1985). Nevertheless, these experiments showed that AVP could bind to two MAbs
simultaneously in a two-site ELISA, although the binding response was ultimately
limited by steric hindrance and only increased if the area of the MAb-coated surface
increased.
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6.3 IMMUNORADIOMETRIC ASSAY (IRMA)
IRMA solid phases were prepared by covalently coupling MAbs and polyclonal
antibodies onto periodate-oxidized Sephacryl S-300 (Section 2.3.5.2). Some antibodies
might have coupled in such a way that their antigen-binding capacity was destroyed
therefore the antibody-S-300 solid phases were assayed for the ability to bind
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I-AVP before they were used in IRMA work. All of the antibody preparations,
except ESVP 3 and ESVP 4, produced solid phases that bound significant amounts of
125I-AVP (Table 6.1). Knutson etal. (1991) reported that IgM MAbs were irreversibly
inactivated by immobilization, which may explain the failure of ESVP 3-S-300 to
bind I-AVP. ESVP 4 was an IgA MAb, an isotype that is so rare amongst MAbs that
little is known about its properties. The failure of ESVP 4-S-300 to bind 125I-AVP
might have been caused either by coupling the MAb too close to its binding site or by
immobilization-induced denaturation.
Oxidized Sephacryl S-300 had a high protein-coupling capacity therefore
impurities in the antibody preparations had little effect on the ability of the
antibody-S-300 solid phases to bind 125I-AVP. ESVP 2-S-300 was prepared from impure
PEG 8000-precipitated ESVP 2 (Precipitate II (Experiment 2), Table 4.16) yet it bound
almost as much 125I-AVP as the protein A-purified ESVP 2-S-300 (Table 6.1) that was
prepared from material that contained no detectable non-IgG substances (Figure 4.3B).
Similarly, solid phases prepared from partially-purified antisera bound only slightly
•IOC
less I-AVP than solid phases prepared from affinity-purified antisera (Table 6.1).
Impurities that coupled to the solid phases were therefore unlikely to cause the
drastic inhibition of two-site binding that was observed in the ELISA format
(Section 6.2).
6.3.1 DIRECT IRMA
Initial IRMA studies with 125I-ESVP1 (Figure 4.1A, Table 4.22) and three
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TABLE 6.1
Binding of 125I-AVP to antibody-S-300 solid phases
Solutions of 1 mg/ml anti-AVP MAb or affinity-purified antibody, 8 mg/ml
partially-purified anti-AVP serum (Section 4.6.1) or 4 mg/ml partially-purified
anti-PAG serum (Section 4.6.2) were coupled to oxidized Sephacryl S-300 then assayed
for antigen-binding ability as described in Section 2.3.5.2.
Pro A-p = protein A-purified; Aff-p = affinity-purified; Par-p = partially-purified.
Solid phase % 125I-AVP bound
ESVP 1-S-300 86.4
ESVP 2-S-300
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FIGURE 6.15
Comparison of three polyclonal antibodv-S-300 solid phases in a direct IRMA
Serial dilutions of AVP, in Buffer E containing 5% BSA, were assayed by
direct IRMA as described in Section 2.5.2.1, using 125I-ESVP 1 with affinity-purified
anti-PAG-S-300 (•), affinity-purified anti-AVP-thyroglobulin-S-300 (o) or partially
purified anti-AVP serum-S-300 (a) solid phases. Non-specific binding of 0.04% (•),
0.12% (o) and 1.72% (a) of added 125I-ESVP 1 was observed with these solid phases.
The symbols show the mean of duplicate estimates, while the vertical bars
show the difference between those estimates. Bars which are not shown are smaller
than the symbols used in this Figure.
polyclonal antibody-S-300 solid phases (Figure 6.15) confirmed the ELISA evidence
(Figure 6.5) that two-site binding to AVP occurred with these antibody combinations.
The partially-purified anti-AVP serum-S-300 solid phase produced an insensitive
-IOC
assay because high non-specific binding of I-ESVP 1 (Figure 6.15), that was probably
caused by anti-mouse IgG antibodies (Section 6.2), resulted in a low signal-to-noise
ratio. However, 1% (v/v) normal mouse serum failed to decrease this non-specific
binding (data not shown) therefore the partially-purified anti-AVP serum-S-300 solid
phase was not used in any further direct IRMA work. Lower non-specific binding
occurred with the affinity-purified anti-AVP-thyroglobulin-S-300 solid phase but low
dose-dependent binding of 125I-ESVP 1 produced a poor assay (Figure 6.15). This solid
1 jc
phase bound well to I-AVP (Table 6.1) therefore the low two-site binding
indicated that the affinity-purified anti-AVP-thyroglobulin preparation contained a
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high proportion of antibodies that recognized epitopes which were too close to the
ESVP 1 epitope to allow simultaneous binding. In contrast, the affinity-purified
anti-PAG-S-300 solid phase, which bound less 125I-AVP (Table 6.1), produced a better
dose-response curve (Figure 6.15) because it contained a larger proportion of ESVP 1
MAb-compatible antibodies, while exceptionally low non-specific binding and good
precision resulted in an assay with a sensitivity of 130 pg AVP/ml. However, the
maximum binding response was only 3% of added 125I-ESVP 1 which was further
evidence to suggest that steric hindrance between the antibodies limited two-site
binding to AVP.
Polyclonal antibodies tend to have higher average binding affinities than
MAbs (Campbell, 1984; Goding, 1986) so affinity-purified anti-PAG probably had a
significantly higher affinity than ESVP 1 MAb (Table 5.1). IRMA sensitivity is
maximized when the labelled antibody has the highest possible affinity constant
(Baker et al., 1985) therefore iodinated affinity-purified anti-PAG seemed likely to
produce a more sensitive assay than 125I-ESVP 1. However, the specific activity of
the label is also important in determining IRMA sensitivity (Baker et al., 1985;
Ekins, 1987). Iodination is most efficient in concentrated solutions (Chard, 1987) but,
unfortunately, the affinity-purified anti-PAG preparation was fairly dilute therefore
it failed to iodinate to a high specific activity and could not reliably reveal two-site
binding with ESVP l-S-300 solid phase (data not shown). The effect of using labelled
affinity-purified anti-PAG could therefore only be studied in the indirect IRMA
format (Section 6.3.2).
Most experiments were done with 100 pi AVP samples although an assay
intended for neonatal studies would ideally use no more than 50 pi plasma per test.
However, as expected, decreasing the sample volume to 50 pi decreased the sensitivity
of the IRMA with 125I-ESVP 1 and affinity-purified anti-PAG-S-300 solid phase
(Figure 6.16). Since this IRMA was insufficiently sensitive to measure normal
physiological AVP concentrations, no attempt was made to use a plasma matrix for
the standard AVP solutions which were instead prepared in 5% BSA. However, AVP
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FIGURE 6.16
Effect of sample volume on direct IRMA binding
Duplicate 50 pi (o) or 100 pi (•) aliquots of AVP, in Buffer E containing
5% BSA, were assayed by direct IRMA, using 125I-ESVP 1 with affinity-purified
anti-PAG-S-300 solid phase. The non-specific binding corresponded to 0.03% of added
125I-ESVP 1, irrespective of sample volume. The symbols show the mean of the
duplicate estimates, while the vertical bars show the difference between those
estimates.
Effect of sample matrix composition on direct IRMA binding
Serial dilutions of AVP, in Buffer E containing 5% BSA (•) or in Buffer F (o),
were assayed by direct IRMA, using 125I-ESVP 1 with affinity-purified anti-PAG-S-300
solid phase. Non-specific binding of 0.03% (•) or 0.09% (o) of added 125I-ESVP 1 was
recorded. Vertical bars show the difference between duplicate estimations.
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adsorbed non-specifically to BSA (Figures 6.2, 6.7 and 6.9), which might have caused
significant assay interference, so the 5% BSA matrix was compared with assay buffer
which contained 2% bovine serum (Buffer F). Lower specific and non-specific binding
was recorded in 5% BSA than in Buffer F (Figure 6.17) but assay sensitivity was
almost unchanged therefore the BSA matrix did not seem to adversely affect the
IRMA. Decreased binding was also reported in other IRMAs when the protein
concentration of the matrix was increased (Hunter et al., 1983; Wright et al., 1984).
ESVP 3 and ESVP 4 MAbs were unsuitable for IRMA work because they could
not be coupled to the solid phase (Table 6.1), and they produced no evidence of
two-site binding when 125I-ESVP 3 and 125I-ESVP 4 were combined with ESVP l-S-300
solid phase (data not shown). In contrast, ESVP 1 and ESVP 2 MAbs combined to
produce a dose-dependent response in the IRMA format, although 125I-ESVP 2 binding
was poor and better results were obtained with 125I-ESVP 1 and ESVP 2-S-300 solid
phase (Figure 6.18). Protein A-purified ESVP 2 iodinated to a higher specific activity
than PEG 8000-precipitated ESVP 2 (Table 4.22) but this did not improve the binding
1TC
response therefore I-ESVP 2 was not used in any further work.
The dose-dependent binding of 12SI-ESVP 1 to ESVP 2-S-300 solid phase was
caused by specific interaction of AVP with the binding sites of the MAbs, and not by
non-specific adsorption of AVP onto the solid phase, since no dose-dependent response
occurred between 125I-ESVP 1 and MAb-free solid phase (data not shown) or between
125I-ESVP 1 and ESNP 2-S-300 solid phase (Figure 6.19). However, dose-dependent
binding was observed between 125I-ESVP 1 and ESVP l-S-300 solid phase (Figure 6.19).
This 'pseudo-two-site' binding was only 10% of the genuine two-site response that was
recorded with 125I-ESVP 1 and ESVP 2-S-300 solid phase, but it was larger than the
'pseudo-two-site' response that had been observed between biotin-ESVP 2 and ESVP 2
MAb-coated ELISA wells (Figure 6.12) even though the same AVP preparation was
used in both experiments. This observation provided further evidence of the assay
interference that resulted from MAb cross-linkage by AVP-BSA complexes, and showed

















Effect of MAb orientation on a direct IRMA with ESVP 1 and ESVP 2 MAbs
Dilutions of AVP in Buffer E containing 5% BSA were assayed by direct
IRMA, using 125I-ESVP 1 with ESVP 2-S-300 solid phase (•), or 125I-ESVP 2 with
ESVP l-S-300 solid phase (o). Non-specific binding of 0.05% (•) or 0.18% (o) of added
12SI-MAb was recorded. Vertical bars showing the difference between duplicate tubes













Comparison of three MAb-S-300 solid phases in a direct IRMA with 125I-ESVP 1
Serial dilutions of AVP, in Buffer J containing 5% BSA, were assayed by direct
IRMA, using 125I-ESVP 1 with ESVP 2-S-300 (•), ESVP l-S-300 (o) or ESNP 2-S-300 (a)
solid phases. Non-specific binding of 0.04% (•), 0.14% (o) and 0.05% (a) of added
125I-ESVP 1 was recorded with these solid phases. The symbols show the mean of
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FIGURE 6.20
Effect of incubation protocol on a direct IRMA with ESVP 1 and ESVP 2 MAbs
Serial dilutions of AVP, in Buffer E containing 5% BSA, were preincubated
with 125I-ESVP 1 for 2 hours then ESVP 2-S-300 solid phase was added and incubation
continued for a further 2 hours (•), or they were incubated with 125I-ESVP 1 and
ESVP 2-S-300 solid phase simultaneously for a total of 2 hours (o), before separation
of bound and free 1 I-ESVP1 by the sucrose layering technique. Non-specific binding of
0.05% of added 125I-ESVP 1 was recorded with both incubation protocols. Vertical bars
show the difference between duplicate estimations.
Most of the IRMA work was done with a total incubation period of 4 hours,
where the sample was preincubated with 125I-MAb for 2 hours before addition of the
antibody-S-300 solid phase, since this type of incubation protocol was reported to
produce the best IRMA sensitivity (Hunter et al., 1983). When the incubation period
was decreased to 2 hours by omission of the preincubation step, the sensitivity of the
IRMA with 125I-ESVP 1 and ESVP 2-S-300 solid phase decreased from 1 ng AVP/ml to
4 ng AVP/ml, although the maximum binding response was unchanged (Figure 6.20).
125A concentration of 50 ng I-ESVP 1 /ml was used in most IRMA work, producing
roughly similar binding with both the affinity-purified anti-PAG-S-300 and the
ESVP 2-S-300 solid phases. IRMA sensitivity can be increased by decreasing the
concentration of added 125I-MAb so that a greater proportion of the 125I-MAb becomes
bound (Hunter et al., 1983). When the 125I-ESVP1 concentration was decreased, the
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FIGURE 6.21
Effect of 125I-ESVP 1 concentration on direct IRMA binding
Serial dilutions of AVP in Buffer E containing 5% BSA were assayed by direct
IRMA, using 5 (x), 10 (a), 25 (o) or 50 (•) ng/ml 125I-ESVP 1 in Buffer F with
protein A-purified ESVP 2-S-300 solid phase in Buffer R. Non-specific binding of
0.14% (x), 0.04% (a), 0.01% (o) or 0.01% (•) of added 125I-ESVP 1 was recorded. The
difference between duplicate estimations with 50 ng/ml 125I-ESVP 1 is indicated by
vertical bars. For clarity, equivalent data for the other 125I-ESVP 1 concentrations has
been omitted from this Figure.
percentage binding to the ESVP 2-S-300 solid phase increased as expected (Figure 6.21)
but the total amount of bound radioactivity was so low that increased counting errors
decreased the precision of the assay (Klee and Post, 1989) and the sensitivity was not
improved. There was therefore no advantage to be gained from decreasing the
125I-ESVP 1 concentration used in the IRMA.
Further studies with 125I-ESVP 1 and ESVP 2-S-300 showed that variation of
the solid phase volume had little effect on IRMA binding. Similar results were
obtained with 100 pi and 200 pi ESVP 2-S-300 solid phase at AVP concentrations up to
25 ng/ml (Figure 6.22), although 200 pi solid phase produced better 125I-ESVP 1 binding
at higher AVP concentrations. Impurities in the ESVP 2 preparation had no effect on
IRMA sensitivity because solid phases that were prepared from protein A-purified
ESVP 2 and PEG 8000-precipitated ESVP 2 produced similar IRMA binding at AVP
concentrations up to 25 ng/ml (Figure 6.23). However, protein A-purified ESVP 2-S-300
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FIGURE 6.22
Effect of ESVP 2-S-300 solid phase volume on direct IRMA binding
Serial dilutions of AVP, in Buffer E containing 5% BSA, were assayed by
direct IRMA, using 125I-ESVP 1 with either 100 ul (•) or 200 gl (o) ESVP 2-S-300 solid
-toe
phase. Non-specific binding was 0.05% (•) or 0.1% (o) of added I-ESVP 1. Vertical
bars show the difference between duplicate estimations, although most of the bars are
smaller than the symbols used in this Figure.
solid phase had a higher AVP-binding capacity, presumably because fewer impurities
coupled to sites that ESVP 2 MAb would otherwise have occupied, therefore at high
AVP concentrations it allowed higher IRMA binding than the PEG 8000-precipitated
ESVP 2-S-300 solid phase (Figure 6.23).
125
In the IRMA format, the concentration of I-MAb is usually much lower than
that of the solid phase-coupled antibody therefore 'plateau' binding occurs at high
analyte concentrations when all of the 125I-MAb becomes linked to the solid phase
(Figure 1.1B). If the analyte concentration increases further, it eventually exceeds the
binding capacity of the solid phase and causes the high-dose 'hook' effect when free
125
analyte competes with I-MAb-bound analyte for binding to the solid phase antibody
(Figure 6.23). In this project, 4 ml 1 mg/ml protein A-purified ESVP 2 coupled to
3 ml (settled volume) oxidized Sephacryl S-300 with an efficiency of 25%, producing
sufficient solid phase for 240 tests, therefore each aliquot of protein A-purified
ESVP 2-S-300 solid phase contained about 4 pg ESVP 2. The AVP IRMA used only
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FIGURE 6.23
Effect of ESVP 2 MAb purity on the direct IRMA binding of ESVF 2-S-300 solid phase
ESVP 2 MAb was prepared from spent culture supernatant by PEG 8000
precipitation (Precipitate II (Experiment 2), Table 4.16, o) or Protein A-Sepharose
affinity chromatography (•), then solutions of 1 mg/ml ESVP 2 were coupled to
oxidized Sephacryl S-300 (Section 2.3.5.2).
Serial dilutions of AVP, in Buffer E containing 5% BSA, were assayed by
direct IRMA, using 125I-ESVP 1 with the ESVP 2-S-300 solid phases. The non-specific
binding was 0.01% of added 125I-ESVP 1 for both solid phases. Vertical bars show the
difference between duplicate estimations.
5 ng 125I-ESVP 1 per tube therefore the ESVP 2-S-300 solid phase had an AVP-binding
capacity that was 800-fold larger than that of 125I-ESVP 1 and 'plateau' binding
125
was expected to occur at high AVP concentrations. However, I-ESVP 1 binding
continued to increase until the binding capacity of the solid phase was reached at
100 ng AVP/ml and no 'plateau' binding was observed (Figure 6.23). This was further
evidence of steric hindrance between the antibodies because 100 ng AVP/ml
125 /•
corresponded to a 300-fold molar excess of AVP over I-ESVP 1. In the absence of
steric hindrance, and assuming that both ESVP 1 binding sites were accessible to AVP,
maximal binding of 125I-ESVP 1 to the ESVP 2-S-300 solid phase would have been
expected to occur at a concentration closer to 0.6 ng AVP/ml.
Most experiments were done at pH 7.0. However, investigation of the effect of






001 ■ "1 1 1 1 1
6.5 7.0 7.5 8.0 8.5 9.0
FIGURE 6.24
Effect of pH on a direct IRMA with 125I-ESVP 1 and ESVP 2-S-300 solid phase
Quadruplicate 50 pi aliquots of AVP (0 (x), 6.25 (a), 25 (•) and 100 (o) ng/ml
in 0.01M sodium phosphate buffer, pH 7.0, containing 5% BSA) were incubated with
50 pi assay buffer and 100 pi 50 ng/ml 125I-ESVP 1 in assay buffer for 2 hours, then
100 pi ESVP 2-S-300 (12.5% (settled volume) slurry in assay buffer containing
3% Tween 20) was added. The mixture was agitated on an orbital shaker for 2 hours,
IOC
then bound and unbound I-ESVP 1 were separated by sucrose layering, at the
appropriate pH. The symbols show the mean of the quadruplicate estimations and
the vertical bars show the standard deviation of those estimations.
The assay buffers were Universal buffer solutions (Britton and Robinson type;
Dawson et al., 1969) in the pH range 6.5-9.0, containing 2% bovine serum.
binding seemed to occur in the range pH 7.5-8.0 (Figure 6.24). Non-specific binding was
unaffected by pH changes in the range pH 7.0-8.5 therefore the sensitivity of the
IRMA could be increased by raising the pH of the assay buffer, although the gain in
sensitivity would be relatively small. Unfortunately, there was no time available to
carry out further studies of this phenomenon.
6.3.2 INDIRECT IRMA
The affinity-purified anti-PAG preparation did not iodinate well therefore it
could not be used as the liquid-phase antibody in a direct IRMA. Biotinylated
affinity-purified anti-PAG had, however, produced reasonable two-site ELISA binding
125
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FIGURE 6.25
Optimization of 125I-streptavidin binding to biotin-ESVP 1
Duplicate 100 pi aliquots of 125I-streptavidin in Buffer F were incubated with
100 pi 50 ng/ml biotin-ESVP 1 in Buffer F for 15 minutes, then 100 pi SAM-S-500 solid
phase (25% (settled volume) slurry in Buffer G) was added. The mixture was agitated
on an orbital shaker for 1 hour, then bound 125I-streptavidin was isolated by the
sucrose layering technique, as described in Section 2.5.2.1. Vertical bars show the
difference between the duplicate estimations.
was used as a universal label to reveal the binding of biotin-antibody. The indirect
IRMA had the advantage that it was not prone to the high non-specific binding that
frequently occurred in the two-site ELISA format (Section 6.2).
A preliminary study with 50 ng/ml biotin-ESVP 1 showed that optimal signal
-| or
generation occurred with 20 ng/ml I-streptavidin (Figure 6.25), which corresponded
to a 1:1 molar ratio of streptavidin to MAb. It had to be assumed that the same
molar ratio would also provide optimal detection of biotinylated affinity-purified
anti-PAG because there was no solid phase available that would allow the study of
125
I-streptavidin binding to biotinylated rabbit antibodies.
The AVP-binding affinity of the affinity-purified anti-PAG preparation was
unknown but was expected to be higher than that of ESVP 1 MAb. Maximal IRMA
sensitivity is obtained when the labelled antibody has the highest binding affinity
(Baker et al., 1985) therefore higher indirect IRMA binding was expected with
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FIGURE 6.26
Effect of antibody orientation on an indirect IRMA
Dilutions of AVP, in Buffer E containing 5% BSA, were assayed by indirect
IRMA (Section 2.5.2.2), using biotin-ESVP 1 with affinity-purified anti-PAG-S-300
solid phase (•) or biotinylated affinity-purified anti-PAG with ESVP l-S-300 solid
phase (o). Non-specific binding of 0.01% (•) and 0.06% (o) of added 125I-streptavidin
was recorded. The symbols show the mean of duplicate estimates, while the vertical
bars show the difference between those estimates.
biotinylated affinity-purified anti-PAG and ESVP l-S-300 solid phase than with
biotin-ESVP 1 and affinity-purified anti-PAG-S-300 solid phase. However, two-site
binding was barely detectable with biotinylated affinity-purified anti-PAG, while
biotin-ESVP 1 produced a reasonable dose-response curve (Figure 6.26). This surprising
result provided additional evidence to support the theory that some of the anti-tail
antibodies in the affinity-purified anti-PAG preparation bound to epitopes that were
so close to that of the ring-specific ESVP 1 MAb that they could not combine with
ESVP 1 to form a two-site AVP assay. AVP bound to all biotin-antibody specificities
during the 2 hour preincubation period but the antibody-S-300 solid phase could only
cross-link with biotin-antibodies that recognized compatible epitopes. Although steric
hindrance prevented a high binding response, all of the biotin-ESVP 1 MAb-bound
AVP was available for binding to the multispecific affinity-purified anti-PAG-S-300
solid phase. In contrast, the monospecific ESVP l-S-300 solid phase could only bind a
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FIGURE 6.27
Indirect AVP IRMA using two polyclonal antibody preparations
Serial dilutions of AVP, in Buffer E containing 5% BSA, were assayed by
indirect IRMA, using biotinylated affinity-purified anti-PAG with partially-purified
anti-AVP serum-S-300 solid phase. The non-specific binding was 0.11% of added
125I-streptavidin. Vertical bars showing the difference between duplicate estimations
are smaller than the symbols used in this Figure.
small fraction of the biotinylated affinity-purified anti-PAG-bound AVP therefore
extremely low dose-dependent binding was recorded (Figure 6.26).
Interestingly, biotinylated affinity-purified anti-PAG produced a much better
dose-response curve with partially-purified anti-AVP serum-S-300 solid phase
(Figure 6.27), which confirmed that the low binding obtained with ESVP l-S-300 solid
phase (Figure 6.26) was due to steric hindrance and not to sub-optimal signal
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generation since the same I-streptavidin concentration was used in both experiments.
These results also showed that the partially-purified anti-AVP serum contained
antibodies to both the ring and tail structures of AVP since it could form a two-site
assay with ESVP 1 MAb (Figures 6.2 and 6.15) and with affinity-purified anti-PAG
(Figure 6.27) provided that AVP bound to the first antibody before the partially
purified anti-AVP serum was added (Figures 6.1 and 6.4).
Although 'plateau' binding was not observed with any other antibody
combination, it occurred in the indirect IRMA with biotinylated affinity-purified
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FIGURE 6.28
Indirect IRMA with biotin-ESVP 1 and anti-PAG serum-S-300 solid phase
Dilutions of AVP, in Buffer E containing 5% BSA, were assayed by indirect
IRMA, using biotin-ESVP 1 with partially-purified anti-PAG serum-S-300 solid phase
(prepared from the 0-4% PEG cut of anti-PAG serum, after further purification by
Rivanol precipitation; Section 4.6.2). Non-specific binding was 0.15% of added
125I-streptavidin. Vertical bars show the difference between duplicate estimations.
anti-PAG and partially-purified anti-AVP serum-S-300 solid phase (Figure 6.27). This
suggested that the anti-AVP serum antibodies that bound to AVP simultaneously with
affinity-purified anti-PAG probably recognized epitopes at the opposite side of the
AVP molecule from the anti-PAG epitopes, so that there was less steric hindrance
between these antibodies than between ESVP 1 MAb and the anti-tail antibody
preparations (Figures 6.23 and 6.26). Nevertheless, the total binding was only 1.2% of
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added I-streptavidin, which suggested that few anti-AVP serum antibodies were
compatible with affinity-purified anti-PAG in a two-site assay. Further purification
might have increased the binding response obtained with the anti-AVP serum
preparation, but there was no time available to investigate suitable methods because
the aim of the project was to develop a MAb-based assay.
Antibody-S-300 solid phase preparation required large amounts of antibody
(Section 2.3.5.2), so few experiments could be done with the affinity-purified
anti-PAG-S-300 solid phase because very little affinity-purified antibody was
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FIGURE 6.29
Immunofiltration assay with 125I-ESVP 1 and PEG-precipitated ESVP 2 MAb
PEG 8000-precipitated ESVP 2 MAb (Precipitate II (Experiment 2), Table 4.16)
was coated onto nitrocellulose membrane-bottomed wells (Section 2.3.5.5) at 5 (•),
10 (o), 15 (a), 20 (x) or 30 (■) pg/ml. Duplicate 100 pi aliquots of AVP in Buffer M
were assayed by immunofiltration through the coated membranes, using 125I-ESVP 1
MAb to detect binding (Section 2.5.3). Non-specific binding was 0.05% (•), 0.06% (o),
0.07% (a), 0.07% (x) or 0.08% (■) of added "5I-ESVP 1.
Vertical bars show the difference between the duplicate estimations in wells
coated with 5 (•) or 10 (o) pg ESVP 2/ml. For clarity, the equivalent data for the
other coating concentrations has been omitted from this Figure.
available. The partially-purified anti-PAG serum preparation (Section 4.6.2) could not
substitute for affinity-purified anti-PAG because biotin-ESVP 1 produced poor indirect
IRMA binding with partially-purified anti-PAG serum-S-300 solid phase (Figure 6.28)
compared with that produced by affinity-purified anti-PAG-S-300 solid phase
(Figure 6.26). Consequently, no further indirect IRMA studies of ESVP 1 MAb in
combination with anti-PAG antibodies could be carried out.
6.4 IMMUNOFILTRATION ASSAY
Immunoassay reaction rates at solid-liquid interfaces tend to be limited by the
rate of diffusion of the reactants (Stenberg and Nygren, 1988) although high reagent
















Immunofiltration assay with I-ESVP 1 and protein A-purified ESVP 2
Protein A-purified ESVP 2 MAb was coated onto nitrocellulose membrane-
bottomed wells (Section 2.3.5.5) at 5 (•), 10 (o), 15 (a) or 25 (+) pg/ml, then
immediately used to assay serial dilutions of AVP in Buffer M by immunofiltration
(Section 2.5.3). Uncoated wells (□), washed four times with Buffer U, were included
for comparison. The non-specific binding was 0.09% (n), 0.08% (•), 0.07% (o),
0.07% (a) and 0.06% (+) of added 125I-ESVP 1.
Vertical bars show the difference between duplicate estimations in uncoated
wells (□) and in those coated with 5 pg ESVP2/ml (•). For clarity, equivalent data
for the other coating concentrations has been omitted from this Figure.
Immunofiltration assays bring the reactants into close proximity as they pass through
a coated membrane therefore maximal reaction rates are achieved and incubation
periods can be very short (Valkirs and Barton, 1985; IJsselmuiden et al., 1989).
Immunofiltration therefore had the potential to produce a rapid AVP assay.
An initial study showed that two-site binding in an immunofiltration assay
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with I-ESVP 1 and ESVP 2 MAb-coated nitrocellulose membranes increased
dramatically as the coating concentration of PEG 8000-precipitated ESVP 2 increased
from 5 |ig/ml to 30 pg/ml (Figure 6.29), although the total binding of 125I-ESVP 1 was
lower than that observed in a direct IRMA (Figure 6.23). In contrast, there was only a
small increase in binding as the coating concentration of protein A-purified ESVP 2
increased from 5 pg/ml to 10 pg/ml and there was no significant improvement at
higher coating concentrations (Figure 6.30), which compared well with the previous
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observation that 6 (ig/ml ESVP 1 filled most of the protein-binding sites in polystyrene
wells (Section 6.2). However, the maximum amount of dose-dependent 125I-ESVP 1
binding that occurred was the same with both ESVP 2 preparations therefore the
impurities in PEG 8000-precipitated ESVP 2 were unlikely to adsorb onto the membrane
but instead interfered with coating by decreasing the effective concentration of ESVP 2
MAb in the coating solution. The efficiency of membrane coating was not determined
but the low 125I-ESVP 1 binding suggested that the ESVP 2 MAb-coating capacity of
the nitrocellulose membrane was lower than that of oxidized Sephacryl. No
dose-dependent binding occurred on uncoated membranes (Figure 6.30) therefore AVP
did not adsorb onto nitrocellulose under the conditions of the assay.
Although the total assay time was only 1 hour, low binding and poor precision
limited the sensitivity of the immunofiltration assay to 10 ng AVP/ml therefore it
was 10-fold less sensitive than a direct IRMA with 125I-ESVP 1 and ESVP 2-S-300
solid phase (Figure 6.19). Variation of the assay parameters might have improved
the binding of 125I-ESVP 1 but the sensitivity of the immunofiltration assay was
ultimately limited both by steric hindrance between the MAbs and by the low coating
capacity of the nitrocellulose membrane therefore it did not offer any significant
advantage over the direct IRMA.
6.5 DISCUSSION
Two-site immunometric assays for AVP could be carried out in the ELISA,
IRMA and immunofiltration assay formats, despite the small size of the AVP
molecule, although steric hindrance between the antibodies was a major problem
which severely limited the total amount of binding that occurred. The epitopes that
were recognized by the anti-AVP MAbs seemed to consist of 3-4 amino acids
(Section 5.4). Epitopes are usually reported to contain 4-6 amino acids (Sela, 1969;
Barbet et al., 1981; Baker et al., 1985; Siddle, 1985) therefore many workers consider
that peptides of 15-20 amino acids are the smallest that will allow two-site binding
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(Siddle, 1985; Gosling, 1990), although a minimum peptide size of 10-12 amino acids
has also been suggested (Baker et al., 1985). AVP consists of only nine amino acids
and is therefore likely to be one of the smallest molecules that can be measured in a
two-site assay, despite claims that AVP could not bind simultaneously to two
antibody molecules (Hashida et al., 1991b) and that the entire AVP molecule would
occupy an antibody binding site as a single epitope (Wu and Rockey, 1969). An
antibody binding site is widely considered to be a pocket or cleft (Roitt et al., 1985)
into which the appropriate epitope will fit, although recent studies have shown that
binding sites can be relatively flat or even protrude from the antibody molecule
(Wilson et al., 1991). Antibodies that bind simultaneously to AVP may therefore
have particularly shallow binding sites that enable them to bind in close proximity.
Non-specific binding was a serious problem in the two-site ELISA format with
most of the available antibody combinations. Polyclonal antibody preparations that
were contaminated by anti-BSA (Figure 6.1A) or anti-mouse IgG (Figures 6.3 and 6.4)
specificities bound to MAb-coated BSA-blocked ELISA wells, causing high background
absorbances despite the presence of BSA and normal mouse serum in the assay buffer.
Affinity-purified antisera were free from these contaminants but probably contained
some antibodies that had been structurally-damaged during the purification procedure.
Non-specific binding of this material was recorded in coated ELISA wells (Figures 6.5
and 6.9) but not in uncoated wells (Figure 6.9B), which showed that the binding was
caused by protein-protein interactions and not by adsorption onto the polystyrene
surface under the conditions of the assay. Non-specific binding of biotin-MAbs
(Figures 6.8, 6.10A and 6.13B) was reportedly a pH-related phenomenon since
biotinylation shifted the isoelectric pH of MAbs towards more acidic values, causing
decreased solubilities and therefore higher non-specific binding at pH values of 7.0 or
less, so that the highest signal-to-noise ratios were obtained at pH 8.0-9.0 (Wadsley
and Watt, 1987). All of the two-site AVP ELISAs were done at pH 7.5, and the effect
of pH was not investigated, but non-specific binding might have been lower at pH 8.0.
Impurities in the biotin-MAb preparations contributed to non-specific binding
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and significantly decreased the signal-to-noise ratio because they decreased the
effective concentration of MAb in solution and, thus, the dose-dependent binding
response. Protein A-purified ESVP 2 contained no detectable non-antibody substances
(Figure 4.3B) and, when biotinylated, produced steep dose-response curves and
negligible non-specific binding in a two-site ELISA with ESVP 1 MAb-coated wells
(Figures 6.10B and 6.13A). In contrast, the very impure PEG 8000-precipitated ESVP 2
(Figure 4.3A) biotinylated to produce a reagent that gave higher non-specific binding
and extremely poor dose-response curves in ESVP 1 MAb-coated wells (Figure 6.13B).
Relatively high background absorbances also occurred with biotin-ESVP 1, although it
produced reasonable dose-response curves in ESVP 2 MAb-coated wells (Figure 6.10A).
The ESVP 1 MAb preparation contained little non-antibody material (Figure 4.1A) but
it was prepared from ascitic fluid by sodium sulphate precipitation (Section 4.5.1.1)
and would therefore have contained a low concentration of endogenous mouse IgG
(Galfr& and Milstein, 1981; Baines et al., 1990). The solubilities of some of the mouse
IgG contaminants may have been decreased by biotinylation (Wadsley and Watt,
1987), thus causing the observed non-specific binding. Further purification of ESVP 1
MAb might have decreased this non-specific binding and increased the signal-to-noise
ratio obtained with biotin-ESVP 1 in ESVP 2 MAb-coated wells, although it seems
unlikely that any improvement would be sufficient to produce a more sensitive ELISA
with this MAb orientation than with biotinylated protein A-purified ESVP 2 in
ESVP 1 MAb-coated wells (Figure 6.10).
Long incubation periods were used in most of the two-site ELISA studies, both
for convenience and to ensure that maximal binding occurred because static incubations
are subject to diffusion-limited reaction rates (Stenberg and Nygren, 1988) and no
plate-shaking facilities were available. However, these long incubations contributed
to non-specific binding and to intra-assay variation (Kemeny and Chantler, 1988).
AVP adsorbed onto BSA (Figures 6.2 and 6.9A) and onto MAbs (Figures 6.8 and 6.9)
during long incubation periods but not during the shorter incubations that were used
towards the end of this project once a plate-shaker became available (Figure 6.11),
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while greater variation between duplicate ELISA estimations was recorded after long
incubations (Figures 6.5 and 6.9A) than after shorter incubation periods (Figures 6.10
and 6.12). A 15 minute incubation period was always used with the streptavidin-HRP
conjugate because streptavidin binds rapidly to biotin-antibody and incubations of more
than 20 minutes were reported to decrease the signal-to-noise ratio (Kendall et al.,
1983). Nevertheless, the streptavidin-HRP conjugate adsorbed to coated ELISA wells
in the absence of biotin-antibody (Figure 6.3) and so increased the background
absorbances, although this effect was insignificant in later work that used very low
conjugate concentrations (Figures 6.12, 6.13 and 6.14).
Antigen-antibody interactions at solid-liquid interfaces are considered to be
practically irreversible (Stenberg and Nygren, 1988), particularly as only 1% of
antigen was reported to desorb from antibody-coated ELISA wells in 3 days (Kemeny
and Challacombe, 1988). However, when a two-site AVP ELISA was used to analyse
the elution of 125I-AVP from Sephadex G-25 (Figure 6.7), biotinylated affinity-purified
anti-PAG displaced a significant amount of 125I-AVP from the ESVP 1 MAb-coated
wells. This suggested that some anti-PAG antibodies recognized epitopes that were so
close to the ESVP 1 epitope that steric hindrance between the antibodies prevented
two-site binding. Nevertheless, these anti-PAG epitopes were exposed on the surface
of ESVP 1 MAb-bound AVP and so were accessible to high affinity anti-PAG
antibodies that bound more strongly to 125I-AVP than did ESVP 1, which eventually
released the 125I-AVP molecule because electrostatic repulsion between the antibodies
exceeded its binding affinity for 125I-AVP. However, some 125I-AVP remained bound to
the ESVP 1 MAb-coated ELISA wells, allowing analysis of the Sephadex G-25 elution
profile (Figure 6.7), because some anti-PAG antibodies recognized epitopes that were
sufficiently far from the ESVP 1 epitope to allow two-site binding to 125I-AVP.
The polyclonal antibody preparations contained a variety of anti-AVP
specificities, many of which recognized epitopes that overlapped with that of ESVP 1
MAb and so were unable bind to AVP simultaneously with ESVP 1. Consequently, the
incubation protocol played an important role in determining the magnitude of the
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dose-dependent binding response with these preparations because competition for AVP
binding was only prevented if AVP was allowed to bind to the ESVP 1 MAb-coated
ELISA wells before addition of the polyclonal antibodies (Figure 6.4). However, assay
sensitivities were poor because partially-purified antisera contained irrelevant
specificities that decreased the effective concentration of anti-AVP antibodies while,
even with the affinity-purified antisera, a proportion of anti-AVP specificities were
unable to take part in two-site binding with ESVP 1 MAb. Many specificities would
also have been incompatible with ESVP 2 MAb in a two-site assay, although ESVP 2
was not tested for two-site binding in combination with the polyclonal preparations.
In contrast, the epitopes recognized by ESVP 1 and ESVP 2 MAbs did not
overlap therefore two-site binding was recorded with biotinylated protein A-purified
ESVP 2 and ESVP 1 MAb-coated wells in all incubation protocols (Figure 6.13A).
However, steric hindrance between the MAbs limited the amount of two-site binding
that occurred therefore the dose-dependent response only increased if the surface area
available for binding increased (Figure 6.14), even though ESVP 1 MAb was in excess,
while the signal-to-noise ratio was improved if competition between bound and
unbound biotin-ESVP 2 for binding of the streptavidin-HRP conjugate was eliminated
(Figure 6.13A). The partial simultaneous incubation protocol therefore produced the
most sensitive two-site AVP ELISA, with a detection limit of 200 pg AVP/ml
(Figure 6.13A), because its large assay volume maximized the area available for
binding and it was free from competition for the streptavidin-HRP conjugate.
Immobilization of MAbs by direct adsorption onto polystyrene was reported to
significantly decrease their antigen-capture capacities due to conformational changes
that affected their binding sites (Suter and Butler, 1986), whereas biotin-MAbs that
were immobilized via a streptavidin 'bridge' onto biotinylated carrier-protein-coated
ELISA wells had antigen-capture capacities that were as much as 400-fold greater
than those of directly-adsorbed MAbs (Suter and Butler, 1986; Suter et al., 1989). The
effect of this immobilization method on the two-site AVP ELISAs was not tested,
although it might have increased the dose-dependent binding response and therefore
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the sensitivity of the assays. However, the results obtained in this project showed
that two-site ELISA binding was also affected by the post-coating treatment of the
MAb-coated wells since higher dose-dependent responses were recorded if post-coating
washes were done with Tween buffer instead of Buffer T (Figure 6.10). This unexpected
observation seemed to result from a change in the orientation of the MAbs on the
polystyrene surface because it was prevented if coated wells were BSA-blocked before
the Tween buffer wash. Proteins adsorb onto polystyrene through hydrophobic bonds
(Cantarero et al., 1980). Although the Fc region is the most hydrophobic portion of
IgG (Ishikawa, 1987), parts of the Fab region will also exhibit varying degrees of
hydrophobicity therefore antibodies are likely to adsorb randomly onto polystyrene
in many different orientations. Non-ionic detergents, such as Tween 20, prevent
hydrophobic interactions (Tijssen, 1985) therefore the post-coating Tween buffer wash
probably disrupted the weaker hydrophobic bonds so that IgG molecules which had
originally adsorbed onto the polystyrene surface through several different parts of
their structures were eventually bound only by the most hydrophobic areas of the Fc
region. The Fab regions would therefore become oriented towards the solvent, allowing
more efficient analyte binding (Tijssen, 1985). In the case of very small analytes, such
as AVP, reorientation of the solid phase-bound MAb would also minimize the effects
of steric hindrance between the antibodies because the liquid-phase MAb would have
easier access to the immobilized analyte.
The dose-dependent binding response of biotinylated protein A-purified ESVP 2
in ESVP 1 MAb-coated ELISA wells was doubled by a post-coating Tween buffer wash
(Figure 6.10B), although there was a much smaller increase in the binding response of
biotin-ESVP 1 in ESVP 2 MAb-coated wells (Figure 6.10A). Since the two-site binding
response of a proinsulin assay also increased when MAb-coated wells were given a
post-coating Tween buffer wash, it seems likely that Tween 20 will have a similar
effect on many assays which use MAb-coated polystyrene solid phases. There have
been many studies on the adsorption of antibodies onto various surfaces (Pesce et al.,
1977; Cantarero et al., 1980; Herrmann, 1981; Soos et al., 1984) but they have tended
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to concentrate on the absolute quantity of antibody adsorbed and not on its functional
activity. There is no consensus on post-coating amongst other workers so the effect on
two-site binding may not be widely appreciated, particularly as general ELISA texts
(e.g. Tijssen, 1985; Kemeny and Chantler, 1988; Kemeny and Challacombe, 1988) rarely
mention post-coating procedures. Reported methods have included plate-blocking with
dried milk (Wadsley and Watt, 1987), BSA (Soos et al., 1984; Aoyagi et al., 1991), or
BSA followed by Tween buffer (Phillips et al., 1994), and Tween buffer washing of
unblocked wells (Butler et al., 1986; Sorensen and Brodbeck, 1986). Although
traditional ELISA methods include a plate-blocking step, blocking proteins are often
unnecessary, particularly if Tween 20 is included in all buffers (Mohammad and Esen,
1989; Gosling, 1990), and they can hinder two-site binding responses by preventing
Tween-induced reorientation of solid phase-bound antibodies. The sensitivity of many
microtitre plate-based immunometric assays could probably be improved simply by
omitting the blocking protein and including Tween 20 in all buffers.
The most sensitive two-site AVP assay that was produced in this project had
a detection limit of 130 pg AVP/ml and used 125I-ESVP 1 with affinity-purified
anti-PAG-S-300 solid phase in the direct IRMA format (Figure 6.15). Very low
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non-specific binding was recorded but the total amount of dose-dependent I-ESVP 1
binding was severely limited by steric hindrance. Good precision was obtained with
freshly-prepared 125I-ESVP 1, but the sensitivity of the assay decreased significantly
as the radioactivity of 125I-ESVP 1 decayed during storage. The total amount of
radioactivity that was bound in the IRMA became so small that significant
imprecision was caused by counting errors (Klee and Post, 1989). The two-site ELISA
did not have this problem because the biotin-MAbs and streptavidin-HRP conjugate
could be stored for long periods without significant losses of activity.
The ESVP 2-S-300 solid phase (Figure 6.19) produced a less sensitive direct
IRMA than the affinity-purified anti-PAG-S-300 solid phase (Figure 6.15) because the
AVP binding affinity of ESVP 2 MAb was lower than the affinity of the polyclonal
preparation. However, unlike the two-site ELISA with ESVP 1 and ESVP 2 MAbs, the
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direct IRMA was unaffected by the volume of solid phase, except at very high
AVP concentrations (Figure 6.22), because the large surface area of Sephacryl S-300
minimized the effect of steric hindrance between adjacent solid phase-bound MAbs on
the observed dose-dependent binding response. The immunofiltration format produced
the least sensitive assay because the low coating capacity of the nitrocellulose
membrane limited the binding response to such an extent that counting errors
significantly decreased the precision of estimations.
Impurities in the antibody preparations caused fewer difficulties in the direct
IRMA format than were observed in the two-site ELISAs. Non-antibody contaminants
decreased the efficiency of MAb iodination (Table 4.22) but were removed when the
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I-MAbs were purified by gel filtration (Figures 4.1 and 4.3) and therefore did not
cause any interference with the IRMA binding response. The high protein-coupling
capacity of oxidized Sephacryl S-300 produced antibody-S-300 solid phases which
bound reasonable amounts of 125I-AVP, irrespective of the degree of purity of the
antibody preparations (Table 6.1). However, solid phases that were coupled to
polyclonal preparations which contained irrelevant antibodies, or specificities which
recognized epitopes that overlapped with that of ESVP 1 MAb, produced poorer
binding responses (Figure 6.15) because they contained extremely low concentrations of
ESVP 1 MAb-compatible antibodies.
In contrast, impurities in the antibody preparations decreased indirect IRMA
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sensitivity because they decreased the binding of biotin-antibody to I-streptavidin
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(Figure 4.4). Two-site binding was therefore detected more efficiently with I-ESVP 1
(Figure 6.16) than with biotin-ESVP 1 (Figure 6.26). Interestingly, however, the
indirect IRMA format could produce an assay which had polyclonal antibody
preparations on both sides of the 'sandwich' (Figure 6.27), a combination that was
impossible in the direct IRMA format because affinity-purified anti-PAG was too
dilute to iodinate efficiently while irrelevant specificities in the partially-purified
anti-AVP serum, which would have iodinated, could not participate in binding to
AVP and would therefore significantly decrease the signal-to-noise ratio.
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A clinically-useful assay, in the context of assisting neonatal care, would
measure physiological AVP concentrations in small volumes of unextracted plasma. It
would therefore need to have a sensitivity of about 1 pg AVP/ml and, ideally, should
produce a result within a few hours of sampling. It should be specific for AVP and so
should not cross-react with closely-related peptides, such as OT and AVT, or with
any other substances in the sample. Good precision and accuracy are also necessary to
ensure that the results are reliable, where precision describes the variation of
replicate estimations around the mean value obtained for any concentration of analyte
while accuracy implies that the estimated concentration is as close as possible to the
true value (Ekins, 1983).
The assays that were developed in this project were insufficiently sensitive to
measure AVP in unextracted plasma because the weak immunogenicity of AVP resulted
in the production of relatively low affinity MAbs, while the small size of the
peptide caused steric hindrance which severely limited the total amount of two-site
binding that occurred, even with high affinity polyclonal antibody preparations.
Nevertheless, ESVP 1 and ESVP 2 MAbs could be used to produce rapid assays in the
two-site ELISA, IRMA and immunofiltration assay formats, with total incubation
periods of 1-5 hours. However, although the most sensitive AVP assay was produced
in the direct IRMA format (Figure 6.15), 12SI-ESVP 1 and ESVP 2-S-300 solid phase
produced a relatively insensitive direct IRMA because the low radioactivity of the
bound fraction decreased the assay precision (Klee and Post, 1989). Better sensitivity
was obtained when these MAbs were used in the two-site ELISA format with the
partial simultaneous incubation protocol (Figure 6.13A) which produced extremely low
non-specific binding and good precision. Immunofiltration produced a rapid assay with
these MAbs, but the bound radioactivity was lower than that observed in the direct
IRMA because the nitrocellulose membrane had a lower protein-binding capacity than
oxidized Sephacryl S-300 therefore the assay was very insensitive.
No other two-site immunometric assays for AVP have been reported, although
an alternative type of noncompetitive AVP assay was recently developed by Hashida
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et al. (1991b). This hetero-two-site complex transfer enzyme immunoassay had a
detection limit of 1.1 fg AVP/tube, which made it the most sensitive AVP assay so
far reported. It was 450-fold more sensitive than a competitive enzyme immunoassay
which used the same antiserum (Uno et al., 1982) but it was extremely complicated
with 11 separate steps during which AVP was biotinylated then transferred between
various different solid phases and the total assay time was 4 days. A simpler version
(Hashida et al., 1991a) detected 11 fg AVP/tube but still had a total assay time of
50 hours so both of these assays were too slow to be clinically-useful.
Despite steric hindrance, two-site assays for AVP were possible with ESVP 1
and ESVP 2 MAbs, with ESVP 1 in combination with any of four different polyclonal
antibody preparations, and with a pair of polyclonal antibodies. The sensitivity of
these assays varied with the format but none of them had a detection limit below
130 pg AVP/ml therefore none could be used to measure normal physiological AVP
concentrations (1-5 pg AVP/ml plasma; Robertson, 1977). However, the very high AVP
concentrations that can occur in infants with birth asphyxia (up to 550 pg AVP/ml
plasma; Smith et al., 1990) were just within range of the direct IRMA which used
125I-ESVP 1 and affinity-purified anti-PAG-S-300 solid phase (Figure 6.15), and also
the two-site ELISA which used biotinylated protein A-purified ESVP 2 with ESVP 1
MAb-coated wells (Figure 6.13A). Enzyme amplification systems (Stanley et al., 1985)
using luminescent or fluorescent labels (Ekins, 1987; Ishikawa, 1987), which are
detected more sensitively than colorimetric substrates (Ishikawa, 1987), could increase
the sensitivity of two-site AVP assays provided that non-specific binding did not
increase, but the sensitivities of the existing assays would need to be increased about
200-fold before they would be clinically-useful. Alternatively, better assays might be
produced with a pair of high affinity MAbs specific for epitopes at opposite sides of
the AVP molecule so that steric hindrance is minimized. ESVP 1 and ESVP 2 MAbs,
although able to bind simultaneously to AVP, had relatively low AVP-binding
affinities (Table 5.1). The highest reported anti-AVP MAb affinity was 1 x 109 1/mole
(Jones et al., 1985), but if anti-AVP MAbs with affinities of 1010 1/mole could be
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generated it may be possible to produce rapid two-site assays that can measure
physiological AVP concentrations. Unfortunately, the weak immunogenicity of AVP
will make this difficult to achieve.
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CHAPTER 7
CHARACTERIZATION OF MONOCLONAL ANTIBODIES
TO ATRIAL NATRIURETIC PEPTIDE
7.1 INTRODUCTION
Three anti-ANP MAbs (ESA 4, ESA 5 and ESA 9; Prowse et al., 1989) were
available at the start of this project. Additional anti-ANP MAbs were produced by
the ANP fusions (Section 4.3.2), which generated 1048 hybridoma-containing cultures
although only seven were ANP-coated-plate ELISA-positive. Four hybridomas were
eventually cloned, and subcloned, to produce monoclonal cell lines which secreted
anti-ANP MAbs (Table 4.9).
MAb characterization work was done with unpurified samples of spent culture
supernatant or ascitic fluid.
7.2 ISOTYPES
The four anti-ANP MAbs which were generated in this project were isotyped
with an Amersham Mouse Monoclonal Antibody Isotyping Kit (Table 7.1). All of these
MAbs had k light chains. The isotypes shown for ESA 4, ESA 5 and ESA 9 (Table 7.1)
are quoted from Prowse et al. (1989), and were not determined in this work. Their
light chain type was not specified but may be k because more than 95% of mouse
light chains are k chains (Goding, 1986).
7.3 ANTIBODY AFFINITIES
The affinity constants of the anti-ANP MAbs were determined by Scatchard
analysis (Scatchard, 1949) of solution-phase RIA binding, as described in Section 2.4.2.
The mean values shown in Table 7.1 were calculated from the results of three (all
MAbs except ESNP1) or four (ESNP 1) experiments.
The anti-ANP MAb titres which had been determined by RIA, in preparation
for the affinity constant estimations, were in most cases significantly different from
the titres estimated by ANP-coated-plate ELISA (Table 7.2). ESNP 2, ESNP 3 and
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TABLE 7.1
Isotvpes and affinities of the anti-ANP MAbs
MAb Isotype Affinity (1/mole)
ESNP 1 IgG2a 2.4 x 109
ESNP2 IgGl 1.2 x 109
ESNP 3 IgGl 1.6 x 109
ESNP 4 IgGl 8.3 x 107
ESA 4 IgG2a 65 x 1010
ESA 5 IgG2b 4.1 x 1010
ESA 9 IgGl 2.9 x 1010
TABLE 7.2
Comparison of the anti-ANP MAb titres estimated by ANP-coated-plate ELISA and
bv RIA
Serial dilutions of anti-ANP MAb-containing culture supernatant, in Buffer L,
were assayed by ANP-coated-plate ELISA (lOOng/ml ANP, unblocked wells) and by
RIA (6.4 pg 125I-ANP, 624 pCi/pg, in Buffer L, SAM-S-500 solid phase, as described in
Section 2.4.2). The antibody titre was defined as the culture supernatant dilution
which produced an absorbance of 1.0 at 450 nm (ANP-coated-plate ELISA) or




ESNP 1 1/440 1/350
ESNP 2 1/840 1/40
ESNP 3 1/3000 1/20
ESNP 4 1/530 1/10
ESA 4 1/40 1/16,000
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ESNP 4 had much lower RIA titres than ELISA titres, whereas the RIA titre of ESA 4
was 400-fold higher than its ELISA titre. In contrast, the titres estimated for ESNP 1
were roughly similar in both assays. Unlike ESVP 3 and ESVP 4, which produced
higher binding in the AVP-coated-plate ELISA than in the SAM-RIA because their
isotypes were more readily bound by the anti-mouse IgG HRP conjugate than by the
SAM-S-500 solid phase (Section 5.4), the titre differences observed with the
anti-ANP MAbs did not seem to be isotype-related because the MAbs were all IgG
antibodies (Table 7.1). The differences were also unlikely to be related to the affinity
constants of the MAbs, but were probably indicative of different binding specificities.
Unfortunately, no ANP analogues were available so the specificities of the anti-ANP
MAbs could not be determined.
7.4 DISCUSSION
Human ANP is more immunogenic than AVP, in mice, because human ANP
differs from murine ANP in one amino acid residue whereas human and murine AVP
molecules are identical. Immunization with ANP-thyroglobulin conjugate therefore
produced higher average anti-peptide antibody titres (Table 4.5) than were obtained
with the AVP-thyroglobulin conjugates (Tables 4.1, 4.2 and 4.3), and presumably
generated antibodies with higher average binding affinities because the affinity
constants of ESNP 1, ESNP 2 and ESNP 3 (Table 7.1) were an order of magnitude
higher than those of the anti-AVP MAbs (Table 5.1). The binding affinity of ESNP 4,
however, was disappointingly low (Table 7.1), and none of the MAbs which were
produced in this project had affinities that were as high as those of ESA 4, ESA 5
and ESA 9 (Table 7.1).
The binding specificities of the anti-ANP MAbs were not determined in this
work, but differences in the MAb titres estimated by ANP-coated-plate ELISA and by
RIA (Table 7.2) suggested that the MAbs recognized at least three different epitopes.
Prowse et al. (1989) showed that ESA 4 bound to an epitope in the central loop of
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ANP, between residues 7 and 12, an area which is part of the most hydrophobic
region of the ANP molecule. Since adsorption to polystyrene occurs through
hydrophobic bonds (Cantarero et al., 1980), the ESA 4 epitope is likely to be in
contact with the surface of ANP-coated ELISA wells and therefore relatively
inaccessible to ESA 4, so that the ANP-coated-plate ELISA produced low ESA 4 titre
estimates (Table 7.2). This epitope would be further obscured by close-packing of the
ANP molecules, which accounts for the observation that ELISA estimates of ESA 4
titres decreased as the ANP-coating concentration increased (Figure 3.18A). In contrast,
ESA 4 bound readily to 125I-ANP in solution therefore the liquid-phase RIA produced
a much higher ESA 4 titre estimate (Table 7.2).
ESNP 2, ESNP 3 and ESNP 4, on the other hand, did not bind well to 125I-ANP
so the RIA estimated low titres for these MAbs (Table 7.2). The 125I atom of 125I-ANP
is substituted into the C-terminal tyrosine residue therefore the ESNP 2, ESNP 3 and
ESNP 4 epitopes are probably close to the C-terminal of ANP. If the central loop of
ANP is the main area which adsorbs to polystyrene, the C-terminal would be readily
accessible for MAb binding in the ANP-coated-plate ELISA, which accounts for the
much higher titre estimates produced for ESNP 2, ESNP 3 and ESNP 4 in the
ANP-coated-plate ELISA than in the RIA (Table 7.2).
ESNP 1 bound to an epitope which was equally accessible in the RIA and in
the ANP-coated-plate ELISA, because roughly similar titres were estimated by both
assays (Table 7.2). The ESNP 1 epitope is therefore unlikely to be in either the
hydrophobic portion of the central loop or the extreme C-terminal of ANP, but may




FOR ATRIAL NATRIURETIC PEPTIDE
8.1 INTRODUCTION
Shortly before this project began, one research group reported a two-site ANP
ELISA which used a solid phase-bound MAb and a liquid-phase affinity-purified
polyclonal antibody (Hashida et al., 1988a, 1988b; Mukoyama et al., 1988c). This
assay was very sensitive because it detected 0.6 pg ANP/ml unextracted plasma, with
a sample volume of only 50 pi. However, the total assay time was more than 49 hours
so this ELISA was too slow to be clinically-useful in the context of neonatal care.
Four anti-ANP MAbs (Chapter 7) were generated in this project. Three other
anti-ANP MAbs (ESA 4, ESA 5 and ESA 9; Prowse et al., 1989) and a polyclonal
antiserum were also available for immunometric assay studies.
8.2 TWO-SITE ELISA
Prowse et al. (1989) showed that ESA 4 and ESA 5 MAbs bound to epitopes
which differed from that of ESA 9 MAb, although they could not bind to ANP
simultaneously with ESA 9 to form a two-site assay. No ANP analogues were
available during the course of this project therefore the epitope specificities of
ESNP1, ESNP 2, ESNP 3 and ESNP 4 MAbs could not be determined. However,
differences in the MAb titres estimated by ANP-coated-plate ELISA and by RIA
(Table 7.2) suggested that ESNP 1 bound to an epitope which differed from those
recognized by ESNP 2, ESNP 3 and ESNP 4 MAbs, or from that bound by ESA 4
(Section 7.4). All MAb combinations were therefore studied in the two-site ELISA
format to determine whether any of them could form a two-site ANP assay.
Partially-purified anti-ANP serum (Section 4.6.3) was not available for comparison
when this work was carried out.
Initial experiments with the separate incubation protocol produced poor results
but suggested that two-site binding to ANP occurred with most MAb combinations















Binding of ANP and biotin-MAbs to MAb-coated ELISA wells
Unblocked Nunc Maxisorp Microwells, coated with ESNP 4 (•), ESA 4 (o) or
ESA 5 (a), were incubated with serial dilutions of ANP in Buffer L, then with
biotin-ESA 4 (A) or biotin-ESA 5 (B) in Buffer L containing 1% normal mouse serum
(Section 2.5.1.1). Biotin-MAb binding was revealed with streptavidin-HRP conjugate.
The symbols show the mean of duplicate estimates, while the vertical bars show the
difference between those estimates.
unblocked, ELISA wells caused high background absorbances. However, further studies
showed that the binding response was determined by the biotin-MAb, irrespective of
of the solid phase composition. Although biotin-ESA 4 (Figure 8.1A) and biotin-ESA 5
(Figure 8.IB) bound to ESNP 4 MAb-coated ELISA wells in a dose-dependent manner,
much higher binding occurred if the wells were coated with either ESA 4 or ESA 5
(Figure 8.1). ANP consists of only 28 amino acids, with no repeated sequences, and is
therefore unlikely to have epitopes that would allow two molecules of the same MAb
to bind simultaneously, which suggests that the observed binding response was
entirely caused by non-specific adsorption of ANP onto the coated ELISA wells. This
was confirmed when further investigation revealed that dose-dependent binding of
biotin-ESA 5 to ESA 5 MAb-coated, unblocked, wells was an artefact of the assay
method because it occurred only with the separate incubation protocol (Figure 8.2). In
the simultaneous incubation protocol, ANP was more likely to bind to liquid-phase




Effect of incubation protocol on the binding of ANP and biotin-ESA 5 to ESA 5
MAb-coated ELISA wells
Serial dilutions of ANP in Buffer L were assayed in ESA 5 MAb-coated,
unblocked Immulon 2 MicroELISA wells, using the separate (Section 2.5.1.1, •) or
simultaneous (Section 2.5.1.2, o) incubation protocols with biotin-ESA 5. Binding was
revealed with streptavidin-HRP conjugate. Vertical bars showing the difference
between duplicate estimations are smaller than the symbols used in this Figure.
conjugate was also more likely to react with unbound biotin-ESA 5 than to adsorb onto
the solid phase-bound assay components therefore the simultaneous incubation protocol
produced lower background absorbances than the separate incubation protocol
(Figure 8.2). Interestingly, non-specific binding in the simultaneous incubation protocol
seemed to decrease slightly with increasing ANP concentrations (Figure 8.2), which
suggested that ANP occupancy of the ESA 5 MAb binding site caused minor structural
changes (Wilson et al., 1991) that decreased the ability of biotin-ESA 5 to adsorb onto
the solid phase.
Although lower background absorbances were recorded in BSA-blocked wells
(Figure 8.3A) than in unblocked wells (Figure 8.3B), with the separate incubation
protocol, BSA-blocking did not prevent ANP adsorption onto ESA 5 MAb-coated wells
(Figure 8.3A) because ANP also adsorbed onto BSA (Figure 8.3A). Unblocked wells
coated with ESVP 2, an anti-AVP MAb (Chapter 5), also adsorbed ANP (Figure 8.3B)














Comparison of the non-specific binding of ANF and biotin-ESA5 to MAbs and to BSA
BSA-blocked (A) or unblocked (B) MicroELISA wells, coated with ESA 5 (•),
ESVP 2 (x) or nothing (a), were incubated with serial dilutions of ANP in Buffer L,
then with biotin-ESA5 in Buffer L containing 1% normal mouse serum (Section 2.5.1.1).
Binding was revealed with streptavidin-HRP conjugate. Vertical bars show the
difference between the absorbances recorded in duplicate wells.
incubations that were used in most of the ELISA work probably contributed to the
non-specific binding (Kemeny and Chantler, 1988), but significant non-specific binding
also occurred when the incubation periods of ANP and biotin-ESA 5 were decreased
from 20 hours and 24 hours to 3 hours each (data not shown). Most of the two-site
ELISA work was done in Immulon2 MicroELISA wells. Different types of polystyrene
have significantly different protein-binding capacities (Kemeny and Challacombe,
1988) but there was no advantage to be gained from using other ELISA wells because
non-specific adsorption of ANP also occurred in Immulon 1 (Figure 8.4A), Immulon 4 and
Nunc maxisorp (Figure 8.4B) wells, although the degree of adsorption varied between
the different types of wells. Triton X-100 was reported to prevent ANP adsorption
onto polystyrene (Lindberg and Andersson, 1991) but substitution of Triton X-100 for
Tween 20 in the assay buffer failed to prevent ANP adsorption onto ESA 5 MAb-coated
wells, although it decreased background absorbances significantly (Figure 8.5).
Non-specific adsorption of ANP onto the solid phase during the separate




















Non-specific binding of ANP and biotin-ESA 5 to four types of polystyrene ELISA well
coated with ESA 5 MAb
ESA 5 MAb-coated, unblocked Immulon 1 (•), Immulon 2 (o), Immulon 4 (a) or
Nunc Maxisorp (x) ELISA wells were incubated with serial dilutions of ANP in
Buffer L, then with biotin-ESA 5 in Buffer L containing 1% normal mouse serum
(separate incubation protocol). Binding was revealed with streptavidin-HRP conjugate.
Vertical bars show the difference between the absorbances recorded in duplicate wells.
[ANP] ng/ml
FIGURE 8.5
Effect of Triton X-100 on non-specific binding of ANP and biotin-ESA 5 to ESA 5 MAb
Unblocked ESA 5 MAb-coated MicroELISA wells were incubated with duplicate
100 pi aliquots of ANP for 19 hours, then with biotin-ESA 5 for 22 hours. Biotin-ESA 5
binding was revealed with streptavidin-HRP conjugate. ANP, biotin-ESA 5 and
streptavidin-HRP conjugate were diluted either in Buffer L (•) or in Buffer K
containing 1% BSA and 0.1% Triton X-100 (o).
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incubation protocol was a major problem that could not be prevented and made ELISA
results difficult to interpret. The simultaneous incubation protocol was free of this
problem (Figure 8.2) but was not used for two-site ANP ELISA work because studies
with the AVP ELISAs had shown that small amounts of two-site binding were
difficult to detect since unbound biotin-antibody (Figures 6.4 and 6.13A) and
biotinylated impurities (Figure 6.13B) competed with the solid phase-bound assay
components for binding of the streptavidin-HRP conjugate. Further purification of the
very impure PEG 8000-precipitated anti-ANP MAbs would have improved the
detectability of two-site binding (Figure 6.13), as would the use of a post-coating
Tween buffer wash in unblocked MAb-coated ELISA wells (Figure 6.10), but
unfortunately there was no time available to carry out appropriate investigations. No
further two-site ELISA work was done because neither incubation protcol could
reliably detect specific ANP binding to the available MAb preparations.
8.3 IMMUNORADIOMETRIC ASSAY (IRMA)
All of the anti-ANP antibody preparations were coupled to periodate-oxidized
Sephacryl S-300, then assayed for the ability to bind 125I-ANP (Section 2.3.5.2) before
use in the IRMA work. Most of the solid phases bound significant amounts of
125
I-ANP, although lower binding occurred with the partially-purified anti-ANP
serum-S-300 solid phase than with the MAb-S-300 solid phases (Table 8.1). However,
a solid phase produced from unpurified anti-ANP serum, which was included for
comparison, failed to bind 125I-ANP (Table 8.1). This result was surprising because the
SAM-S-500 solid phase was also prepared from unpurified antiserum (Section 2.3.5.3)
and yet bound strongly to mouse antibodies. The anti-ANP serum was therefore likely
to have contained relatively little anti-ANP activity but, unfortunately, no other
polyclonal anti-ANP antisera were available for immunometric assay work.
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TABLE 8.1
Binding of 125I-ANP to antibody-S-300 solid phases
Solutions of 1 mg/ml anti-ANP MAb, 8 mg/ml partially-purified anti-ANP
serum (Section 4.6.3) or 25% (v/v) unpurified anti-ANP serum were coupled to
oxidized Sephacryl S-300 then assayed for antigen-binding ability as described in
Section 2.3.5.2. Par-p = partially-purified; Un-p = unpurified.








Par-p anti-ANP serum-S-300 49.3




Direct ANP IRMA with 125I-MAbs and anti-ANP serum-S-300 solid phase
Dilutions of ANP, in Buffer E containing 5% BSA, were assayed by direct
IRMA (Section 2.5.2.1) using 125I-ESNP 1 (a), 125I-ESNP 2 (□), 125I-ESNP 3 (+),
125I-ESNP 4 (■), 125I-ESA 4 (•), 125I-ESA 5 (o) or 125I-ESA 9 (x) with partially-purified
anti-ANP serum-S-300 solid phase (prepared from a 5-10% PEG cut of anti-ANP serum
after further purification by Rivanol precipitation; Section 4.6.3). Non-specific binding
was 0.17% (a), 0.30% (□), 0.12% (+), 0.09% (■), 0.11% (•), 0.13% (o) or 0.24% (x) of
IOC
added I-MAb. The symbols show the mean of duplicate estimations, while vertical
bars show the difference between those estimations. For clarity, bars are not shown
for 125I-ESNP 2 (□) and 125I-ESNP 3 (+).
8.3.1 DIRECT IRMA
Initial IRMA studies with all possible 125I-MAb and MAb-S-300 solid phase
combinations failed to produce any evidence of two-site binding to ANP (data not
shown). This result was disappointing because the anti-ANP MAbs had seemed likely
to recognize three different epitopes (Section 7.4), although confirmation was not
possible because there were no ANP analogues available for epitope specificity
studies. However, the MAb epitopes were probably so close together that steric
hindrance prevented detectable two-site binding.
Further studies showed that most of the 125I-MAbs could take part in two-site
binding to ANP in combination with the partially-purified anti-ANP serum-S-300
solid phase, although the maximum binding responses were very low (Figure 8.6). No
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significant dose-dependent binding occurred with either 125I-ESNP 2 or 125I-ESNP 3
(Figure 8.6A) which suggested that iodination disrupted the binding sites of these
MAbs. ESNP 4 had the lowest ANP-binding affinity (Table 7.1) and produced the
least sensitive assay yet, unexpectedly, the maximum binding response of 125I-ESNP 4
was higher than that of any other MAb and it produced a high-dose 'hook' effect at
a higher ANP concentration than the other MAbs (Figure 8.6A).
The analyte concentration required to saturate the binding sites of an
antibody-S-300 solid phase is a fixed characteristic that should not be affected by
the liquid-phase assay reagents. Nevertheless, the ANP concentration required to
produce a high-dose 'hook' effect was inversely related to the binding affinity of the
inc
I-MAb, as was the maximum binding response (Figure 8.6). This surprising result
suggested that the partially-purified anti-ANP serum preparation consisted mainly of
low affinity antibodies, many of which would have recognized epitopes that were too
t • 1
close to the MAb epitopes to allow simultaneous binding. High affinity I-MAbs,
such as ESA 4 (Table 7.1, Figure 8.6B), bound strongly to ANP and were likely to
remain in the liquid phase because steric hindrance severely limited simultaneous
binding of the low affinity partially-purified anti-ANP serum antibodies. Higher
two-site binding occurred with low affinity MAbs, such as ESNP 4, which were less
able to compete for exclusive binding of the ANP molecule because their affinities
were more closely matched by those of the polyclonal antibodies. Antibody binding
sites have widely varying structures (Wilson et al., 1991) therefore the low affinity
MAbs possibly had shallower binding sites that minimized steric hindrance and so
allowed more two-site binding.
-tor
Additional work showed that I-ESA 4 produced a more sensitive direct
IRMA than 125I-ESA 5 (Figure 8.7) but the total amount of bound radioactivity was so
low that counting errors decreased the precision of the assay (Klee and Post, 1989)
and limited the sensitivity to 1 ng ANP/ml. However, the high-dose 'hook' effect




Comparison of 125I-ESA4 and 125I-ESA5 in a direct IRMA
Serial dilutions of ANP in Buffer E containing 5% BSA were assayed by direct
IRMA, using 125I-ESA 4 (•) or 125I-ESA 5 (o) with partially-purified anti-ANP
serum-S-300 solid phase. Non-specific binding was 0.05% (•) or 0.09% (o) of added
125I-MAb. Vertical bars show the difference between the binding in duplicate tubes.
8.3.2 INDIRECT IRMA
Iodination seemed to disrupt the binding sites of ESNP 2 and ESNP 3 because
they produced no significant direct IRMA binding with the partially-purified
anti-ANP serum-S-300 solid phase (Figure 8.6A). In contrast, biotin-ESNP 2 and
biotin-ESNP 3 bound readily to liquid-phase ANP (data not shown) therefore the
anti-ANP MAbs were studied in the indirect IRMA format with partially-purified
anti-ANP serum-S-300 solid phase. However, the only detectable two-site binding
occurred with biotin-ESA 4 and the total amount of bound radioactivity was very
low (Figure 8.8). Further investigation revealed that impurities in the biotin-MAb
preparations decreased the potential signal-to-noise ratio of the assay since
inc
PEG 8000-precipitated MAbs bound much less I-streptavidin than MAbs that were
prepared from ascitic fluid by sodium sulphate precipitation (Figure 8.9), a


















Indirect IRMA with biotin-ESA 4 and anti-ANP serum-S-300 solid phase
Dilutions of ANP, in Buffer E containing 5% BSA, were assayed by indirect
IRMA as described in Section 2.5.2.2, using biotin-ESA 4 with partially-purified
anti-ANP serum-S-300 solid phase. Non-specific binding was 0.05% of added
125I-streptavidin. Vertical bars show the difference between duplicate estimations.




Binding of I-streptavidin to biotinvlated anti-ANP MAbs
ESA 4 (•), ESA 5 (■) and ESA 9 (+) MAbs were partially purified from ascitic
fluid by sodium sulphate precipitation, while ESNP 1 (a), ESNP 2 (□), ESNP 3 (x)
and ESNP 4 (o) MAbs were concentrated from spent culture supernatants by PEG 8000
precipitation. The MAbs were biotinylated (Section 2.3.4.5), then assayed for
25I-streptavidin binding as described in Figure 4.4.
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binding was detected more efficiently in the direct IRMA format therefore no further
indirect IRMA work was carried out.
8.4 DISCUSSION
Two-site binding to ANP was observed only when liquid-phase MAbs were
combined with partially-purified anti-ANP serum-S-300 solid phase in the IRMA
format (Section 8.3). However, the anti-ANP serum antibodies seemed to have low
binding affinities so two-site IRMA binding was limited both by steric hindrance and
by the poor quality of the solid phase, although non-specific binding was very low.
In contrast, non-specific binding was a major problem in the two-site ELISA
format (Section 8.2). Many workers report that plate-blocking decreases non-specific
ELISA binding (Campbell, 1984; Vogt et al., 1987; Pruslin et al., 1991). Detergents such
as Tween 20 (Campbell, 1984; Mohammad and Esen, 1989) or Triton X-100 (Campbell,
1984) also inhibit adsorption onto the solid phase, although Kenna et al. (1985)
reported that non-reactive proteins, such as casein or BSA, were more effective buffer
additives, while ANP adsorption onto polystyrene was reportedly prevented by
buffers containing 0.1% BSA (Artner-Dworzak et al., 1991), 0.1% human serum albumin
or 0.1% Triton X-100 (Lindberg and Andersson, 1991). However, ANP adsorbed onto
MAbs (Figures 8.1 and 8.3B) and onto BSA (Figure 8.3A) during the separate
incubation protocol, despite the presence of 1% BSA and 0.1% Tween 20 in the assay
buffer (Figure 8.2), and high background absorbances in the absence of ANP were
caused by adsorption of the assay reagents onto the coated ELISA wells. Triton X-100
also failed to prevent ANP adsorption, although it decreased non-specific binding of
the assay reagents (Figure 8.5). ANP adsorption onto uncoated polystyrene was not
tested, but it seemed more likely that ANP adsorbed onto the protein coating than
onto the polystyrene surface, as observed with AVP (Figure 6.9B), therefore small
differences between ELISA well types (Figure 8.4) were probably caused by differences
in the concentration of surface-adsorbed MAb. The amount of ESA5 that adsorbed onto
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the wells was not determined, but there were only slight differences between the
adsorption of ANP onto ESA 5 MAb-coated Nunc Maxisorp, Immulon 1 or Immulon 2
wells. In contrast, much higher ANP adsorption was recorded in Immulon 4 wells
(Figure 8.4B) which have a very high protein-binding capacity and so would have
adsorbed significantly more ESA 5 MAb.
Interestingly, vitronectin and clusterin were recently reported to adsorb onto
polystyrene in the presence of detergents, and clusterin adsorption was actually
increased by Tween 20 (Hog&sen et al., 1993). These adhesive proteins adsorbed more
readily onto Nunc Maxisorp ELISA wells than onto Immulon 2 wells, and this
adsorption was not prevented by plate-blocking with BSA, gelatin or FCS, although
it decreased if the buffer pH was decreased to 6.0 (HogSsen et al., 1993). The effect
of pH on ANP adsorption was not tested.
The two-site ANP ELISAs that were reported by Hashida et al. (1988a) used
an affinity-purified C-terminal-specific polyclonal Fab'-HRP conjugate in combination
with solid phase-bound MAbs specific for either the ANP N-terminus (Mukoyama et
al., 1988a) or the N-terminal half of the disulphide-bonded loop (Mukoyama et al.,
1988b). The N-terminal-specific MAb had the highest binding affinity (Mukoyama et
al., 1988a) but did not produce the most sensitive assay (Hashida et al., 1988a),
which suggests that there was more steric hindrance between this MAb and the
polyclonal Fab'-HRP conjugate than between the loop-specific MAb and the conjugate.
The hydrophobic Fc portion of IgG causes most non-specific binding (Ishikawa, 1987),
therefore use of the liquid-phase Fab' fragment ensured extremely low background
absorbances so that two-site binding could be sensitively detected by fluorimetry
(Hashida et al., 1988a, 1988b). However, preparation of the affinity-purified
Fab'-HRP conjugate was very laborious and liable to variation between batches
because supplies of polyclonal antisera are limited. The use of Fab' fragments might
have decreased the non-specific binding problems that occurred with the two-site
ELISA format in this project but, unfortunately, there was no time available to
investigate this possibility.
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While this project was in progress, three other research groups also reported
two-site immunometric assays for ANP (Lewis et alv 1989; Watanabe et al., 1989;
Tattersall et al., 1990). None of these assays used a pair of MAbs, but all were
sufficiently sensitive to measure physiological ANP concentrations in unextracted
plasma. Watanabe et al. (1989) described a two-site ELISA which required a
50 pi sample and used wells coated with the F(ab')2 fragment of a MAb against
the C-terminal half of the disulphide-bonded loop, in combination with an
affinity-purified C-terminal-specific polyclonal Fab'-HRP conjugate, but which had a
ior
total assay time of 44 hours. An IRMA which used an I-MAb specific for the
disulphide-bonded loop, and polyclonal antibody-coated microtitre wells, was reported
by Lewis et al. (1989). This assay required a 150 pi sample and had an incubation
period of 16 hours, although the maximum recorded binding was only 6.6% of added
125I-MAb. However, Tattersall et al. (1990) obtained a maximum of 19% binding in a
liquid-phase IRMA which used iodinated affinity-purified C-terminal-specific rabbit
antibodies with a mouse polyclonal anti-ANP antiserum and achieved separation of
bound and unbound radioactivity by second antibody precipitation. This IRMA required
400 pi samples and had a total assay time of 23 hours.
A noncompetitive hetero-two-site enzyme immunoassay, which used a MAb
specific for the disulphide-bonded loop, was also reported for ANP (Hashida et al.,
1991c). This assay was less complicated than the hetero-two-site assay reported for
AVP (Hashida et al., 1991a, 1991b) but still had a total incubation time of 50 hours.
However, it was 4-fold more sensitive than a colorimetric two-site ELISA that used
the same MAb (Watanabe et al., 1989) because very low non-specific binding allowed
the use of a fluorometric detection system.
All of the reported two-site ANP assays were very sensitive, but they
required long incubation periods and so were too slow to be clinically-useful in the
context of neonatal care. The sample volumes required by the IRMAs (Lewis et al.,
1989; Tattersall et al., 1990) were also too large to be obtained on a routine basis from
small infants. Nevertheless, these reports showed that antibodies could be raised
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against four different regions of the ANP molecule, and that C-terminal-specific
antibodies could combine with antibodies against the N-terminus (Hashida et al.,
1988a), or against either half of the disulphide-bonded loop (Hashida et al., 1988a;
Watanabe et al., 1989), to produce two-site ANP assays.
The reaction kinetics of MAb-based assays are simpler than those of assays
which use polyclonal antisera and so reach equilibrium more rapidly (Baker et al.,
1985). Two-site assays which use a pair of MAbs therefore require the shortest
incubation periods. Unfortunately, the MAbs that were studied in this project were
unable to bind simultaneously to ANP, and two-site binding was observed only when
MAbs were combined with a polyclonal solid phase. Nevertheless, it should be
possible to develop rapid two-site immunometric assays for ANP if pairs of MAbs
with appropriate specificities can be produced, although steric hindrance is likely to




Despite problems caused by the weak immunogenicities of AVP and ANP, four
anti-AVP MAbs and four anti-ANP MAbs were generated in this project. Most of these
MAbs were produced in bulk culture and then concentrated by PEG 8000 precipitation, a
method which was reportedly suitable for isolating MAbs from spent culture
supernatants (Baines et al.7 1990; Brooks et al., 1992). However, all of the
PEG 8000-precipitated MAbs were contaminated by large quantities of high molecular
-i^ir
weight materials (Figure 4.3A) that decreased the specific activities of I-MAbs
(Table 4.21) and biotin-MAbs (Figures 4.4 and 8.9) and increased non-specific binding
(Figure 6.13) so that the signal-to-noise ratios of assays which used these
preparations were decreased. Impurities in the MAb preparations had a much smaller
effect on the ability of MAb-S-300 solid phases to bind 125I-Ag (Tables 6.1 and 8.1),
although they decreased the efficiency of MAb adsorption onto nitrocellulose
(Section 6.4) and presumably also onto polystyrene.
Nevertheless, two-site binding to AVP was observed with ESVP 1 and ESVP 2
MAbs, which bound to the AVP ring structure and the tail tripeptide, respectively.
These MAbs had relatively low binding affinities and so produced insensitive assays,
although AVP consists of only nine amino acids therefore steric hindrance was a major
problem that severely limited the amount of two-site binding that occurred. Two-site
binding was also recorded between ESVP 1 MAb and four different polyclonal antibody
preparations, and between a pair of polyclonal preparations, but none of these
combinations produced an assay that was sufficiently sensitive to measure
physiological AVP concentrations.
The binding specificities of the anti-ANP MAbs were unknown but there was
no evidence to suggest that any pair of MAbs could bind simultaneously to ANP.
Two-site binding was observed only when the MAbs were combined with a
poor-quality polyclonal anti-ANP preparation in the IRMA format.
Non-specific binding was a serious problem during the prolonged incubations
that were used in most of the two-site ELISA work. Adsorption of the biotin-antibody
preparations and the streptavidin-HRP conjugate onto coated ELISA wells caused high
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background absorbances, while dose-dependent adsorption of AVP and ANP occurred
during the separate incubation protocol but not during the simultaneous incubation
protocol. However, the simultaneous incubation protocol was unsuitable for two-site
ELISA work because competition between the assay reagents inhibited the detection of
small amounts of specific binding and therefore decreased assay sensitivity.
Non-specific binding of biotin-antibody preparations might have been decreased by
the use of Fab' fragments instead of intact IgG molecules (Ishikawa, 1987), or by
higher buffer pH values (Wadsley and Watt, 1987), but analyte adsorption onto the
coated wells would still have occurred. Shorter incubation periods, which were
possible when a plate-shaker became available, decreased the non-specific adsorption
of AVP onto MAb-coated ELISA wells while an improved plate-coating procedure
dramatically increased the two-site binding response and so increased assay
sensitivity.
Low non-specific binding occurred in the IRMA and immunofiltration assay
formats but specific 125I-MAb binding was also low therefore counting errors decreased
the precision of these assays. Nevertheless, these formats showed that rapid two-site
assays for AVP and ANP could be carried out with relatively small sample volumes.
The materials that were available during this project could not be used to
develop sensitive two-site assays capable of measuring the concentrations of AVP and
ANP in unextracted plasma, but the results showed that such assays could probably
be developed with appropriate pairs of MAbs. Steric hindrance is likely to be a
problem with all antibody combinations but sensitive assays might be produced in
alternative formats that use high specific activity labels (Ekins, 1987) to increase the
efficiency of signal detection, provided that non-specific binding remains low.
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la) (6)
Fig. 1. Circular dichroism spectra obtained of ferrocyto-
chrome b<; (a) at pH 7.4, (b) at pH 5.5
the c.d. spectra. The concentrations of cytochrome b5 solu¬
tions used for c.d. analysis were adjusted by appropriate dilu¬
tions in order that all the samples had identical absorances in
the Soret region.
Although identical in their absorption spectra (both ferri
and ferro protein) the native and the treated protein were
significantly different in their c.d. spectra. Fig. 1 shows these
spectra for protein which is returned either to pH 7.4 (Fig.
la or to pH 5.5 (Fig. lb). The c.d. of the native protein is
closely similar to that reported by Strittmatter & Huntley [8],
Immediately following "pH-jump' the positive peak is seen
to have increased in amplitude and to have shifted from 420
nm to 418 nm. Similarly the negative peak increases in
amplitude and moves from 428 nm to 430 nm. With the
elapse of tine (2-3 days) the spectrum of the 'pH-jump'
sample reverted to a spectrum very close to that of the native
protein. An indication of the time course is given in Fig. 1(a),
where spectrum of the protein 24 h after exposure to low pH
is shown. It may be noted that all spectra pass through the
A c = 0 point located at 424 nm.
By analogs' with the results of Aojula et al. [6], who
showed similar c.d. changes to be a reflection of haem
disorder in myoglobin, we interpret the results shown in
Fig. 1, to be an indication that the 'pH-jump' procedure
induces haem orientational disorder in cytochrome b}. The
relaxation of the c.d. spectrum back to that of the native
protein indicates thai the "minor' form becomes populated
(at this time to an unknown extent) on 'pH-jump' and shows
that slow reorientation of this form occurs returning the
protein to the equilibrium (90% major, 10% minor) seen by
proton n.m.r. [1].
The kinetics of the reorientation in ferricytochrome bs at
pH 7.4 appears to be significantly more rapid than those
observed for sperm whale myoglobin [6] and approaches the
rate (t1/;= 16 h) found for sperm whale myoglobin at pH 6.5
by Bellelli et al. [7], who also used the c.d. method. The
kinetics of reorientation have been discussed by these latter
authors in terms of the rate constant for dissociation of the
haem from the protein. This implies that the dissociation
constant of haem for ferricytochrome b5 is greater than the
corresponding constant for sperm whale myoglobin under
the same conditions. This is a somewhat unexpected result in
that the protein provides two ligands to the iron, thus helping
to stabilize the haem-protein complex in cytochrome b$.
This enhanced reorientation rate must reflect a more general
flexibility of the haem pocket in cytochrome by
1. La Mar. G. N.. Burns. P. D„ Jackson. J. T„ Smith, K. M., Langry,
K. C. & Strittmatter. P. (19S1) J. Biol. Chem. 256, 6075-6079
2. Docherty, J. C. & Brown. S. B. (1982) Biochem. J. 207, 5S3-587
3. La Mar, G. N.. Roff. J. S.. Smith. K. M. & Langry, K. C. (1980) J.
Am. Chem. Soc. 102. 4833-4835
4. Aojula, H. S.. Wilson. M. T. & Morrison, I. E. G. (1987)
Biochem. J. 243. 205-210
5. Mauk, G. A. & Reid. L. S. (1982) J. Am. Chem. Soc. 104,
841-846
6. Aojula. H. S.. Wilson. M. T. & Drake. A. (1986) Biochem. J. 237,
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A two-site immunometric assay for arginine vasopressin
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Arginine vasopressin (AVP), the hormone produced by the
magnocellular cells of the hypothalamus and released by the
posterior pituitary gland in response to osmolar and volume
stimuli, is traditionally associated with the control of water
balance in the human. More recently AVP has been identi¬
fied in the adrenal gland, testis, ovary and thymus gland
where its function is less clear. AVP is a nonapeptide
composed of a 6-residue ring structure (Cys-Tyr-Phe-Gln-
Abbreviation used: AVP, arginine vasopressin.
Asn-Cys) and a 3-residue C-terminal tail region (Pro-Arg-
Gly-amide). Measurement of AVP in plasma or urine is
normally achieved by radioimmunoassay although an
enzyme immunoassay has been recently reported [1], Physio¬
logical levels of plasma AVP are extremely low (1-5 pmol/1)
so extraction of the samples is required both to achieve con¬
centration and to remove substances which interfere with the
assay by causing tracer degradation or increasing non¬
specific binding [2]. In addition, all assays so far reported
require a prolonged incubation time of usually 3-5 days to
achieve maximum sensitivity. Although this may be accept¬
able for research programmes and even for clinical diagnosis,
it is of little use for everyday clinical management.
Two-site immunometric assays have increased both the
sensitivity and the speed of performance [3] of many clini¬
cally important assays. They depend on the binding of two
different antibodies to separate epitopes on the analyte.
Using a mouse monoclonal antibody, ESVP1, which recog¬
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Fig. 1. Standard curve for immunoradiometric assay ofA VP
100 id (5 ng. 7.6 pC\/ug) l2jI-ESVPl, prepared by the
chloramine T method [6] was incubated with 100 /d AVP
sample in assay buffer [0.05 M-sodium phosphate buffer, pH
7.0, containing 2% (v/v) bovine serum albumin] for 2 h at
room temperature. A sample (100 /d) of a 12.5% (settled
volume) slurry of Sephacryl S300, coupled to affinity-
purified rabbit anti-AVP tail region at 1 mg/ml [7], in assay-
buffer containing 3% (v/v) TWEEN 20 was added, then the
assay tubes were agitated for 2 h at room temperature.
Separation of bound radioactivity was achieved by the
sucrose-layering technique [8, 9j.
purified rabbit polyclonal antiserum specific for the tri-
peptide tail region of the molecule, we have developed a two-
site immunoradiometric assay for AVP (Fig. 1). This assay
has a sensitivity of 200 pmol/1 and is therefore considerably-
less sensitive than existing radioimmunoassays but may be
carried out in a few hours rather than days. The monoclonal
BIOCHEMICAL SOCIETY TRANSACTIONS
antibody ESVP1, which has an affinity constant of 4.5 x 10s
l/mol, appears to be the factor limiting the sensitivity of the
assay. The maximum binding achieved was only 2.6% of
added i:5I-ESVPl which is very low compared with the
binding that we have achieved in other immunoradiometric
assays [4], Selection of a monoclonal antibody with a much
higher affinity constant should increase the maximum bind¬
ing and also the sensitivity of the assay. A useful diagnostic
assay would have a sensitivity of 0.5-1.0 pmol/1 and be able
to measure AVP in unextracted plasma or urine samples.
We have shown that it is possible to develop a two-site
immunoradiometric assay for a peptide containing only nine
amino acids. Since an epitope is thought to consist of at least
4-6 amino acids [5], AVP may be one of the smallest
molecules that can be measured in a two-site assay.
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Lactate utilization by neonatal rat liver in vitro
ANGELES ALMEIDA, JUAN P. BOLANOS and
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Lactate accumulates in blood during late gestation and the
first minutes of extrauterine life to reach concentrations
higher than 9 m.\t [1-3], However, it is noteworthy that most
of the lactate accumulated is utilized within the first 2 h of
extrauterine life. i.e. before the onset of suckling takes place
[2-4], During this presuckling period, liver glycogenolysis is
not induced [1] or its rate is very low [2, 5]; glycaemia is very
low [1, 2. 6] and other relevant substrates are negligible [1, 2],
Consequently, under these circumstances lactate plays an
important role as a source of energy and carbon skeletons for
neonatal tissues. It has been reported that lactate is probably
the main metabolic fuel for the brain during the presuckling
period because its rate of utilization under these circum¬
stances is much higher than other well-known brain fuels
such as glucose and ketone bodies [7, 8], In addition, other
tissues such as the lung [9] and the heart (E, Fernandez &
J. M. Medina, unpublished work) may also contribute to the
high rate of lactate utilization observed during the first 2 h
Abbreviation used: PSWL. partially sliced whole livers.
after delivery [10 . The present work was thus designed to
study the possible role played by the liver in the postnatal
utilization of lactate. It should be mentioned that the gluco¬
neogenic capacity of the liver within the presuckling period is
negligible [6. 10], Accordingly, we studied the uptake of
lactate into CO- and lipids in early neonatal rat (1 h) liver
incubated in vitro. The effect of hypoxia and maternal starva¬
tion on the rate of lactate utilization was also investigated.
Well-fed or 48 h-starved pregnant rats at 21.5 days of
gestation were sacrificed by cervical dislocation and the
fetuses were delivered by rapid hysterectomy. The newborns
were carefully wiped and the umbilical cords tied and cut in a
cabin at 37°C. They were then weighed and sacrificed by
decapitation. Their livers were immediately removed and
used for the experiments. Partially sliced whole livers
(PSWL) were incubated at 37°C in 3 ml of phosphate physio¬
logical saline [11. containing 0.25 ,«Ci of L-[U-'4Cj-lactate
and the desired concentration of the unlabelled substrate.
The gas phase was O- except for the experiments on hypoxia
in which O, was substituted by N:. Incubations were stopped
after 1 h with 0.2 ml of 20% (v/v) HCI04, although shaking
was continued for a further 20 min. The radioactive CO;
trapped by 20% v/'v> KOH was measured by liquid-scintilla¬
tion counting. Blanks without PSWL were carried out in
parallel to measure volatile radioactivity, which was
subtracted from other values. After incubation. PSWL were
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Pitfalls in the use of ELISA to screen for monoclonal antibodies
raised against small peptides
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Small peptides are often conjugated to large carrier proteins such as thyroglobulin to increase their
immunogenicity. Antibodies are raised against peptide, thyroglobulin and contaminants, such as im¬
munoglobulins or BSA in the thyroglobulin preparation, but anti-contaminant antibodies will not be
revealed if immune serum is diluted in buffer containing immunoglobulin-contaminated BSA. This may
lead to the development of an inappropriate hybridoma-screening assay which detects more anti-con¬
taminant than anti-peptide antibodies if ELISA plates are coated with a capture antibody or blocked
with BSA. Dilution of culture supernatants in buffer containing BSA and Tween 20 minimises the risk of
false positive results and makes plate-blocking unnecessary.
The high affinity peptide-specific antibodies in immune serum, which are more readily detected than
lower affinity monoclonal antibodies, may result in an inadequately sensitive hybridoma-screening
ELISA.
Key words: Monoclonal antibody, anti-peptide; ELISA; Supernatant screening; Anti-immunoglobulin antibody; False positive
results
Introduction
Hybridoma-screening assays must be capable
of rapidly processing large numbers of samples.
The assays have to be optimised before mono¬
clonal antibody production can begin, so they are
frequently set up using serum from the immune
Correspondence to: N. Mcintosh, Department of Child
Life and Health, 17 Hatton Place, Edinburgh EH9 1UW,
Scotland, UK. Tel.: 031-667 2617; Fax: 031-668 2605.
Abbreviations: AVP, arginine vasopressin; BSA, bovine
serum albumin; ELISA, enzyme-linked immunosorbent assay;
FCS, foetal calf serum; i.p., intraperitoneally; IRS, immune
rabbit serum; NBCS, newborn calf serum; NRS, normal rabbit
serum; RIA, radioimmunoassay.
spleen donor (Campbell, 1984; Goding, 1986).
Enzyme-linked immunosorbent assays (ELISA)
and radioimmunoassays (RIA) which detect spe¬
cific binding to the antigen have proved useful in
screening for monoclonal antibodies which are
intended for use in immunoassays. However,
problems arise with both types of assay.
The radiolabeled antigens used in RIA may
have altered epitopes which are no longer recog¬
nised by the appropriate antibodies. This is a
particular problem with small peptides such as
arginine vasopressin (AVP) which contains only
nine amino acid residues. Iodination of AVP
increases its molecular weight by 11% and signifi¬
cantly increases the risk of obtaining a false nega¬
tive screening assay result. An anti-AVP mono-
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clonal which does not bind well to 125I-AVP has
been reported (Hou-Yu et al., 1982; Valiquette et
al., 1986; Valiquette and Neubort, 1989).
ELISA methods seem superior because they
avoid this problem, but may detect antibodies
which cannot recognise the native antigen in solu¬
tion if conformational changes occur when the
antigen adsorbs to the solid phase (Mierendorf
and Dimond, 1983; Vaidya et al., 1985). However,
if the antigen is large enough to bind two anti¬
bodies simultaneously, a capture antibody can be
used to immobilise it without loss of its native
conformation (Smith and Wilson, 1986).
Successful monoclonal antibody production re¬
quires that the spleen donor be adequately immu¬
nised. Small peptides such as AVP are poor im-
munogens and therefore they are usually conju¬
gated to a large protein such as thyroglobulin
(Skowsky and Fisher, 1972) in order to induce a
better antibody response. Unfortunately this pro¬
cedure causes difficulties when hybridoma cul¬
ture supernatants are screened by ELISA. We
report the problems encountered during screen¬
ing for anti-AVP monoclonals raised against an
AVP-thyroglobulin conjugate and describe a sim¬




12-week-old female BALB/c mice were immu¬
nised i.p. with 300 /jig AVP-thyroglobulin conju¬
gate containing 50 p,g AVP (prepared by a modi¬
fication (Staros et al., 1986) of the method of
Skowsky and Fisher (1972) using bovine thy¬
roglobulin (T1001, Sigma Chemical Company,
Poole, UK)) emulsified in an equal volume of
Freund's complete adjuvant. After 6 weeks, the
mice were boosted i.p. with 300 fig immunogen
emulsified in Freund's incomplete adjuvant and,
after a further 6 weeks, with 300 /xg immunogen
in alum. 3 days prior to cell fusion a final i.p.
boost of 300 ixg immunogen in PBS (0.05 M
phosphate, 0.9% NaCl, pH 7.5) was given. Ani¬
mal care was in accordance with institutional
guidelines.
Cell fusion
Hybridomas were generated by polyethylene
glycol 4000-induced fusion of immune spleen cells
with NS-0 murine myeloma cells (Galfre and Mil-
stein, 1981) at a spleen cell-to-myeloma cell ratio
of 2:1. The fused cells were seeded into 96-well
tissue culture plates at 2 X 105 cells/well, in 0.2
ml HAT medium (RPMI 1640, (Gibco, Paisley,
Scotland, cat. no. 041-02402) containing 15%
heat-inactivated foetal calf serum, 2 mM l-
glutamine, 1 mM sodium pyruvate, 50 U/ml
penicillin, 50 /xg/ml streptomycin, 100 yuM hy-
poxanthine, 0.4 /xM aminopterin and 16 /xM
thymidine), supplemented with rat mixed-thymo-
cyte culture-conditioned medium (Micklem et al.,
1987). Culture supernatants were assayed for the
presence of antibody as soon as large colonies of
cells were observed.
Screening assays
All incubations were carried out at room tem¬
perature, using 100 /x 1 of each reagent unless
otherwise stated.
Antigen-capture ELISA
Polyclonal rabbit anti-AVP serum (0.01% (v/v)
TGI (Smith and Mcintosh, 1986) in 0.05 M
sodium bicarbonate buffer, pH 9.0) was adsorbed
onto 16-well flat-bottomed Immulon 1 microtiter
duo-strips (M17916A, Dynatech Laboratories,
Billingshurst, Sussex) by overnight incubation.
Each well was washed three times with bicarbon¬
ate buffer and incubated with 400 /xl 1% BSA
(A7030, Sigma Chemical Company), 0.1% lac¬
tose, in bicarbonate buffer, for 30 min, to block
remaining protein-binding sites. After washing,
50 ng/ml AVP in PBS, 1% BSA, 0.1% Tween 20
(PBS-BSA-T) was added and incubated for 16 h.
The assay strips were stored at — 20°C, or used
immediately, after rinsing with PBS.
Hybridoma culture supernatant was incubated
in the wells for 16 h. After removing the super¬
natant, rabbit anti-mouse IgG (whole molecule)
horseradish peroxidase conjugate (A2028, Sigma
Chemical Company, 1 /200 dilution in PBS-BSA-
T) was added and incubated for 1 h. Unbound
peroxidase conjugate was removed by rinsing five
times with wash buffer (0.1 M acetate-citrate
buffer, pH 6.0, 5 mM EDTA, 0.02% Tween 20)
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prior to the addition of freshly prepared substrate
(100 p. g/ml 3,3',5,5'-tetramethylbenzidine,
0.002% H2Oz in 20 mM acetate buffer, pH 5.0).
Colour development was stopped after 30 min by
adding 50 pi 2 M H2S04 and the absorbance
measured at 450 nm on a Dynatech MR700 auto¬
matic microplate reader. Negative control wells
contained HAT medium in place of culture su¬
pernatant.
Antigen-coated-plate ELISA
AVP (1 pg/ml) or other test material in PBS
was adsorbed onto Immulon 1 microtiter duo-
strips by overnight incubation. After three washes
with PBS, hybridoma culture supernatant was
incubated in the wells for 16 h. Incubation with
rabbit anti-mouse IgG peroxidase conjugate, and
the remainder of the assay, was performed as
above.
Radioimmunoassay
Hybridoma culture supernatant was incubated
with 50 p\ 125I-AVP (7 pg, 1700 pd/pg) in PBS,
2% NBCS, 1% Tween 20, for 16 h before separa¬
tion of bound from free tracer by the polyethy¬
lene glycol (PEG) precipitation method (Des-
buquois and Aurbach, 1971). 50 yul NBCS was
added to the incubation mixture, followed by 500
^.1 PEG 6000 (25% (w/v) in distilled water). The
assay tubes were vortexed and then immediately
centrifuged at 2000 X g for 30 min. The super¬
natant was decanted and the inverted tubes al¬
lowed to drain on tissue paper before counting
the radioactivity of the precipitate.
Results
Antigen-capture ELISA
The antigen-capture ELISA appeared to be
specific for anti-AVP antibodies because immune
mouse serum produced higher absorbances than
non-immune serum (Fig. 1), and its response to
IRS-bound AVP was greater than to IRS alone
(Fig. 2). RIA confirmed that immune mouse
serum contained anti-AVP antibodies. However,
high background absorbances were caused by
non-specific binding of the second antibody-per-
oxidase conjugate to wells coated with IRS, NRS,









Fig. 1. Binding response of immune mouse serum (•) and
normal mouse serum (x) in the antigen-capture ELISA.















Fig. 2. Binding response of immune mouse serum to IRS-
bound AVP (antigen-capture ELISA, •) and to IRS alone
(x). Serum dilutions were prepared in PBS-BSA-T.
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TABLE I
NON-SPECIFIC BINDING OF ANTI-MOUSE IgG PER¬
OXIDASE CONJUGATE TO MICROTITER WELLS
Various protein-containing solutions were adsorbed onto Im-
mulon 1 microtiter wells. The antigen-coated-plate ELISA
was performed as described in materials and methods, except
that 100 /il HAT medium replaced hybridoma culture super¬









ence of BSA and Tween 20 in the assay buffer
(PBS-BSA-T). It did not bind to uncoated wells.
One cell fusion generated hybridomas in 378
culture wells. Undiluted supernatants from 26
hybridomas were considered antibody-positive
because their absorbances in the antigen-capture
ELISA exceeded 0.3. These supernatants were
subjected to antibody dilution analysis (Van
Heyningen, 1986) to identify high affinity anti-
AVP antibodies. However, dilution in assay buffer
virtually eliminated antibody binding in most
samples, even with a dilution factor as low as 2
(Table 11A). Dilution in culture medium did not
have this drastic effect (Table IIB, Fig. 3). In
contrast, although dilution of immune mouse
serum in assay buffer caused lower readings than
dilution in culture medium, the recorded ab¬
sorbances were still substantial (Fig. 4).
Antigen-coated-plate ELISA
The specificities of antigen-capture ELISA-
positive culture supernatants were investigated by
antigen-coated-plate ELISA (Table III). Undi¬
luted supernatants bound strongly to wells coated
with 1% BSA and all, except that from hy¬
bridoma 6, also bound to coatings of 0.01% IRS,
0.01% NRS, and 2% NBCS. Readings from wells
coated with 2% FCS were similar to those from
uncoated wells, which were caused by sample
adsorption during the 16 h incubation period. All
supernatants appeared to bind AVP at a low
TABLE II
RESPONSE OF HYBRIDOMA CULTURE SUPER¬
NATANTS IN THE ANTIGEN-CAPTURE ELISA
Culture supernatants were assayed undiluted, and after dilu¬
tion with an equal volume of assay buffer (PBS-BSA-T) (A),
or HAT medium (B). The absorbance due to non-specific
binding of the second antibody-peroxidase conjugate has been
subtracted from the values shown.
Hybridoma Absorbance
Undiluted Diluted (1/2)
A 1 0.976 0.097
2 1.493 0.020




B 1 1.368 1.139
2 1.815 1.734
3 > 2.000 > 2.000
4 1.862 > 2.000
5 > 2.000 1.974
6 0.415 0.357
level (compared with their response to IRS and
BSA) but this was probably non-specific. Many
supernatants bound strongly to wells coated with
Supernatant dilution
Fig. 3. Effect of diluting culture supernatant from hybridoma
4 on its response in the antigen-capture ELISA. Supernatant
was diluted in culture medium (•) or PBS-BSA-T (X).
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TABLE III
BINDING OF HYBRIDOMA CULTURE SUPERNATANTS IN THE ANTIGEN-COATED-PLATE ELISA
Undiluted culture supernatants were assayed in microtiter wells coated with a range of test materials. The absorbance due to
non-specific binding of the second antibody-peroxidase conjugate to each plate-coating material has been subtracted from the
values shown.
Hybrid Plate-coating material
None 10 ng/ 2% 2% 1% 0.01% 0.01% 1%
ml AVP FCS NBCS BSA IRS NRS milk
1 0.190 0.410 0.135 0.603 1.658 1.073 1.120 0.924
2 0.409 0.822 0.181 0.717 1.855 1.449 1.609 0.553
3 0.485 0.746 0.256 1.000 > 2.000 1.606 > 2.000 > 2.000
4 1.733 > 2.000 1.843 > 2.000 > 2.000 > 2.000 > 2.000 1.693
5 0.290 1.063 0.378 1.484 > 2.000 > 2.000 > 2.000 1.184
6 0.045 0.073 0.045 0.088 1.084 0.040 0.102 0.019
1% non-fat dried milk (Table III). None bound to
125I-AVP as determined by RIA.
Dilution of supernatants in assay buffer pre¬
vented non-specific binding to AVP-coated wells
and decreased binding to IRS, NRS, BSA and
thyroglobulin (Table IV). Immune mouse serum
reacted strongly with thyroglobulin, even after
dilution in assay buffer, because it contained
anti-thyroglobulin antibodies in addition to anti-
AVP. In comparison its response to IRS, BSA
and NRS was weak (Table IV).
A second cell fusion, which generated 461
hybridomas, was screened by antigen-capture
ELISA, AVP-coated-plate ELISA and RIA.
Undiluted supernatants from 110 hybridomas
were positive in the antigen-capture ELISA but
did not contain specific anti-AVP antibody be¬
cause all binding was prevented by dilution with
an equal volume of assay buffer. One monoclonal
cell line was established after its detection by
AVP-coated-plate ELISA and RIA. It could not
be detected by antigen-capture ELISA (hy-
bridoma 7, Table IV).
The anti-AVP antibodies in immune mouse
serum were detected by the antigen-capture
ELISA (Fig. 2), although low titre sera gave poor
results (data not shown). In contrast, the mono¬
clonal antibodies which we produced were not
detected even though they could participate in
two-site binding (Smith et al., 1990). They also
responded poorly to low AVP concentrations in
the AVP-coated-plate ELISA. Higher coating
TABLE IV
EFFECT OF SAMPLE DILUTION ON ELISA BINDING RESPONSE
Culture supernatants were assayed undiluted and after dilution (1/2, figures in parentheses) with assay buffer (PBS-BSA-T).
Hybridomas 7 and 8 produced specific anti-AVP monoclonals. Immune mouse serum (1/1000 in culture medium, and after further
dilution (1/2) with assay buffer) was included for comparison. The absorbances shown are the means of duplicate determinations.
Sample Antigen-coated-plate ELISA Antigen-capture ELISA
1 /ug/ml AVP 1% BSA 10 /rg/ml bovine
thyroglobulin
0.01% NRS 0.01% IRS +
1% BSA
0.01% IRS+ 1% BSA



































serum 0.700 (1.324) 0.000 (0.000) > 2.000 ( > 2.000) 0.279(0.140) 0.118(0.074) 0.159(0.208)
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Serum dilution
Fig. 4. Effect of diluent composition on the binding response
of immune mouse serum in the antigen-capture ELISA. Serum
was diluted in culture medium (•) or PBS-BSA-T (x).
concentrations improved their detectability but
had relatively little effect on the binding response
of immune serum (Fig. 5).
Plate-blocking was omitted from the AVP-
coated-plate ELISA because BSA increased
non-specific binding of the second antibody-per-
oxidase conjugate (Table I) and decreased spe¬
cific binding of anti-AVP antibodies (Table V).
Dilution of culture supernatants in buffer con¬
taining Tween 20 prevented non-specific binding
to the plate and thus rendered plate blocking
unnecessary.
Discussion
Arginine vasopressin and oxytocin are closely
related nonapeptides, differing in only two amino
acid residues. Iodination of the tyrosine residue
of AVP masks an important epitope because the
adjacent phenylalanine is the only amino acid
which distinguishes the AVP ring structure from
that of oxytocin. Hybridoma screening by RIA is
unlikely to detect antibodies specific for this re¬
gion of AVP. We therefore chose to use ELISA
screening which avoids this problem because it
does not require labelled peptide.
A two-site antigen-capture ELISA (Smith and
Wilson, 1986), using rabbit antiserum to immo¬
bilise AVP, seemed ideal for supernatant screen¬
ing because we required monoclonal antibodies
suitable for two-site immunometric assay devel¬
opment (Smith et al., 1990). This type of screen¬
ing assay was reported to be more sensitive than
those involving direct adsorption of antigen onto
plastic (Al Moudallal et al., 1984; Brennand et
al., 1986) and was the only system capable of
detecting all antigen-specific monoclonals (Bren¬
nand et al., 1986). Initial tests with immune mouse
serum suggested that the antigen-capture ELISA
was specific for anti-AVP antibodies (Figs. 1 and
2) despite non-specific binding of the second anti-
body-peroxidase conjugate to the solid-phase
components. Flowever, the antibodies detected in
undiluted culture supernatants failed to bind af¬
ter dilution in assay buffer (Table IIA), even
though significant adsorption to uncoated wells
(Table III) had suggested that the supernatants
contained high antibody concentrations (Miller et
al., 1983). Investigation of this phenomenon re¬
vealed that undiluted positive culture super¬
natants bound strongly to IRS, NRS, BSA and
NBCS (Table III), whereas the response to FCS
was the same as to uncoated wells.
TABLE V
EFFECT OF BSA-BLOCKING ON ANTI-AVP ANTI¬
BODY BINDING IN THE AVP-COATED-PLATE ELISA
Immune mouse serum and a monoclonal antibody-containing
culture supernatant diluted in PBS-BSA-T (1 /2000 and 1 /2
respectively) were assayed in AVP-coated wells, as described
in materials and methods, or after blocking the coated plates
with BSA (1% in PBS). The absorbance due to non-specific
binding of the second antibody-peroxidase conjugate has been
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Fig. 5. Binding response of a monoclonal antibody-containing culture supernatant (A), and immune mouse serum (B), in the
antigen-coated-plate ELISA, with AVP coated at 10 ng/ml (X), 100 ng/ml ( a ) and 1 /xg/ml (•).
Many BSA preparations are contaminated by
immunoglobulins (Boscato and Stuart, 1988)
which were also present in all the sera used in
this work, except FCS. Since antibodies are raised
against all immunogen components, it seems likely
that the bovine thyroglobulin (Sigma, T1001, de¬
scribed as 'electrophoretically heterogeneous')
used in immunogen production in this study, was
contaminated by immunoglobulins, and that anti¬
immunoglobulin antibodies were contained in the
antigen-capture ELISA-positive supernatants.
Anti-immunoglobulin antibodies have often been
reported to cause interference in immunoassays
and have been described in the literature as het-
erophilic antibodies (Boscato and Stuart, 1988;
Nahm and Hoffmann,- 1990). The thyroglobulin
preparation also contained BSA because a spe¬
cific anti-BSA antibody was detected (hybridoma
6, Table III). When culture supernatants were
diluted 1/2 in assay buffer, anti-BSA and anti¬
immunoglobulin antibodies reacted with the BSA
and immunoglobulin contaminants in the buffer
and so binding in the antigen-capture ELISA was
prevented (although a few high titre supernatants
might still show some binding due to inadequate
neutralisation, Fig. 3). Dilution in culture medium
did not have this effect because it contained no
immunoglobulins and relatively little BSA.
Traditional ELISA methods include a blocking
step whereby an inert protein adsorbs onto unoc¬
cupied sites on the solid phase to prevent non¬
specific binding of reagents (Campbell, 1984), but
there is then a risk of interference by anti-block¬
ing-protein antibodies (Schonheyder and Ander¬
sen, 1984; Kemeny and Chantler, 1988). BSA is
commonly used as a blocking agent (Gustafsson,
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1990; Pruslin, 1991) although casein (Kenna et
al., 1985) and non-fat dried milk (Vogt et al.,
1987) have been recommended as cheaper alter¬
natives and serum has been used occasionally
(Campbell. 1984). These materials all have the
disadvantage of containing immunoglobulins and
will therefore be bound by anti-immunoglobulin
antibodies. Campbell (1984) suggested that anti¬
gen-free plates should be used to check that
antibodies do not bind to the blocking protein or
plastic, but this increases the work and expense
involved and is undesirable because a specific
antibody might be overlooked if it occurs in a
supernatant which also contains an anti¬
blocking-protein antibody.
Omission of BSA blocking from the AVP-
coated-plate ELISA prevented binding of anti¬
blocking-protein antibodies and increased spe¬
cific binding (Table V) by removing the steric
hindrance (Hobbs, 1989; Mohammad and Esen,
1989) caused by BSA molecules (67 kDa) sur¬
rounding the AVP peptide (1.084 kDa). Dilution
of supernatants with an equal volume of assay
buffer introduced Tween 20 which prevented
non-specific binding to the plate (Mohammad
and Esen, 1989). As an additional benefit, dilu¬
tion often increased specific binding (Table IV),
probably by a buffering effect because spent cul¬
ture supernatants tend to be acidic (Campbell,
1984) while most antibodies bind optimally at
neutral pH values. There may also have been a
prozone effect because concentrated antibody so¬
lutions tend to bind univalently and may leach off
the assay plate during subsequent incubation and
washing steps (Nygren et al., 1985; Vos et al.,
1987).
Caution is required when immune serum is
used to develop a hybridoma-screening assay be¬
cause the binding properties of antisera differ
significantly from those of monoclonal antibodies
(Al Moudallal et al., 1984) and normal mouse
serum may not be an appropriate negative con¬
trol. Serum from an animal immunised with an
unrelated peptide conjugated to the carrier pro¬
tein is more likely to give an indication of possi¬
ble problems, particularly if it is diluted in culture
medium instead of assay buffer. The antigen-cap¬
ture ELISA and the AVP-coated-plate ELISA
described above were set up using immune mouse
serum which gave misleading results because it
concealed two major problems.
Firstly, the presence of anti-immunoglobulin
and anti-BSA antibodies was masked when im¬
mune serum was diluted in assay buffer and only
became obvious when undiluted culture super¬
natants were assayed. This problem, which was
also encountered when screening hybridomas
raised against thyroglobulin-conjugated peptides
derived from parathyroid hormone (unpublished
observation) and HIV (J. Boyd, personal commu¬
nication), might have been reduced by using a
mouse carrier protein in the immunogen. How¬
ever, it has been shown that the choice of carrier
is important in determining the immune response
to small peptides (Skowsky and Fisher, 1972).
Bovine thyroglobulin was selected because it is
known to be a good carrier for AVP and has been
successfully used in anti-AVP antibody produc¬
tion by many research groups (Hou-Yu et al.,
1982; Jones et al., 1985; Robert et al., 1985;
Smith and Mcintosh, 1986).
Secondly, our monoclonal antibodies were un¬
detectable in the antigen-capture ELISA (Table
IV) and difficult to detect at low AVP concentra¬
tions in the AVP-coated-plate ELISA (Fig. 5)
even though the anti-AVP antibodies in immune
serum produced high absorbances under these
conditions. Monoclonal antibodies do not bind
well at low epitope densities (Lew, 1984) particu¬
larly if they have low binding affinities (Nygren et
al., 1985) whereas the high affinity antibodies in
immune serum will bind strongly, leading to the
belief that an appropriate screening assay has
been developed when much higher antigen-coat¬
ing concentrations may be needed for efficient
monoclonal detection.
Early screening of hybridoma supernatants is
vital because cultures often contain more than
one colony of cells and non-producers are liable
to overgrow antibody-secreting cells (Goding,
1986). Antibody concentrations are initially low,
therefore screening assays must be very sensitive
to avoid false negative results and supernatants
are commonly tested without prior dilution
(Galfre and Milstein, 1981; Robert et al., 1985;
Vaidya et al., 1985; Smith and Wilson, 1986;
Gustafsson, 1990). While this is acceptable in
liquid-phase RIA screening (because buffer is
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introduced with the labelled antigen and only
specific antibodies are detected), ELISA screen¬
ing of undiluted supernatants is prone to many
problems. These may not be anticipated by labo¬
ratories whose previous experience of hybrido-
ma-screening has been restricted to RIA.
We recommend that all hybridoma super¬
natants, particularly those raised against thy-
roglobulin-conjugated peptides, are diluted in
buffer containing BSA and Tween 20 prior to
ELISA screening. This will prevent non-specific
binding and so make plate blocking unnecessary,
maximise specific binding by buffering the sam¬
ple, and neutralise most anti-immunoglobulin and
anti-BSA antibodies.
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